var title_f39_32_40448="Subtotal stomach preserving pancreaticoduodenectomy";
var content_f39_32_40448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F77363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F77363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Subtotal stomach-preserving pancreaticoduodenectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subtotal stomach preserving Whipple with end-to-side (left panel) and end-to-end pancreato-jejunostomy (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_32_40448=[""].join("\n");
var outline_f39_32_40448=null;
var title_f39_32_40449="Normal sonohysterogram";
var content_f39_32_40449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transvaginal sonohysterography of a perimenopausal patient with abnormal uterine bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The endometrium surrounding the fluid is thin, measuring 1.9 and 2.0 mm at the anterior and posterior walls, respectively. This is a typical picture of a patient with dysfunctional anovulatory bleeding best treated hormonally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_32_40449=[""].join("\n");
var outline_f39_32_40449=null;
var title_f39_32_40450="Patient information: Radiation therapy (The Basics)";
var content_f39_32_40450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/35/24114\">",
"         Patient information: Brachytherapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/27/17842\">",
"         Patient information: Hair loss from cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/40/1667\">",
"         Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/59/11186\">",
"         Patient information: Mouth sores from cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/57/19346\">",
"         Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/7/18546\">",
"         Patient information: Preserving fertility after cancer treatment in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/57/11154\">",
"         Patient information: Preserving fertility after cancer treatment in men (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/18/12579\">",
"         Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/4/29762\">",
"         Patient information: When your cancer treatment makes you tired (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Radiation therapy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/radiation-therapy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H28823010\">",
"      <span class=\"h1\">",
"       What is radiation therapy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Radiation therapy is a type of cancer treatment. It uses high doses of X-rays, called radiation, to kill cancer cells. There are 2 types of radiation therapy, depending on where the source of the radiation is.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        In &ldquo;external-beam radiation therapy,&rdquo; the radiation comes from a machine that is outside the body. This article discusses external-beam radiation therapy.",
"       </li>",
"       <li>",
"        In &ldquo;internal radiation therapy,&rdquo; the radiation comes from a source that is put inside the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Doctors can use radiation to treat many different types of cancers. Some people are treated only with radiation therapy. Other people have radiation therapy along with other cancer treatments.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28823017\">",
"      <span class=\"h1\">",
"       What happens before I start radiation therapy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before you start treatment, you will meet with a team of doctors and nurses to plan your radiation therapy. They will probably do an exam and tests. They will put a small dot of ink on your body to mark the area that will be treated. They might also make a mold or mask of a part of your body for you to wear during treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28823024\">",
"      <span class=\"h1\">",
"       What happens during radiation therapy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People get radiation therapy in the hospital, but they can go home after each treatment. They do not usually need to stay in the hospital. The number of treatments a person needs depends on the type of cancer. Some people get radiation only 1 time. Other people get radiation 1 time a day, 5 days a week, for up to 7 weeks.",
"     </p>",
"     <p>",
"      For each treatment, you will wear your mold or mask (if you have one) and sit or lie down in front of the machine. You will need to stay still. Your doctor will line up the machine with your dot of ink. That way, the X-rays will travel only through the part of your body with the cancer. The X-rays will not travel through other parts of your body.",
"     </p>",
"     <p>",
"      It doesn&rsquo;t hurt to get radiation. The machine sends radiation through the cancer and the area right around it for about 1 to 5 minutes.",
"     </p>",
"     <p>",
"      Your doctor or nurse will give you instructions about what to wear and what you can or can&rsquo;t have on your body. For example, most people should not have bandages, jewelry, or other items on the skin in the area being treated.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28823031\">",
"      <span class=\"h1\">",
"       What are the side effects of radiation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People can have different side effects from radiation. The side effects will depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The part of the body being treated &mdash; As the X-rays travel through the body, they can damage the skin and the organs or tissues next to the cancer.",
"       </li>",
"       <li>",
"        The dose of radiation",
"       </li>",
"       <li>",
"        The number of treatments and the treatment schedule",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People can have side effects hours or days after treatment. Common ones include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling tired, weak, or having no energy &mdash; These symptoms can get worse over the course of treatment.",
"       </li>",
"       <li>",
"        Skin changes &mdash; The skin in the area being treated can peel, blister, itch or turn red.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other side effects can happen hours or days after treatment. Depending on your treatment, your doctor will tell you the ones that you are likely to get.",
"     </p>",
"     <p>",
"      People can also have side effects from radiation months or years after their treatment. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble getting pregnant",
"       </li>",
"       <li>",
"        Other types of cancers, although these are rare",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28823038\">",
"      <span class=\"h1\">",
"       How are the side effects treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor can treat the side effects in different ways, depending on your symptoms. He or she will also suggest things that you can do on your own. For example, to ease your skin symptoms, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Use creams that your doctor or nurse recommends",
"       </li>",
"       <li>",
"        Use sun block and wear a hat or long sleeves to protect your skin",
"       </li>",
"       <li>",
"        Not put anything too hot or cold on your skin",
"       </li>",
"       <li>",
"        Try not to scratch your skin",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28823045\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When you have radiation therapy, it&rsquo;s important to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Follow all of your doctor&rsquo;s instructions about treatment and visits",
"       </li>",
"       <li>",
"        Let your doctor or nurse know about any side effects or problems you have during treatment or if your health changes. You should also let him or her know if your dot of ink wears off.",
"       </li>",
"       <li>",
"        Take care of yourself by eating well, getting enough sleep, and exercising. To keep your energy up, try to eat foods and drinks with a lot of protein and calories.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28823052\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/35/24114?source=see_link\">",
"       Patient information: Brachytherapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/40/1667?source=see_link\">",
"       Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/27/17842?source=see_link\">",
"       Patient information: Hair loss from cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=see_link\">",
"       Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/4/29762?source=see_link\">",
"       Patient information: When your cancer treatment makes you tired (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18546?source=see_link\">",
"       Patient information: Preserving fertility after cancer treatment in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/57/11154?source=see_link\">",
"       Patient information: Preserving fertility after cancer treatment in men (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/18/12579?source=see_link\">",
"       Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/59/11186?source=see_link\">",
"       Patient information: Mouth sores from cancer treatment (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/32/40450?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16301 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-869C284B9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_32_40450=[""].join("\n");
var outline_f39_32_40450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28823010\">",
"      What is radiation therapy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28823017\">",
"      What happens before I start radiation therapy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28823024\">",
"      What happens during radiation therapy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28823031\">",
"      What are the side effects of radiation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28823038\">",
"      How are the side effects treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28823045\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28823052\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/35/24114?source=related_link\">",
"      Patient information: Brachytherapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/27/17842?source=related_link\">",
"      Patient information: Hair loss from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/59/11186?source=related_link\">",
"      Patient information: Mouth sores from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18546?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/57/11154?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/18/12579?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_32_40451="CPAM prenatal ultrasound_axial";
var content_f39_32_40451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound of a congenital pulmonary airway malformation (CPAM)*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 364px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFsAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Xdm3t8x6+tJub+8fzof77fWkoAlABgZzMocMAIzncRzyOMYH1710fhGKWFJr5QXYHy0UHn3rmEUswUDJJrq7RZLaBRCw2gcgdKEBrQzo7sySSxseqMcirUc5K4ikPmDt0rM+0QTBfMWaO49eoP40xpQH+ZnVvccUwNqNQyZExSQnleoP0NT2p3SPmZ1cc7Qf6GsaGdhg4DleQQea2Jb2G5hQrKA6joybT9MigB8t0gKyBh5wPOw7W/EUSvPlTLbPhj9/1oNrod+qu09zaXi9ScOjH+YpyG7hwLeUTxjoYpBn8jQB0GmS3AthFaz/AGdzztnZdp/A10Fpqr6YEi8SaRDcwt92e3ZSMe4HFef/ANorK8iytPHNjlJV4/OtbRJroWrJbJHNE38HmgkH6GgDspovCGrYU2bQb/uyiFk2n6jiorvwU9vYv/Z11pkqHlVkQq/4NnrVPw/rmlwObXV7y/sJs8RTRfujW1f+KIZQbSz/ALOnjxgSElcfhQB59f6NqlpumhkSVB96Mtkj6U3T9dktHEkFw6MBhkc/0NdSba+khM4a2kZT0tWBOPoa5HWbfZdbri3aI9ctGFH6UAWl8Uec7LdRDJORuYhfyqnf31vcukjJBA6nrCDg1nTR/ahwOR0ZHBx+FW7KaWG2aJxBOOxmTkfQ4oA6bTtMh1C08xdSQvjueQKzdRs7a3nEcd/HKx6lGII+tZCSOwJnijiUfxhMZ/EVas1g5xDPt7SMRg/1oA6TQ9Ok8syw38kWB1UZB/OqOoT3wuHEJmmz/wAtXGP/AK1QiW+2KqPIUX7uPnH4irR8T3ttD5U4gyvTdBt/rQBRax1G9iKtHPn+8q5H5CqzeG9XtzuW0j2Ho042/pWrH4n1K5O9ri2hXP3owVP6UzUNcu5ldBevcjHIZ+P5UAc1dWN/FIVM0Im7rHx+tVvLkjGHgaSb++WJAq7LfzL8iw4z/Gg5/Oqb320FY9wY9Wk5oAQNcSPhYWZh/HuzSL9pdzukAx6qQB+NNjuCpwrsHPUrkVM4DDdJOqL6dc0AUZppvN2J859c1ELhoSRtyfrU/ko7k5OOxPGahlNrbZcozTDpk/LQAx7uRTn51c9954qJpp8ZV3Zz75psskkxDuike3aoj5sjfKpA9uKAHyzT4O+QD26mozKwXJkwBSyxrGoO7Ld/aoCyuNu0yMaAJvOkcZUPg/xZqNmMZypJ96XJEe37v406KMEj5sv79KAASyMOp57E1MLjbEA0mT6Z4qKd4oyFYhn/AEqq0ilgxzgdOMUAX1uZMBgPLQd84zViPVJN+Cz+5HBrK8tpwDLKY4xyKfaRm5lEdsJJCeBxQBupqCOAERgR3ZiTUq3QkDeZKFrOvrNtNVVmdPMPUZ5FVGmQgfKSB1J4oA14b2ZX22ZIA6ympy80x4mY+rE1hRXTE7Qp2+ma0I7gADI3uegB4H0FAGgVWM/M5kkH8INULqaVpOGJboAPuircFs0il5Zkhz2J5qT7FEzoqTjBPLNQBlSqUcF5W3n8fyFIjsGCL5jMefmrp59Q0zSbXyrezFxOf+Wh5NcvdalNLO0nlCInsBQA95XSXa789xnp9arzymWTCsdo79s1EWaQFjwO/vUEh+XJ4HoKANK1TzCR5xZuhOeBUsvlQfKDvesq0LBgI/vHgegq5MYY8QxPvnb7z+lACKC8hZ8sx/hJ4/GsPWdOksZ0dd3kyHj/AGT6V0duIoGBX99N/d7Cm6grXo23BUgnAUdBQB9a+D/hZ8Pr3wv4fuLzwvYy3VzYW0sshZ/mdo1JJ59TXxb43toLPxnr9rZxLDbQahcRRRr0RFkYAD6ACvufwXfFfC/hoZ+7p1oPyiSvhvx8c+OvEZ9dSuT/AORWoaAzNOws/mHoldDHcKy7gSh9qzNOsLmSwuLqBUMduA0paRVxnpgE5P4A0+K5mYYeNWX1FIDaE0MsO2Vkx2YDkU6G4ZSFMqSp0yetY6qjNuxt9QBircJQD7zbx0+XrTA6WG1tbmEDekcnUEHAqT+y3iQyrb+co/jjbNYtjdRE+XIWRvpXU6YDHEZIJGdD18o/MP8AGgDOhjWSULHGRKehc8Ve/sWQTZvIjATzuj+6auwDT/OWW7klkiJ+bZjev/ATXT2KWbQldH1uGaNuDa3Y2H6c0AcZf6eqFDbXrSD0ZDlaotCwOPsnmf8ATSM4r0cw3cEixHTXh7hs74z9DjipBYtJHLMTa24HVHTn8DQB5xdQySxIt1cSumPlVicrTopIrNQj/OD2dcV0l28EVwCG80Hj5ouF96z9W0QkfaLS9glkI3bMj+RoAqXFnHsjmiukjVh0EvNJHPezAQJI0sY4IZu341k3UGoSITJEoA9FyKoST3yALIVIH9xMEUAdPNpW11MKQMerL5g4pnlSBS0Uipg88/KKxYdTkhULKRLCeqmMAj8artOJJStusqxn1b+lAG+rkn98VfHdHzn8KlW6s2XbtKSD+MtgfkK5+SSRCpMk7OP7yggU1rkg52Zf12AfpQB00NxaxI7Rz7JD0C3HB/CoiFugJJ7yHjrGvzE1gLIkuTJJGpHUnj+lVLi7jdwFKFF6sgwaAOvQaVDl5r2dD2jjVetVNTu7N1YRSeazf31wa5NrpWzsfj3GTQJo413SSZHcZxQBq/Zy6nbKFB/gB5qKSIwsPmKDHQjBrJbWIkb5Cyj3NV5dZXfuIaVvQnNAGxksx2O4B9+tKhdJP3kakdj3rEXU0k5ZlQelPGqwxNkOXNAG7LfKi7NoUn0QE/nWfK4LFg/mH37fhWZJqXmuW8zYPTGTSpexnGZgW9MYoAumdycRAqB1LUC4mC48w7T3ziq0lyhHMqov51Te9CkhNv8AvEZoAvys3IDKq92psIySFYBfXOTVFL2JSC4Ln3FPk1QbNqooHsKALUsgQgDkU5VlcfM+xPaqKXqsRthZjU5eaQjePLU9FFADgoR9sfJ9eppAu9zgMxHQAZpywyj5kXI75qxFJLGoyCmO/SgDV0rw5cXY827k8mHrgmr9xe2WkRtHYyL5o43jBb8K5x3urldgmfy/TOAaryQJb4wxLnrQBLJdGSZpSpZz/FIetRbnkYliN3YCoDy2T8wHXJqRDufPCr7UASMHUAuy8dhVu1u0RS5kO7tgVQZtxKKCR+lCjaeAT74/lQBdW6Yvkk89BVu2ugjhrhmYD7qDvWXG6x88ZP402WXDZU59zQBvGaRSXwFZufUgf0qujo7OWBZu5NV7K/UwlG7+nU04zADZGuPU0ARzPg9OOwFIIZH5ZaWNSp3tkntntUjO7jGdq+tAFOQFCRv2/Soo1zJuGQo9OpqxJECeufrQoJIWMZ7D3oAsQuY0IBwT1NSQ4kkBYkLnj3pgttpG9lZ/r8oqWN9syhCBz940AfWfhGcjwz4eGelhbD/yEtfG3jIeZ4417PQ6hcE/9/Gr618KTY8O6EM9LG3/APRa18l+KcHxhrjE/wDL9P8A+jGoAzgw3dOlKjHOVIFMJBY4OKaM7ieD7UAaAlP8QB9SDSi5VJOj/UGqXK4KoR9TUivkgqvzD1FAGrHqKSABnG5e+3mtCyvGik8y2nMMnqhwDXOu6uwZtqyDsVp9vMysCNp+lAHqmkeITNGI9Z0aDUY+nnRACT/69aKWfhrUXJs1mhmA/wBVI5Rx9M8GvJo57pD5tqWUjk7WxWtb67NcKEu0Dyr0d8hh+NAHpmmSmxuRDLqV/BADhTlsL9RXd20kgtQy6lYXsR6FwC3414nY6/d5Qec6beNxO4fiPSuri1NLq2O0aKJgOWiiKsf/AK9AGpq9281/sjjt45AeCj7QfwNU7pL+aFtwtyB1DLz+BrJRJlk33DLtJ43xlR+fSthdSlsY8wCFuPuswCn6GgDmpEuJSyxK+wHDbZOBUGq6ffwwgjz2jxySQw/MVBreoRzXLSvC9s7dTG4ZT+VSWMkE67Y7iVTjox4NAGHIxZdq25Df3qmtmAX96+5v7siDAq7M6203l3ADxHowHIq4tnbyW/mwxrNH3w53D8KAOfeEs7eWiZ+vFRSL5ZBmn+Ydk5Ircn02AR+YkV0Y/VD0qNNJgmXdFPn0QglqAMdLZJ9zeaF4/j71UMC7/LiKsfULXT/8I1f+WJGhYwnoQKv6TYWtix85Imcc4bg/hQBj6F8PtW16VEsyu5jgbuMV694Y/ZemuQsnifWJYx18qDB/U1h+H9VlFyPsdxJaAdHjGcV1Ul54ivUCLrN3Ig/jBwfxoA6BP2d/AVmoWe9d2H/PaUD+RFVp/gd8O06am0IHJETZz/OucltJzlbzVFU93luRx+FVLm0sZMRpr0sp/iKTKAKANLUvhb4B81obSSSPHAlkYZPvVWf4NeFUhDW18t/IewlVdv4VjXuk2bpsW6mdPUybifyrIbw/JCxmstQ8vHQMSTQBcv8A4SRpcbYyYID0YgEf/XqO1+BY1ByLbUoWPTLIQBUkcWrxQCW4upmUdGaU0iarqhQrBqM8IHUo55oA10/Zm8rabzWoFJ52hgP5mup0r9mjwvbwJLqWpyTZ6/vAq1yGmajf8btQneQ9csT+prtbGS81ONYTeKoI53vub8hQBaf4E/DmRSkF8IsdT5mT+ZNQn4J/DGyixLqRd89fM3H8hTpfCkMqqLnVDCp4IUAE1mX+haDpLIiTu8xP8LHJNAEeqeBfhxpcDFFuZG/gByM/TmuB1bSvD5Zhptu0I6Ayc5ro9XNuzGO3SeaTpndkgVgTSR2SSFtN4/vONzGgDm57O0tonAcSzH7qIvA/GsWXTbgPve2dh2OMiujWWN2aRbV1J6bx0pVvzkRSTMi98DJoA4fUDMoKsrRj0AwawnYqxAOf1Jr2BNJ0i+3YaYtj+LHJrJu/DClJPs0GWHfjFAHmw3uuCSq+gqdVOAuc57Cr17p0ttIyyxsAPUVRCPCd5GBQBbVEiT5m5/uioHdgfm4BpsU6JlsEt70O0spLkBR2z2oAazbRkgD0yaieU7MDgdyaY+ATk/nTJBgb8j2oAswsvRW6VraZIhfYy5z3rmi/ORxVi0u5Yn+UjB9aLgdNMg34Az6L3NV5srIEPX27VDZ3eTu3ZJ71d2pKCwZR64oArSDn5R9TUUg2gFpAD7dqlCmR9oPAqKeLknGWoAglnIQ+Wen8TVXikdJVJc5z3p7xM3C8479qi2BZFHqetAH1X4ZnxoOiDPSzt/8A0WtfLficb/E+s4x/x+zH/wAfNfRvh64xoukD0tYP/QFr5w8RFW8RaqyEgm7lJH/AzQBnGJtpZQxAOCccA/WmguOhqQ3E/ktB5riFmDtGSQrEZwSPUZP51GADjHX0NIBySyJnk7T1HapfNDLwQP6VA2APusp+vWlUnttP4UAT7m4yyuPep1zgBk+X2NUlkYHGfw7VZjlyuG+73BpgW4nw4BWQA981PveNwyZOPfNZySbTje4T25FPMuHGwsf92gDdtdVlWUNG0W4dVdBWxJqb3MYJht4pAOGQYzXKxusq/MCrjvtp0btGwLYI9TwKAN8a3rMAKLfSCL+43zKabHrc3SSAzA9Rnj8qovJI0W77NEw/vK/NU2eNshnKn0FAHQRahpk7cwyWkvrncPyrZ02KzuXAt7u03+kxx/OvPZYIZAdz4bseRVJ2iXCCRyR230Aeq6to900OJIbWVOzRTisCRLrToyYEmiB/6abhXNabaahdSKtu0oTuC2RXeaNpESwgXjyPL6AHFAGfpFnd6hLuSKR/7zHkV0UWkCJ1+Uo565HGa3IEhsbAsbfA/h/eFSfyrIk1aeJyGjVgegD5xQBoppmopGGMu2I/dVjgU6HSdQnmBEEcjf3kj3/oaxJNe1JWDRSyFh91FAIFWLbxF4nuphFFevb8c5AAoA7vRfCmo3BIuUe1gPJKgIfyFdfp/gazt7Np7nW2WPGdsjY/QV5M3ijVLWJo55xPP03Ek4rnZ9avZLhpbzVJHTP+r8wgfTFAHtkukeEYkaS9vIHAPQ5JNOt9J8FXaDy42c9j90fhXk1j49trNFEGnRy7eryHcap6z8Qbq/Zfs6fYwDwYvlNAHtMun+HLAkQ+Srn7vnHP5Cse+udAbJkmjEvQBB0/KvONL1O91Fds4lu3YcB+CfxrUttN1UsP+JWI0zgZbBNAEfii6sbLAtDcSluowSKwIbXUb9z9gtZQp7ZxivUNGszbtm+sYnP9+QBgPyro7rxvpOkW6QxaNHLKB8zCIAflQB4vY6PqltdB5EkyeAWyRXZaJpmpSk/u54mP8cOBgfjWhP4wXUCyy21vCh6IvWodP8RtH5u6JPLH3cnbn8TQB2mnWlja2ipOxebHJmfkn61R1TT7MxPJFbKHI+8jGuI1bxtdWoKrHBEzfxxJ5jY/Gud1LxlqV7GIopWRO5Y/Mf8ACgDtrDTtLt5Wa7u9rsful8VX8SW1lZW4uIbhfLI/iYfp3rjNJ8O6xr86DayIT3fbn+tesxeBoNJ0cJqsEHmuuFJbJoA8Z1LxVZ58qGEeZ034pNOha/IEMb5P3nPU1a8b+Ab3TpzcxQuLdvm3gYArloJri0Oxbh4yO6nBoA6+7sDakI24HHoNx+grJi1M2N0XZZpG/hiViT+OKqWs371WmuJJmPUBv5mu/wBJ1bT109LWWK2gR+GMY+Y/U9aAOEuP+J7e7rpRbRLzt704eHYLhiIihHYngCuh8S/2Wp26YFij/wB0lnNc1LcXcONp8rHQsMY+goAr6r4I8m3MplVmPRV71xOrWFzayBdj4Hb0r0zT7xwMTyyy55ZzwB+NSa1Fp99brHArbj/dXrQB48ruX+ZcntmmluTuOW/lXb6x4Skhj8wD5T2FctdWBgBXYSR1FAGbgE05Rz0608AcgoQaAoOAT+FICWFtuAST61r2E0TDafy9KyEg+f5mwPTvV9LiG0TZGP3h60wNeGMKGKLx/Oop0ITLZx6CpLeUm3Gc81K8omj8tRuPtQBkTO2w5XCDt61QLNJIDwBnpWlfp5alWHNZkYJmHGQD+FAH0LoU2NK0sZ6W0P8A6AK+fNdOdd1L3uZf/QjXt2jzgadpw3dIIv8A0EV4hrQ363f9ibiT/wBCNAFPPocj3pyru+6BThbuBlh8vrTlKrwM/lmkAxo2XlwQOxHIpVj3DO4Y+lB3FvkJ+macikE7v1FACm3cLuVkcU3JUdPz5FSLuU/Jjnt2p3lndkYU0wI0lK/wkfhxUqGVmDRYX3HFKkcit90kf7NPRM5zhT2yMUAWYzJKQJWO7se1PkVkOJMqPXtUccfybhIq+uR/Wo5LtFBVnc+/UUAWFY4+UBh7ikmlXaMqAfpzUNlHLeuIoU35OOeK9J8KfDf7QBNqM626AZ2ZyTQB57Y6ZqGoyeXYwTMT6Cut0vwK8DodVglMpP3R3r0iy0O20yDfFdeUo4BHU1d0/VNPhYt5pLjrI4yM0Ac9beEbHYPJaS14/jODUMjrodnKyIzSDo7DOa62QDWnZYr2PY3bdjH0q5Y+HJbSNvMvEvN/HksuRigDxy48VTS7vtSK4/hHTFZAvllnMkismeig17J4j0SwispGPh5xMBkPEQw/IV4/qALXDRi3WHBx0waANfRtYtbWXdNH8ndT1rWeaLW7pI9HgIf0wRUXgbwTHqVylxfI8kAOdqnk17loNha+HE3WOhSSgjq64H60AeU69oJ0nS0kupFSVhyoJri08mIsSkJU/wATZr37X/D0fiU772U2YP8Ayyz/AFrBj+FmltJtEjzY65fr+VAHikrQySfKfMHoowBW/wCGtFk1K5VLXTXuZCcZLABa9Zh+D2mqGlMN1BtGcg8H86YbNdBRhYu4CcZ3ZY/gBQBLZ6Onh6yVb6xYXB5JLA49q2rbWdPvrJYEt2+0jjdjJH49K851Bbm6mNxdmafd03ykD8q3PDKxwspurYRjoGaXgfgKANiWDy5CCreWDknnAqUac+oyIlooZm4/1XAr0LQdH06aNLhiHH908j8q6T7Va2KZS1jA9VXmnYDhNP8ABljpOmzm6igN4653kciuDk8N2d3rcazAtbKcn5tor0Pxh4pEUDJY6dmZvVsk15frY1m7jE0ttLbknkq1AHpL/Dbw7q8UcVrfAMRkpGOn41yGv/Ae5tpmm0e8jK9g+SxNWvBfiCW0CRNeyrIuBjZ3+teu2eryXFvFmRDJjJbAz/8AWoA8W8N/DrxRo8hmmRA54Ds2MVPqVvPa3byy3PnXqjAkkbcFPsOgr0fxbqqeT5ckzBccndzXnU0CX75jk2245Yv1agCoNe02DT5W155b656In3hn6dK4k6Wuv3MjWenF3c/KoHT8q799EtL/ABFaWkewfemfoP8AGtzR7i08L2jLZLvuBwCi5JNIDza0+EXiG7haYxxW0C/eZxjH0HerrfDx9MRS8vmT443DFd2fEmuX5PnSSJCDnYXA/Osa/uNVu5XfzggPGdpOB9TQBwF14bubSWSTLSTN3x8q/wBTWbD4bvDIZpYjM/q/AH1Jr1G1uGiQRiPzgPvygZ/Wopb23jiMstu0sin5ECZ5/lQB59F4D1C/k827eOOAc53fL+Fc9q8b6bdGMM8iodoIXCj6V6W/igQSsTbLJO3H72TOPYCs2/aDU0mkvo4/tGPlC9hQBwMGpxTfLOruemWOAKo6nZ28/EMRXPQKvLVa1ZXtdxhjAUHgkcfhWdpWqyxXRIi8yU9N3agDmNY0+WzZj5RUCsFGwxyOTXsupQLeafuuVR7hui9l/wDr1wGs6QgY+SA2OpHSgDnonVc8/N69cUi/NKCpA+tQ3EbQyFWoXagBbJ9qANgXUjqIozn1x/U1tadDIqbgo5rkorgq4I49q37K9cJxIR9OtAEt/ATIWkBZv0FUkh5A4yT1Hat+BoXgJkBeQ9BWVdRMjhgRjPAHQUAd/pkuLKyGekMf/oIryXVCRqt98uczv1/3jXpVjLi0tRnpEn8hXmeoFjql2fWZ+v8AvGgCS01Ke1s7m2VYPKuAAxkgR2GP7rEZX8CKqlGA3ADFOIZcZBK0qQmXIjbB9DSsAzc235F6U5ZEPPzBv0q7aRhVIkYZ96qzwtuJxx2NMB0c4Ax5aOPRuv50r7XPyDA/uk/1quAVzvAB9akikIGMhh7jNAEscdyh3RLIB6YyKmRLhyDNExH+zSpOY1O1mU/7Jx+lPtry4lfbK5cHpnrQArklgqqGz2IxWx4c8NXGqXip5C7epx6V0Pg3wncavN5jRDyhySwr2vw3oNto9uskdq3m4xkAEUAc94a8D6bYQJJcW4zjksM10U1ppUMPmzzEqo+VM4qr4l1hLcASFxt52D5a8y8Q+LBNIRGkoxxhnyKANrxTqFhNiO0d41B6PGePxrAsdTtrfd9oVplPAOMYrnJLjUNQbJSQx57VZtUDTCJrWaRj3AORQBtbpr65/wBCK46gA4Na1r4l1TSnMVvauZQNpZ2zWVCq2oVWglgl7P8A/WrYSNofLm1CGGRD0kTO78aALkGq6jdqX1FJ0LDqQVBrCFo0+p+VDaNPcseCVyK6u5c3Nikdl57xNxgMCK7HwlodtpcCXUkLtNjJJyaAOn+F3gu6gghubyGOA4B/1fB+leo3ykwmEfMuMDgV5u/xLs7KEW1wxtlQYBGAcVn3PxZtLhPJsHmx03hCWNMDptUtrQSYuZJFY9FGDWXJa2qEPbztFtPUt1/KueTxis6ljaPMf79wmBVe68X6tDAWtYbRox/DEuCBQB1L6hJIBFdTt5A9TtBqnqepaRax7LYW25uDySc1xUHiDUdTDO0s+e64Bx+NRf2vo9spSZZvtB6kp3/OgCbxAbOJfNIRt3ZVziucF66NuhZgnoyjP69K2LvW4PsLqseQ3RsZP86881mXzZMjLDPL4pAeqeGfFptGCy5Rc9n3/oK6bW/HdgtmMO24DJbp/OvE9J1xLaExysqoO7L1rN1HVru9uC8AiEQPBZBj8qYHo8PjlJrxmeJ5UH3VjPJ/E1rzaprurWytYWEFvD2aQ7yB715Il3dOgkkUzBOyAKPyFXNN1jxFNMP7OhuI4gcLGqlgfwpAdjd2ustOXlLME6yJhBV7SvFV/p7+WMMvQlCWJ+pNJGNSuNNVNRu72OUjlRFtH0ziuG19WinKeddLjnnvQB6Rd+KrO4g3PCZrk9FA3fr0p3h26gvnkBX5s8qvzEV49pdxLeaolvNdSCInBBfGR6YFeoWt3DpFuEt3SEkYVF5Y/gOtAHZwyRwqWZGiUdCy5P4CoBHFJIZpw5Q9EB5b8ulZuj2GqaiPtV+k8Vp1BYYLVvnT7O0i81bjdMwwFd+n4UwK9zfRpHtt7ZYkH97rVK6ZSimSQvK3IQnt9KmFuC5a7QkH+PoB9KhlWJYX+y2yiM/eklzlvoKAFNyTEsaASqvXYMKKZdW0l5BvuZ8R9ooVA/WrcVlF9kWSeOR8D5Il+RaguruWK1aOKSKHHXaN22kBgf2NaSb1tLTbcHgPjew/E1xeu+H7rRpjLLc5JOdpyzH8K9W0m9e3tfMaQbW4XK5Zz7Cqt/fs+5Tpkkkjfd3gA/rQB4tcv9oR3vQ4OMLkc/gO1ZkOmMxDBhHuPCryQK67xNour3cjy/ZDBB1O2uNu9QniH2G2X5hwT3z7mgCzfT29ioiLiQj72W4HtUwitr6zBiCKxHU4UAewrCvNElgiWa/ZnduVQHgVJYMElRVhfA645JoAzfEHhqUjfEMoOd+MCuOuIWhcqx6cV62zzX0giJVIwOVHJH1NcZ4u0uOGUiL5iOaAORO0Hg5q3aXXlHkZ9BVKlUnPFIDq4LnfEqqeTycVcnVZUUZBf0Hauas5tmF557DvXSacSUBK/LnoKYGnaS4t7ceka/yFcLfMftdzhQQZW/ma6y3k/cQ/7i/yrkbzm7n4P+sbkfWgB8UkKpht0bjt1Bo8yKTqrKR3WnLDFLaskcYeYsGEm8gqBnI29Dnjn2qCFFWTY5/OgB+7DErh/rT45XbOWKj9KfLaMoBiIP41BjB2upD+xxQA5o12nOW9war/ACjjdz7DNWJVGzCqwYevFNtdwmDbFBoASGzLsPnI/Cu38HeD73UryExR/Ln77qQv41P4O0GbXL+NVh3Lnnaa+jfDWg2+m2KwGVoox97IzigCj4e0O50yx2m3tt2OTGxBpmt397DasFJhHrxT/EfiK3ss2tnOJ5FPAU7TXlPirW725d2MrR542FqAGa3Kbm5ZJXEjd+cisl10+2XLRI0vpVG0iuXczM6KPU9aayE3JJYykngAUAbNitrOmUheNz0x3/Ku48N+do8BuFt4t5HDTDGfxpvw38IapqkwmiglCDngc/rXaeJdFjs1VbmaUSpwY2I5oA8i8V6pJqepbrgR27g8GE7gaxdZ1GcRJALouoHpitTx3cwwy7FAjcf3cZ/Ss3wJpjazrMSsuIgclmTIoA7L4cXelWdu0uuGQH+HJwK1fEXja12mCynmSMdAZMGpfF2qWelWgsoLK3klC43CMACvP7aw1HW5smJBGpznaDQB0lp4gllUf8SkXKn/AJasN5Na0Go3BK77UW8XZWTbWFCkOlxhZGuUP96N8AfhVi0u5Jpcxyy3AJ4DnigDrH1BnjVVtlkHTJHy0CVQDiNgT2QbVqhBPPCyma2ManoUG6lvL+yihd5w0g9OaALl3qtzaWxEMcaqeOnNc1Ne2AQz6hZ+ZODkDpmo5NWglbdaWShOmC+2obmytpmEty5Rm7Bs4oAzLrV3nYrBFHbxk/dVefzqtql3YxwKVnPngcoea1I4bGGfb5iO5+6CMirN/EljbZlsbb95/HgUAcQ10kvJLv7BeKv2CPecfaYoIx/s4x+dZ2qL9ndmG1A/YA80WcdrIg8yPJ7jNAHW6Slit6kP9ozTjPzEYVK+ifAcmn6fYBk0sysRxKsec/nXgXhFdNgdHZRFjktjIH4d6948E3tjfvEkd3eSL0BCbFH4UAY3xF8X7GbytImBAOWxwPqa+e/EniaK4uW8uFnnz0bO0V9d+J/BVpqlrIJ3lfI+7kkn8BXhPi74VWWkxT3VzObWIAsFc4P4k0wPJNJnuWvlcFQ7H+DAxX0J8PtG0yyQajfH7VchcgOcjPpXg1k1lb6iFgPmANxtz/OvZvC8YuY4jbEx4Hzc8D8O9IDq9Q1jUdVnbEZFqnAjRgi1Se4upVKoLW3C91Us35mtKK0lYiOPznT+Isu0H8KV9MhQH5WVj13HpTAgtZo2twJbqWVx/sinRMrSqwQsQfl3jvUZtbqNx9nlT28wf071J5FzJua81Eqw4CRKF/8Ar0ASX0UsjebdsAoGNofGBTFggltt7CNIE5CJ3PuaqrbCKQPPHLOP4Vd8L9T61cmMrIvmQxRxDoqc4oAq25mYtNbRqrDhSx6VVMd+iSXDQiYjnfz8x9AKvKRJGwG4RfkKab6S3TMswWAcKn/16AOfuI9e1G0kjukSEScADqB9a5W/+G8mg2zapeSBn+8DIOn0FelWmvpCWuJojsXlSw61h+KtVm8S27s6jywMICePypAeNTA3kzyMru/RSx4FZF39otZxEGOW6joT/hXRXCvZ3jL++uZ+gjiTp+Pao3s5/Ka4uLcIx/hHOPqaAKtjcRWmw386rn7sMY/nV7VUsbvT3lWMcjhj0/8Ar1y8wQXTSzAsR0U10mk2n9pWZcKS2MKW6D2AoA8s1iwMMzugwpNZcYJbHrXeeJ9FniEhKMMdWbr+ArhUBWYAg5BoAtxjy2BZeO5zW9Yah8qrHHknueAKy4YWkAJAb27VMq7HG98HPQdqANGGX9zF/uj+VY9wWhuJHjAcEkmrqPiJTnoor1Twf8DfEniCztr5GjgtrmNZkZ+QVYAj9DQB4u8nmfMqFW9qhdxJn7SGB7MOa+p4v2cLxIT5l7ZySAfdUFT+dWof2fdOWNUvdQihn/iidwpP0NAHyQJpIz+7clR0NWBctPjcF3D1r6uu/wBmjTLhf+JTrypLj5kdQ4B/CuB8Z/s5eI9KtnubBoL5U5Ih+U4+lAHivlyOBuYYqeytXaUbQvFaC6Tc28r2dyr29ypwUkGDmt3w94a1JrhVmglKHo6LkUAd38I7Oc6hGbQ5cdVIwD+Ne367o5hsUnnhuYmfrk8GuA+H+iXGk3kVzEpjZDkqV+8PpXrXju+OqeHo57WXbIoO+Mc4P0NAHiPicWEcrrFArNjLbgQfwNea3d7CLllWN254DN/jXbXsSRXLzalLujbsoxiuJ1nUoo7too4v3BOULpQAyeacyJG6NFG3Q16T4A8Gy6lcwTyCIpkYznmvNxqEYVPtGWX/AGOcfhXq3w38a6PYhI7m8aFVxjzARmgD6I0iyh0PRJITJGsgXqjZz9M14z4/l3W88m1UkGT5h611GqfFHwv9kMdgyy3GOTIDz9DXhfxC8UJq8pEXyDuATTA4bWmN7fkli5zjcea9D8DwvZaYSjPFuHL7SAPxrkfD0lnDcq1zCXX8DXd32t20liII7aSFcfKAcBvwpAUdQ0yO7vBvZrkscAmWt230C2tLIDbJDJj+GUgGsvQo7Fwz3kTRKO6E1Zu/sqMGWWf7L/eZycUAZuq28cCHzbGNw38W/JrNtZIVlVYoGgbPUEsf1rc1KOxuo4jZXkTn0c81lz2gt2Uy3BJPRY/l/WgCxfy3O1ALy4f/AGQQMVY0+GcR7zK6E/3o91VrfUGtHB8lcHoSxY1v6TqT3bCNkEqtwRtxigClMks8ZE0a7R/GqhaktbRAv3IxGerHBNXdb0pbKP7SZG29RH0FVtJ1CdB5q28TLjhXNAFQ2bi+EkEdqyqPvHk/lVLU5NQvJilvcQpt4OVHFWLm6uLy/ke88u1gHaJe1VoZEu7opALiSBemxMZ/IUAc3r2nTxIXZvPYjk8Vy8ErI7AeYG74Fepa5C8cC7bKaJf+mnGa861kxpOyhMN3xQAWGpzxSbY3f/dK5rt/DHijUbe4UmacKp+6jqgrzBWctxIQvoorZ0nT575x9kjlbHV2OBQB77N8UNUishFazQxOerSS7j+ledeOtdl1mDfqeoPcOOiICFH51zC6bcxzkSs647qC36mtGz0sTtieUon95yMn8KAOchjwweNGjX1716N8P9bktb6JPtKxW46q3JJrltUtreGJo7eV2PrtxS+BZXTV41AJ+bqAOPxoA+k21l7i13NOLWEjmUjBP0rIaeN5x9luJpwDyzHrUCafBd2yzahcMyqMhAeBSQSCRzHpkDBF6s/Q0wNy2mlKltiKfXqaj8+ziDyygNN69cUxLWUW+5pUiP8AFtHJqNdNsJo919OViXkqWxu+uKAM03n2+7xp8Uk5HVgCQK2pIr2WBY3gitoh95pDlj+FTLfxJAtrosYiToGVduau22kxuM30h39T8/SgDmZ7Y3UyrGJ5EXoT8oNV5LMS3GxGVGXgux3EfTPArc1sNcOLbTpdkScFl5NY84S2h8tRtC8sfvOxoAZLY2ZdUd5ZyvZzwT9KyPFFlcwW4aGQIO0Ua9q1lupZIt6IIlHHYsf8KqG+nuZxDHGkjDqQQSPoKQHAakzWsLTSq0bEYCr1JrmX1p7Xc0tlJNI3KiZsKPfb/jXuUuixi0ee7gSM4zuc5b/61eK+L7AxX006MVjz8pbqfpQBxmozSy3RmuiPMc8IB0/CvS/hwEWPfOQgI5Zjz+favOLhRChmmyc9D3Ndz8LbiC41CMXEZY5+RSM/kOg+tAGp8RNHmuIPOtkb7Oem1eWP+FeGX1q8V8QyAAHnvX3BqGkQX2hP91iVwyrzj0ya+UfiPpn2DWJYFATnkCgDlovMkOyLj1x1onhSAAucuT0FW7NWWLZAuP7zEVDJbyXE6pCMnPJNAFJpP3PX+H+lfd3hPX7eH4eeGYIbh4LgaVajeANpPkrwa+Bnk+Qj2r6n8KXtzJ4c0Uskc8KWMC4U/MAI1HSgD1k6E2qP9pn1JllJzuifr9cGnT2sVvIIZb9rhOgMyhgPxrh2tjqUJGk3fkXS87PMKP8ATBrltam11ZTCb2QSr/BONu7/AIEOtAHtCeH5bmHekgjP8MsLfzFMkbWdJtyRe/aFQ8K/pXn/AMNPGsmn3DWOtkwTHhSTlWH1ru9U1m1kXCSLKXH8LYNMDzL4h6HpXihJbw2wg1EdTGuOa4PwWb/T9UNpHO+3O0JJ0P0r12WONnZcNG56Fz1rnLzwpG18JwzqxOSq/Mp/CkBb/wCJgLpWYyRMO4jyDW9JefZtNfzmYkjktHV610xLTRDLv+fsN+0/hmuB8S3xlcwzSTqh4LMP6imB5p45uklu5DAVyW5VScH8Kwl1i2+yiK8swWHAbJrd1PStJmusG7dHz/E2QaxNW0toJU+zxCVSeGDUgM7e8r74kjdQeFzzV+GRo4j9qsFmQ/3T0res0t5rIQ6jZRxvjiRGxSnStCgsWkN64m7KJR/KgDm1dD8yPLCq9ExyKp3+pNIwVTOxH97vV17wjdGFVo+zHms+8JuRhQn/AAE4NAGtoF5DCwMyMrH1AYVpSXD3N0FtCu0nnaOa5G2ma2GGjfPqeldb4Lt5bjUY5l42nOOKAPQvD9t/oPlGWMyEdGGDTLzTYLQmSQzSOOdjcrVnVNQ81UhJijmUYVgeRTNPn1UH95cQtEvd1zn8aAMrVrm1NmjrbrGy/wB2KsH7Yt6QFsGlI7hSoro/Ed1ZOP3jBZvWLOKwrB77dmDUoUh/uyA5oAiWOaOUbImgz/DkNWzaTR2kRadJ9+M5UgVCHsPPH9pXu4DtEpGa145bCUbdLAhGPvyx7iaAOc1LxTpsimC7gvJG6AsTgVHpOqW9vITJDcvAegVc4qfUIGW5L3CrcD/dCio474KVWBUjOfu5wKALFxK13KXsFMMXdmTJoPiS40lNtmFuZQOrJgA/nWrDaz6vb7V1BEA4MUSjJ/rWZfaLdWcqw6dEXY9SRzQBk3mo6prhM+oTuMfdjRQFFcvqFi7TM91PhPbg131zp0lpabbtJInI5+fFcB4i2KxXeWHopoAk0y48OWE4e/ikuFH8Cnk16Bo3xR8OWEXkad4bAJGAzHJ/IV4bdOqBvkIrW8JmVrlHcqkYPcUAettczeKb4SNaG1gPb7o/KtKTStPsWX960kv91ecUmj39tJbqlsUZ8cs5xUWp6nf2wKQG3jTu/UmgDE8SzIyFAxijxj5Uxn8a5zQ4pYL4SQ7mGep4rpLq4SVd92Ax/vOQB+ArLkWKVtttHLISekQzmgD0+01F7nTY42CwDoWDZJrf0q6NvbeWnmEY5Zuprz7wzpl2yiSY+Qo4VW+Zv/rV2cOjaosRe3l8tD1kZdx/CgDRjuYEk3zuz8/6sA81Zk1SW9kWC3toI0HXYNxH1PSsie0NrahLu5xu6Zxlvwq/o7RQxhpHlnTsoICj8BQBuRXtvYwLv2LKeNz9WPsKJ7myeDLmWWVv4AcVlXkTXBMkcRiB6HGWP+FFopgQqQEHd5OtMCS4aRV+byolx8scbc/iazvsUk8mbiT5f7qHFaPnojbE8vL/AMR+Z2+gq2loixFy2DjJz1oA5u/jtlVokiaQ46KDgfjVnRdKTTLJrqcpb7uSR1NWLlY0AkmkEcYPCKeT9ajtTJqshjt0bYn8bLwPpQBMLqC7gbzFnaMDguMA15V43s5Li9e4x/osfQMMDPtXo+sz3MTi1t1yvRpGIyfoK4vxQ09xKkBVIrRPvZ+ZmNIDx7VC8speQ/KD8uaveD75oNViIfaoYbmJwAKk8TtHNdeXbxMqLx0xWJDDJFOu0gPnjPagD6z0nxDANGEduwfK8k9TXhHxMSGfVZJgyb2PzEcsfxrofCrXA0UxRM085Gc5wq1wPiWRotTaKZlZs9F7n3JoAy47JzHvc7Y+yj+vrULxuzCKI7VzzjjNbdvYi4tw894qL2RTVKS2SOUCNiRntQB5278sK938L6rLZWulu8bSQi2iG9cnHyDrXSaD8LPD2peGtNu18NLcTTWkUjvFeShmZkBJxux1JqR/Btra7ILFbu1mjAVYXkKsAOAOetAHWWuq2d+kTJlZsfK2Ac0X7pKjRapaiRT92ZD0+o6iuUNhrGkgTTrIkCsBymX/AN7gYwK6/TItS1i3UkQ3CAcnbtYigDhDcCz1MxiUGPP7sSH+prvrCSK+tE+3SeSQOCqj+dYHi/wzc2lvkWshDc4Pasbw7fy6eDa6it0kLcAgZAoA7jfboTE0i3Sdtxww+lTW10QpWJZI2HQPzmueWyErCSJmltz0decfUVZluDYhXjv4JR3jdtrfhQB39gZrjTGjukZwRwy4IB9wa8/8V6UIoZGkt1c4PzKcGu9+H2t6RdOY5LgozDBjk+6f6VlfE7RH0+1kvLZYJ7VskAdR+RpgfPeqpIgbdbs391ivSsrzdREJSQZhPTAziurnDyK89q6so+9C+TXM6jqsWWAtPLYf3HxSAp/aSImRndj2B4rH1FkCjMQDeu6tAXcl6CqxNu9zzVFrOWS5CEDn+92oAk0hBJkyBmHpmrFyyo/EQX6da1dNie2hYNLbqAOhUGsHVLphcHcnyZ6qvFADrmaNoxlZc+5yK7b4bMqTeYF3AdVJrh2lgkt8YG76V0nw9E8OpIQkckZPIegD0LXljuZRJZW6pIDySf6Uy3u9S8oRXEETQ452jBrT1mwtPIEkcIWU/wBw1jI6xJskjkHupyaAKGqaTbXLGSG7dJu0cj8fhWW+k6qygeWZE9mAFbtxZWsyb4hcPL1HmLgCoIWuLZv9cQe4UbgKAM5NEuioP9nMW7Mrlq07BNW0/wCQW1xGfaMH+dWDqF4/yQ30qAdkUJUb66kLYvLmR5PSQk5oAhuoZ7mTN3POc/w7QT+nFZ2r+F7y3jF1b/axGef3mP5CtUa+spAtfKhGeWNaer+Kol0oRwATzBeWZSBQBS8Kajf6bF8kCRnH3/Lyat32tSzXHmmeXzl6ADGa42HxFdSuQ5Vf90dK17W600RefdX7NP2TbkZoAqaxf3lxKW1KUpH/AAruBNcXr0sZyUGT6lq2PEU63m6V5SqA8ADHFcqZLfcSqs7DuaAMl7eSeUfKzEnoK7bw7YLaoj3cRGe1cyL0xzDgp6Yrb0+aW7kAbUJFHpigDqnuELbbY+SB3xzVyze1mbbcyXNxJ/u4FZCXltYFViUzzH+J+lakN+8sXLKmeyptoAsNp+l7ybhkjz0Rm3NTU+y27YtZQijsOtZNxAryEyzKo9AaouqiTZbs5PYAUAdjp+uS2Ug8tPMOc5Y8CtTUvGl7eWhihugmBjbEMmvPLOOT7R/pDqecbRXeeHdLdwG+yqI+2MZNAFbwr4X1zxJfme4Z4bYHJeZzk17Jo+n6Vo0KxK7Xtyo7D5VrEi1y30SyAvIdvGBGvzE/gKy/+En1C9m3WVg9vB/ekXbTA7OTWM3HlrAWkPTcMItY2uzQXE6wtP5s3Uqh6f4Vz95dahfYhSZbcHhpRy30UVpaL4dlt4P9GtpJC3LT3L7Qfc+tAFqyZYct5sMKjuBuY1dHkyKJLosyk/Lu/i+gp0dmihfNubYFf7i8UySaBdxiy7DgysOB9M0AXmXT7e3NzdhFAH3Ty35VlTeIXkjZbRBbWx4DMNu7+tRXMazQkoQkQ5LHktXPzXbw3SrDAJ3/AIQW4X3NAGmJ9+5kiJLDm4mGB/wEdawtYlWG0aKNgJH6E8u/5dBW7ZTSzHJjjlnPHAO1fxNO1uK2tIC0mz7U45KgfLSA8Q1i2a2kZ5kJc8gAYxXPWAWW+5z17f4133ieCJ43MTmQ92bp+ArjNOjSC93TkMAehPH6daAPTvDMiWunu4faoXl8cfnXlvjKQPqMksccmwkkMwxmvYPB8kV86+aobA+UMPu/Re341zfxa0+GORWRDlueB/WgDy/TLiUMNse5uwY8flXQ26o2Wu5fMfrsThR9TXKO0kc21cqvfHU1uW93vgSJcRoTyFGWP1NAH1B4E0y8s/DGhXGnzZ8zTrZyjHI5iU11qWEt9Mr6vpscigY3KwNT+B4LdPAHhhy6qx0q1JB/64rWwoDqGUB/TBpoDAu9EiEbJZSMUPWCY5H4GuYitjpl1siiWLLfdyRg16FKqdXQ47t6VTvYA8B5jlX0f/GgChdhr/SjDcqHJHBzzXm95ZJaTlLreYc8F1LAfjXX3MRgfc6yGMHIXccD6EVJMbO8t82yTrIeqggj9aAOa+x2z2nmWU2x/WNuDXOtp8EzyG4AeTPKSqDn6EVd1hJ9Nu3CJLMG6xkBT+Bpmn6xpakLe6fNG3q2CaQFK1uBY3ANlM0JU/6qZCyH6HtXoemeKLDU9Pay1e12MRgPGnFcndQ2NyPMs5mhGP41wKx7SW9t7n5riOW3B6xkN+lAGT4z8PTWWoPPobMY2OSGTp+VcjceH7y6cG4it5Wf+42GFez6XNNcTFrOe3uFPBjcFSKyPE/hy6llzZwW9tOTkMWwc0AeY/8ACufEHliXT7NyOvLDNc/qmi67ZXBTUbG4jA/iH+Nesy+GfGNpbiWTU5REOht35H4d6hsLfXZCw1OdrqBf+eic0AeRtbXEcDNIpZf9oc1hzTFZDuOMdBmvc9T02O9t3WGz8sqPvdjXjfim3W2ndWXBB7AUAZcs5POf0rvPh80NzhGlKP7jNeaWqGaXg5X3NdxoQls/LeJvLAOSwGaAPS7ieexlAHmMPURmtCJ7G/iBnZ4Zx0JXaTSaPqS3dipaUXBA6KOaz9Xv5klDWsFwMdigNAAJns5ZFWSZkPdhwazr+W5cfukVF/vk1Xv9Wa4VVnklVx/CVAxVGO+kichvOlQjgRnFAF+zsnZy73AL+x4qSWygSUSTyJJj+ErWZHLE8uTDIGP94kmpjpF1cyL5HmnPT5ulADdTvoUK+WqxKOwXFZdzqR8sgTZB7AVuv4VvAm66Vyg64asK4kstOu9stqzKp7mgDLt7O5vJS0KMU9cVbP8AoIwI4pJf9sVf1H4gWsNr5Gn2CJxjJrj5tflnkMnlqpPcCgDXurtZoyLl9v8AsRjArGWONpWCbEX1PJqBr7zj8w30JKc/Iu3NABParvyrhvoKckU0fzRD86Rt2d5Zs1PFckAbiDQBs6LeSQ8zFc+m3NdjY3VvdwHfER7kYrkNHQTSg849hW/ObeEAPN/wHOc0AOukswTtUDHpyfzqOOIODiJwh6N0zUD3VwCDBDGB2JTJp8jXckXm3E7yMOinoPwoAsJoNw0wkiAUDnJau40ufULOzG5rSMAfeYlz+VcRZatM37swEgfrW9pOtweaIbiEpnqSc0AWTrzfbtxEt3KP4iAiCujtiupoDdXUSL3EROB+Pesa6spNSdV05rZUHUuc4/AVs6fBdabCoe6t5Hx3AUD6CgDf0g6RpKMbVC83/PWYdPzq0lw15KXnvWdD0UcCuaSOfUJT9pnDemzgVqS6dbRRLG07Fz/DuyTQBaa5toZNsZWZgeEjG78z0qO5kkuXQTWkhA5A/hWkjiNlsKKkaf3m/oKlvNQhSEuJHGOrnjJ9hTAJ4ZpogttYAtjAed8KPoO9c82nXdrdGS6uI2djxHEMCtnTYb3UFebzpCnbPX6Uz+x7jMktxthUfxFtzY+vagCOLVbfT5UinQtIRnbGP5mq2pXljqYeMSKZMfMEPC/U1QewsJp2zczXDucFV4H51rPolollti2QJj7qjkmkB5nrtrCGco7SKv3c/drhrghrjbAec/wj+td14wtJ7eYorF0x0JrhlMokYRKC3+yKAO48D6glhMBcyEKOQi8An3Per3xG1y0vLIbpIozj5VHJ/KvMZmvISSzHd2GeBWe0U88wLEzS/XpQBYjjh+aRgWJ6Duasacpa5UmLdg8Rp0H1NJa2ihx9qlDkf8s4zkD6mteWRYLXcoVUzwi8D8T3NAHvPhfx5BH4Z0G1LxLPDp9tF5bfKxxEo6Hr06iuutPFlthTvktz/dlT5fwNeC20seoaVpP220jlSK0hQMhywwijp1/Kti01FdPjEcb+ZbH/AJYySHj6Zp3A+jdK13T9ShYPc26so+bc4ANXhYwXEO+0ERU8ZBGD+VfOcFtpOrYltjJaz/7DZGa2dO1HxN4bO+zmlvLQfeTGGA/rS1A73xNoWuWTtPpEG4HqsRyPxWuIubvxCswF5aLAw4+4QG/wrorD4nX5UHyDIw6xPGQavzfFWyMYTUdJlBxykiHB+mRigDgvEc9+2nhvIcMOrK27Fec3N7O8/wC9kjmUdiCDXsGoeJtH1cn7NYEA/wDLPgEViTWOmsS8dpESeqt94fgaAOFtLyTeBaHym7gylAfz4NTagHjjM11pqb+vmW0gz+laGpQWAn8sbIG7b2wP1rIvrVLdWWQTPGwyGgw4H4CgDS8Ga5CbnbND5ZzgMwIavXYVi1GxBSSGUgdGB3fhXzfFcx2l6HtbssQfuvlDXunwt8U6dNLDbX8zI5GMv2P1xQBs28EyIUjvJAv91l4H51x/ihHtJG/eGQN1CPtNejeMYWgIltj9pt3GQwGSPxrgNXsbe+tmZC6zdt3FMDgbzxHeWSPCsgWM8AS5z+deU+KZHubp5WkTJPY16f4hiMcLpfmA7funOa8v1hF3tsUN9DSAxLDKXAzk16BohEsQVtig/wB7OK4C2UiX5uDnpXX6I8uAFI+gNAHR+Xd2koaySL6xSf0rpdO1zUfJCXMKEf3ytZ+kWhmTIuGik9CgNb1hpNwVLSXJfHRQgANAGRqE9nev+8hVGHVhkZrnbzekpW1Pye9dBrmoNYl42hiPvwTWFFdaZIrPfMwPXarY/lQBJYwzzEDCKfUmuzttTsNEst99f2yvjopJP5V5VrPiCCMtHYEonrmuYub3z23SyM59zQB6L4o8f212WS2lk2f3s4zXn+o6z9pclMn3YmqMr7vQD0xSYB4CkmgBnnMTl8Ae1KJk7n9aU2znkKKkj0+Vjkpge1ACfahjC8fQUR3En8O76k4qY2Tp1Vse9QyHb8pIH4UAWYbncxEnP0NTgqCDHx9ay0ODndx7Cp0Yufl+agDobG8uSVRPlHqtdZpqrCokWBZJD3Y5P51xFjvXBYYHucVvW1+RiMzoB6LyaAOl86W6f968cQHbNRPDK5Ko5kX/AGeBWY3zr8h2Z/iJGaktQyMFXzZvXB4oAupiNhHIwiHcqQTWjBPYuDEu2RvUcmsDUIFVSzp8x6LnJqxoFu6yB9wT2oA6nSYd84SFJ5FB+6HCL+Nd9YadcPCDKtnbJjsdxx9TXM6RbKAjRfNIe7f4V2KWsAtwbkl29DwKAFTTbAOFhuDJMerA9K0ItGsYB5vn/vccs56Vyt3PHFKRE8mOyKdqj8q07DUIUh/fvIQeypgfmeTTAvvFaOxSOSW4uT02jOP8Kr6npkvkBUe2t27vINxAp0d60v7u1ikgjPVzT49NSeT5pp5s8nI4oAzrW5t7OPyLe4mvbgdl+VB+ApjtfXCk3krxqeiDniuigtI4pQIljTHUkc0O9pC5kupQV7LjGaAOSsrOaa9O1XS3Tq/TNXhLJPOY7UMsKcGQr1PsTWvc6lYxRYm/dxN/Bt5b8Kr/AGoak6W9hatbwdN0nBP0HWkB5n48t443Zt5YHrznP+NeaS3bxOQv7sH1HP5V7b8TdPSy09YVVvObknGD/jXi7WJeQsI2fB6scL/9egCByHty+WZj1Y8D8+9YkjyKxUMwTv2BrXv45Yk3Njj0+6KwZZvMl2r19T/hQBq6S3mSqGyyjtnCitDU5xK6JDlsdMdBVCxhihUPe3Gxe0acu3+FXHuTMVjtoPKjzwo+83+8aAO/0o21pZaakys8clpC24LnBKLnkVv2qwSxMunzrLjkxNh/0PNeZQasZLO0i83YqwouBlSMKB1rZ0a6S2kEs6vcRZySDhloA7bTWaS8WNlaxnB4aP5SfwPBr1PQk1V7TypJba/hxgq8e1v0rz/QbuyugJbadpY+8bjOPzr1nwrqiLaD7PBG+0daEBj3XhG7usvpMj2U56LIodPzrlNW0DxvDLi/FsYV4Eixbl/TpXot/wCN7aFmS4t5reUH/WINwz71mz+Nbq6Xy0UGM8bkB5pgeX6noGqXCqrtp5b+8AVYVSXwNrTlZFvI3x0w+cV6BeRJdfvVnbzhzh1AIrMvZmt4yz6nCmOdrKMj8qQEVj4N1GOzD39vaXUWOefm/I1x/iuw06xLNaKLadey5X+VXNe8ZzWlsyQ3qSL/AHkfP6GvJNW8SyS3Mkn2iR2bqC2BQBZ1W9ilJ84xO47k81Y8Pa41nOhV3AH+0K4K/ummkLYxnvnNSWzNsyHBPpmgD6X0Px6ZIEgkmZQRjEv3fzFa4vFuHBcwEN0ZHzXzJp+p3dqw2Biv413WgaxeXDRsLlFK/wAJNAHrXiDQLi805xGLV0I67ORXz14u0prS8dPl3A8jkV9C+H9Rl1CDyneNZMYOw8mvMfijYRW9yzSyEyHkbhQB5dbWe4ZIwa2tFVkuFVWJ5/ug1Qs7wCYI6Bl9a7fQ4LNnR/LUP2xigDfsHihiRnXc/ptxWhf6pMlmxgRYwB361kajdMjRoQQM8HFUvEaTxWP2j7QDkdA1AHD+IL53u3Z33MTzzWBd3czLtRzU9/KZJWLcnPaqg2nqDQBCtvI/zOwP4VYjgIHJX8qCSOi8VLDKqnmPJoAhMYH3h+OKfGqg9anuL75Nvlqo+lZjXKeZljQB12i2EM5HG9vTFbk+jmKP5kKrjqK5zw1dIkisCM5rvbnUVezUMxLYoA881mPyiwRmx71zbozOSVY11mtqskjMME1z83HAH4k0AUCzJxj8zQZJB9xwv0NOmA21TOc9cUAaVu7fxyOcdquxvjkFx9K58OUOfmNaNjOGPP60AbSXkqY8tWJ9WOa0LW9v2+9OI19utZfm4QHt7VpWvlGLcSM+goAtsQxG+4kdj6H+tdZ4ajghdHniG3OcsSxrmdLjSSYGZtkY79a6uDU7a2QR26qw7u5xQB6FaeKdFs4dqo4cDGdmCfpThrH20NJEixJ2aQ5P5Vx1i8N9Mu1V2+veumt7ZYo9yxqxHT5d1ADbe9hW5cMsk75+83QfTtWrb6nFbsHaESv2RRk1hGNru4PnDCr23YA/AVZjuoLQ/uYw+ONznAH0A5NAHXWmp39yoVbW3tgem47m/Stm0tL6KIOzqyt17VxCX95LseMFIx1O3YP15rorbU7nyNvmbB/eH+JpgWtRnntNzw2oLHuTjNY32u5lffLbwq47ls4p7WrajdBRdSuT12tmtFLGz09vK3GaTHzADdj69qAMcJNNLljGWPoOldZotrDplnJdeYv2nb8ozls1zmpXVsbhVhYRsOvPP4VveHbpWt3itrWS4bHL9APqx/pQB5T8Qr8PNI0vmlmJ3OTgfmeTXEaX5N9eLEjYycdMmu6+LNvHnMzBH5wqD/JNVPhPp1mZjOYxuz95hk0gIPFHhiys9DMhDNKRyzcn8OwrwjUofLvjtkxg9Aa+jPjTqUcGm+TCcHp6V8+WkPnTtJIOM9TQA20jw4aRyPX1rVF8igRQIQueWz1/Gs68ZVcAEhfQVLbbZGRMKkYPJJoA9V8J+EtJ1Ozsn+0XEMzQRsyy/dJKjODXa6B8Pm07UfOjkaeNuiDH9K43Qtc0+HR7GOVLiKZbeJcseDhR0P8AQ1tW2vajCnmaXPHMF52q211/CgD1jTvBeXxDBLaliGYbdqsR39DXR2+iXOiK06XEGVGSj9GrxK2+MXi3S1IaJbqJeCs0ZDfnVbWvjzqWpW3k3GkCP3U55+uKAPQvEfiFJLlvMt9jn+JQCPzrntQ8TNYWXmC5RT2Dx7h+leQ3vji8vJGZZXhJ7EVz+q69cXA2yTZPscUAdrr/AMQJZyykhMfxRniuE1PxHc3LsReMUP8Ae5rBnlZ33PIR9arsgk+64/nQBbuLtpM5n5/2TWXctIpJRtwPrUxjVBnd+RpjMpX5iWH5GgBkL8fPjP5VMkxQ/KAT6ZqsDFnCkkHs3ao50Ucpk/rQBuWup7Ttf5fY1rabqQgulcIrc9AetcXBINwDj8c1qxSFQOhHqaAPpHwZ4lsLuwWKSCVJQOCVz+tcb8SIbqdmYmZ4+2VBrlPBl28d1HnzRHnkKxr0HxOI5tM8yzuiWxzHKR/WgDxBv3Nxhg+c+leieB7c37ojeW49GGK4W/gLXLFgVOedprsvATf6VGkM+x892NAHqN7oaWdiZI4EJAydprzzXitxbOpYxsP4cV7VHGzaauCXO3nBzXkfjW1AuG2hlbPcYoA8ymtisrHK4zUMsJfjI/E10U1i2MuE/Mmof7NlkX5LYsPVRQBzT27KeGXH1p6rgYJP4CugbRZChYoUPoQayprLY+GVs/WgCpIBt/irPmhLngYrXa2cDo2PpTDEMcg/iKAIdLJt2GDXZ29/5tns3fNiuTiiOflq/DIygKVz+NAEt0rZPykg+prIu0AzyB7CtsxmUDHH0qhqMRRcbQD9aAMCUZ/i/Cq7KR0Aq6y881Vm64U0ARZyQGxVm2RVOQcVWBA6AZqeJieBnHqKANSNyR1B+tXYJiq9vyrNt+APmOanJJP3m+goA1ba7ZXBYZ+orSW8R5AVdR6kjpWAiSBRyEz68mphEVA+YkmgDvfDRjnuAInDN1LHJruBePFCc3HlgdyK8v8AD9xFCVRZQG7kmu/tbeO9gVYiXPdsZoA6jQUbVY9ol2xd2IwWrVn0uK2OI5I1x3xuNY+k6clsgWW4Mf8AvPitkRhQGgl+QdWPegBbGCSWX91C7EdJJzx+ArQl0wZ33LCZuynhRWfFqZU7YpUB6FjzWtZzQuOQ0sp/iboKYEKzLbjyU2xg/wAMIxn8avwIvkELEsSdyTkmoUtLSa6DNJ5k3oOi1a1Way0+ALKXnmP3UX/CgDI+wWUt6GSFpJWOM4zXob+Vo3hd5ICpkK43sMBciuQ0F9RvpAscUdlBnkt98j6VL8RNTTT9K8mKQyOi8EncQfoOB+tAHh/jK9kvtZlMiyXAz9+Q7U/+vU+j+Jf7Ng8uIIgAxthXk/jWVdQXN5cNLMjEsc/vHxmkuIbaytmlur+KNgP9XAMn86QGB421O41GdpL1/LXshPJ/CuO8xVU7cse2egqfVZ1u7tvJ3bc9WOSaiEMix5C5X1oAqbSXJY5Y/pVu1aGJ1K/vHBHJ6CqV1/tttH90cVAkih1CkkA9uBQB38cssWnWuxCUMKZVhuH3RVNr1ckRSSRy+iNVvfHBploBMyOYUO1uQflFZkyLcgkxxSMPQ7WoAmTW76L5DezAej1BJqJkkzNKoY99uM1a0bxCdAS4jfQ9J1ASlT/xNLUz+XjP3DkYznn6Ct+w8SeE9R8K+LJvE2k2FjfuLZNMg0qHyiJQJMuAScL93dngjHfFZym49B2Rxt3eKV+ZImPqOKxrmQyE4jYfQ0szq/KkOvtxTVYKOFbHtWgig5Z8qTimC2UfNITj2q8/lnna31FRkqfusfxoAqtHGOYmYH3NR7h3LH6CrRDH7oH86iwo/wBYgJoArlmU/IDj3FNZlByQdx7VbKIw+TA/4FUTq3QqDQBCG3N8xIFXLV38xVDbl9DVQDDcgg1MqoSMhs+oNAHbaC8drNG+6RPXa2K7281WG808IkzZx/Fhv515Jp13dQEBIiyf7VdDHqUXlDz4RG2OoagDP1xxHIxDr17Lirngu9YXyMU8z8cVmalfWbkjDs3tWfZP5VwJIi6DPbigD6z8DX1tc2wW5tZMY6gg4rmfiJo1u9w1xDK8f+yVOKq/CPxGRGiPIrlcYDJ/WvX9c8nW9KbyGEc+3BXZkH9KYHzbBGkhKechI6cdasQ2TbstKVHuMCjX9J1DT9Wk82F9pbhkTAqyHKwKZ7dmA7nP8qQE+wRpj7ShPbIBrl9etJJCW3o3uK32mhKZSFV/CsPVJixOMKvptzQBydwJE4OeKplyODn8q1L1wQQBz6kVlvjnOc0AJ5gI6mnJMF/iP0xVOR2VshsimiUt1xQB01hJHIgzjPuatT2QuEPlIG/GuZtrjae+fauy8MOsxCkDn1oA43VLZrdmDLgjtWBI+CePwzXqvi3SMRmSMDGO1eY6hbukh+U/gKAKJJJyatW8nYDP61UPX/GpI3K9z/KkBswYUcjk/hV+2A3ZABb3rDt7g5w3H61pQSHgqaYGr9nlb55Cqj1NO82FPlULI3qelURIWx5jMRUieWehYCgC/EyEjLYPogwK7HQtTS0iVRcE5/hDGuFRlHyx72J7ngVpaW5juUAG9s/hQB7HosVlMUmnjkd26Y710t5FO8ICLHFCB/E2K4vQZnjiR5LkBhjCKvT8TXTJeNdbRMYyo6AjJP8ASgBNOtsSn7MYpHPVySVFaVwzsvlR3Cyv3WLhR+NUnuC/yTTxQQjjYuMn61ZVoIYgRKu09AOBQBNZPdW6CPfEmegXtWtF5duoYsrTsOXIz+VYsE2X3RxSyE9wuBVkXcdud9wAG7JnLH6CgDqNMuYdOiku7mYFscKVyT+FeT+OfEdxqV66W0U0gz95sD8h2ra8Q6xdy2xjgtzbxEcvKwU4/HmvOL3XHhdo7cIfVlGcmmBnXsd23+sXyE65Zslq5XWpFTKmTcfat+/upJVaa4dicelcJqt2885SI4HcikA63kVJNzDOOi1cuJ55UztKr2B4H4Cqmmsyn9zECw/jerrPPM+A289yOAPxoAypLaQndOwUHseppYlRCoK5OegqzPhTyd3qRVQykuAkZxnt/U0AexWs0E/h6wgvoI5FFtEFkC8j5B1rjtVtkgmIicbD0yK07Wa+bTbRYyJEWFPlPUDaOlVrlhNGR56bh1imXB/OgDCuBLGudxx78is508zJPlEe/Fa8kzxqyInX05qnsbrJBGwPtg0AYk1vJCxZANn1zTGORknHuK2JzbYIKbPbNZM6xgnYxI/OgBu7aMhufWozKSfmKfiKhaREJB6+pGKjLkn5Rn6UASM6buAPw5poIzxwKhkkB4YEUqN6SDPoRQBKI8ngqTQYiO5/Dmomk56Ln24pUkyeSQaAEZOedwpyMF6MCaHdh2yKgdsnI4oA3bGVnUArn9K6fT7Kzni/ft5Z9+a4SC8miUYIIHvWraais6YeXY340Aa2qaTZqx8uZG+gwayFjSJyFlYj0JqWbDL8k/ze4qqSVYeZIh/3aAOp8NapJYzKYnCnPc17h4E8XmdkinWZs4BZHOP1NfNnmgDKuMj8K6Twn4juNMu43wXTPIDYoA+l/GGiafqlmLiN5i2M/Pjg151DpwQMmd4B/ibArsPDPiqDUrBdqlSRyoIc/rUl5LD53mPceWv9xgBmgDy/WLLy2Ywqo9dr7qwJIzhjIoB9cV6Zr95ojRNi4/feiVwF0iSStsbC54yaAOS1BDubaR+VYs7srYFddqNoRk8sPyrmb2I7jxigCi6g8sxA9qrOQrfu8t9amkR1HQNUtlB5r4ZQg9aAIYRISDt/Kun8O3pt513YX61TNjEqgiXJ9hSwxlG/d7ifpQB6NcXMV/aqpk7dFXH6muA8SaYInZkB2+5rRsb9rYg3Eh2j+EVJq+rW95alEU7vWgDzuZFVjuUflVV8E/LWpewfOSHrPaPDcmgB8UR4PFXoZCgwGAqpFgHqBU4Uk8EUAX4VL8lsmr8EMh/gDD3OKzYmEa/Pz9KtxakyDbGpHueaANmNorZf3ke5+yKKuabjzfNlGwema5+B3ml3SSNj6VpwujMBuIA96APU9CiF1CohaNc92PStxLbTrNGbU9YKn+5G2M/1rz7QZI12pHnc3Gck119lZ6dFIrTxPNIeelAGpZQ2U8vnWdvO8Y6STDGfpmprm6t7WUNd3NvEvZAcsaivb6B4fKt1jVx2GXI/LiqNpBa2+6e7lhTPdgM0AS6t4zVYvKshIOPvBDk1l6Vc6ndSGUsbSA8tK/3jVnUdb0W0iMvnxs4HGRnNcwupT6tOWDSTKD8sa/Kg+tAGtr+pW4Qx2cU95IeGmkJ21x15dzQxs6JGH9QMha3bmzuJiX1G+W3t1H+qjOSa4nxJq0UshtbBCsC8bmOSaAMrUr+eckTSMw9SayRmSTCLgdzU08iqhC5Zu5ptpG0h3Plv9kUAWo1AXAY++2pop5DhIkUL6saHZlUJIRGn91RzVu1ih2bgm3/blP8ASgBhtIuHuZjI3YDp+AqtcEbwETagPTua0jaBssNzsfUfyFZl6GWQJwvPQc0AaVlr95BBChbzVRFA9QAKln8SPc/Jcwq4/wBtefzro/8AhU2v3Oj2V9ps9tOk9vHMFPBG5QcfrXJar4e8Q6M5TU9Mk2j+OP5hQBP9otZLV1SN1nZgVctkKuDkbe+eOe2Koy5Un5m/D/CqQuHiOAjL9eKnGpSEbXOR6MKAKV9+8OHfI9xiqQjRT0yPUGr080MhPKA/lWdM5Qn7jD1BoAZLjPBJH1zRC4X+IfiKjDIx6nP0pef4SD9QaALDIsg52k+1QSQY4JH4ilGwckHP5U554mXaUII79aAKzpt64+tM4NPaTsrce4phNIAJwe1IaQ0UAGaejkN0GaZRQBpQzsFwyNj86kbDdAR+FZSsy9Cfzq9bTcfOwI9zTAWSFsZAOPpUcU0ts+VJPtmtGHD/AHQhX2NRzwgHIGD+FAG34e8WT2UyMqdD/eNem2fxPtfsuLqylkbGMcEfnXiaAIQxLj8BW7p2ooibchh9RQB11/4qTUbktDbG3Q+wq7aTWk8f7yUbsdSa4ae6jaQkIafbXNyrgxqVX6UAdVdko5EJV19yTVJ9OS6/1iqpPpxUttdzXEO1m5+lRlZ0c4ZfqTQBVl8ODBMUgH4Zqk2lNC2HkJHr0rbhmmDENub6cVOzLIMGNSfQigDnWjhhH+syaglvZo1IgIx/u1066Ys/WFE9ycVXutEgjHzyD/gJzQByDzzysTNz9KesigfcbNbU2mxg/ullkqB7N0HMTIPcUAYVzIr5AVqzpBtztroJ7UrkjH5VnzwFuNtAGSrHdlgfwq/bOgGfLZjSNasO4FIUCcbix9BQBbjk3H5o9o+lWo1HUAj8KqWgkJ+4cfStJFk4yc+gC0AWIVYx8gKvqxp0ccjSBU249QKciQBczjLdgf8ACrFvYXEg3Qq4j9W+VaANXRHktZcs6qO5JrrodURkBllhEY/2sk1xFtprSSBXlVz3Cgmugt9CXhpHBAH3d2B+QoA09Q16N4xBp5HoWC8VUWyhZRNqd9LjqF6Vo2EFhaRF2jVpB9TUf2W91O5/0K32x/3vL5/WgDLlsrW5f/QbKR8f8tpjx+Aqa3tlt/8AWXLqfQfKPy6mr+p26aXDjUbqUtj/AFayhc/lXCaxrsasyQbYY/SPJY/VjQBd8UahtjaKGTYvck/Mfwrgpbgs5WNSf9o1aursT8IpJPdjmqrLs+8RmgBscRc7nJx+latphFzkAewyfwpllZSSgP5bFfUirrqR+7ijw3c9aAIgMyZCZPuck1cjhJI3lA3ZQelQx2qq2Zptv+ynJP8AhVh7yG3Gy2g3Se43H/CgC1IyW8BLMZCf4V+VfxPU1zV3cB5R8wznhV6Cr9zBdXQ8y7kEMfpnn8BWeUghcYHfqeSaAPQfD2vaxpttarpd5dRARJ8hbK/dHY8VtalrviS+iAuUiYsMbmixn8RxXqPhXw3CPDeiSahCYvMsbd1kkiypzGp+8K6U2EdnHmOO2uEHYEc0AfMl/o19MrST6PMwPVo03L+lP8L/AA3tPE8xR5rizbOMqM4/CvpZbzTijr/ZE8U46eWuQfxzXI+IIdLmuDNPZ3NtKOkqRsrD8RQBw+qfsu6tFZ/adI1y3n+XcFkQrXk3iP4aeJdEldbmzWYL/HCd1fRVlqV/AmNM8R3G3srSZI/OoJ5vEzuZBLbXY/21wT+IoA+TprS7tmxNBKhHqDUXnSDgk/jX07rUd9cQN9u8LyTDHMlvh/061454q0u2Fy/lwT2x/uSxlCKAOGLE9WpuQD3q3PaGF+HyKYUBHJFICHy8rnNRkYNTHcOA2B7Go2GehzQAyilNJQAUUoxnmtKzsI5wOQfo9AGZQCR6V0yaFEFyzIPq1bWh+D7G/kAlu7OMd99wF/nQBxVtcFTjA/CtWACRQxIH1r01Ph1oMMe9tSsw2O10prF1Lw9p9uWW21G2bHZW3UwOTECSfKVVqG0zZyIwv0rVFiisQtwT7gGrMdqQR5kw2evNAHOralXzls/Wun0GSR8QmMn0+XNXo9LtJYcxS73/ACqjPatbP8jkY9HoA6I6PchN2GVT/sgUxbURLljuPsDWfp2rzxMF+1sAO3LV3eiak80Q3Ox9gF/qKAOVjETnGxw3rg1ct9OkkYeVnJ9EzXS3nm3DhY7eIA/xO4H8q6zw34Qs5oVm1C/WMYzhDQBymm+DprgBp5W/FgK3rfwRpgA+0XqKf7ocZrQ1uysLb5NNcXDD+87VxesRXkZMkslrbL2CudxoA6qbwloUCFpL3y1HVmkA/pXKatJ4UsN6ws15MP7vIrlNQuVl+W4eVk9S/wDjS6bdWcDf6HYXN1L2C8D86AMbW3huZmeGLyk7DYa5y7Q543Y+mK7vU9N8RamC0Wkx2sR7u/Ncbqthe2DlboDd320AZ4ibbk4UeuaaqwhuQWPsKbuLdQc+9BJUfcZvrxQBdinKYWJVUH866HRtHvdRZREq4PVmOAPxrmbGRgwKxKMfjXQWt5d5UGdlHYFsfpQB31j4JsrGMTXl3A0mM4QZ/U1l+IL23toylsY5cdON2Px6VmDUJo0BlcHHrlz+tZ0+q+ZJhYN59XO4/l0oAbbXtxLJw0cKnq2ziuhsL/T4wPtF1LcEdlGFrH2TzRZkhjgjP8bjJ/AUlnZpJLiBJJiO5H8gKAOhubyW4TdZQlYx0LkKKg/tbVEiaNboRJ3bdgD8arXDXEEf72NIEHd2Ga5PV9Xi3FY/3zeuCf50AXNXuoWZm85p5e7Dn/x41x93KhkJ+83oDmn3U13PksAi+9Z5YK+N2TQBPHLtPOc+grVsc5DLEufVqzLaEvIMfeP412Wh6fkL8mWPVmGcfhQAln9puT5NsrSv7DCip7mwFombuQySH+FegrqEuLTTrTZEuZm6nGT+AFc5qrPKS8pCA9FHzMf8KAM/YzqfLCxJ/eNQFjHnyFLnvI/A/CjILfOGwPU1HcTNINkZWNB1JoAq3EkjsQ8nPrVORQrgknr36mpZXjQ4Ql2Pf1qMRO8i9hnmgD06L9obxbo1jb6PDDp8lrZwR26eZCCSqoAM/lVIftA+JBIZBYaaGPYR8flXlGtf8hOf6j+QqjSA9uh/aP8AFcJ/d2Wlj/tgKLj9o7xVcrtnstLcD1gFeI0UAetXfxu1W7OZ9E0Yt6rDtP6VWi+MeqRHMWnWaf7rNXBaBpEur3qwq3lQ5HmTEZCD1967HUtItZY5oNbtBb3VuUgivbMgLKoAUHbja42jg5UknkmgDZg+O2vwDEVjYr74NVtU+M+patEY9S0fS7hT/fQ5/OuZt/CSS+IJdOb+1cozAxpYhp8djs34P0BNdto/w8vWtUt7bTFtor1BA9xeOGmkY4JVFx8uCO3PYnGRR6gcBc+IdPuXLSaDACeyTuBUH9r6X/0AkP1uXpvjPwzf+E9dm0vU49sqfMjg5WRT0IP5g+hBB6VhUoyUleLuh7G4dT0g9dBT/wACnpP7R0f/AKAS/wDgW9YlFMR1NlbabrGn6l9m077JPbxrIji4Zxy4Ugg+xrIm0meLurfSuq+E6xPf6os8QljNsMoRnPzrXosel6JIcz2XlA+zChAeDvaTr1Q01YJv4VYV7pe+HfDcikwTwK/o0hrldX0uzgJEEtrj1UsaYHnkUUn8e78TV2BcH78n4GrF/CUc4kQj2OKigZFHzHn2oAuxFCMMM/Wl/dIfmfH4VXzE3Tfn604FB0c/Q0AXrbZKcBz/ACrTghQYXzTk++RWRbOyn5Sn41s2MwBBZVLdiDQBcjtmiIfz8fSnuUJ/fXJI9OlTO08keA5UewqpI88PO/cP9oZoAjntGZg1qsjD1OTW7pE9zax/vTJGP+uRNZ+n6uTKFmfZj8BXSC/QwY84MCP4Y/6k0AKuvRxnc63EpH+wFqxbajdag48kSRKfUkn+VYi6bHqMn7lpC+eocAV02j6LNYFftM2F9WkoA1bbQtYliEluVPvK7fyqlqGn6swMRtrd3HHyEk122mXelpCEl1CM+zSHFWJ7/RowSt/bj2iHP5mgDyuLQ7+1k8660ZpEHOX2gfqa1k168hi8rTtMtoGHGSM/yrp7u8t7ri0tvtHo8kuf0qr/AGXqV0Dtit4l9gSR+lAHFarf6/KubrUkhU/wRoB/9eucvLCeWNpHMs5P8TKQPzNd3qHga7nuN73wiB6uW6fnXNeJNI0jS4SlzrjXc4/5Zh8jP0FAHn91aASkKFLei81PbaTJMpLRlVH8TnAqdwz/AC27pHH245rQ03RLq+YCW6VY+7O2B+tAGfa2cSuVF6qY67UzVnyrKJ8tfgt7JzXdaN4U8NREHVLuJlHLEzYH6V0UWrfCfQVy8aXMy9o4i/6mgDy22sJdRP8AoYlkHrsJqO70y+sZPkWTf7LivQ9a+MvhaKIxaVpk20DADFVH5CvNdd+Ij6i7fZbJI1J7ZNAE0DXiLvniRiP4pmz+lVbzXbuMGOGYRg8YTiuYvdbvrkkFyo9BVDzJCcySHP1oA2bq5eY7rmV5D6M1VzdBBlUVR64rN8wk4Qsx9hTvLc8ygge5oAlmnM5wvzVWZCjYAG4095Y4xiP861PDWlXGr3yRWkEs0rHoBQBf8MaaskqtOskx/uIOPxrtGL4EMULkj+CNcAfU10Ft4cHh7TA1+8KTsOELZINQQWbzKXuboJGeQqjAoAyUtLiQ8wl29M4AqG9spUTEpii/2U5Nb8UNvu220crqvWSc7VH0HeoL54iwSIq792C5/LtQBx11aoseQpH+03eufu2jRyoDE+9dhrs0UEJG7c/fnOP6VxkrB3JAFABGFAzgA+1TxIu9SzqvPpk1UwxPXA9utKu7zFAyq56jqaAMXWv+QnP9R/IVRq9rX/ITn+o/kKo0gCpYIWnkCIOT+lMVSzBVGSegrXsY1giLbjnIDH19hQB678OrjRdG0b/TbjY5AUoqc7c5O49yf6CvQz4h0OzuYrV57RJUXfILhX3IzKCFVgcLgEZBB5zXzvol01zqgkvObOyQ3UyHGCqc7cf7TbV/Gux8E6cmvXc194gMhEh892gUBlZzuGc9eO30rOcfaS5Xsv66DWh7PJrfh+5RIjffaGRCdschfjPIHGR9c1wnjLx9NarNp+kp9ht+MSP88pyMffJJX6DFdRp2taZJcW9il1evcLJFawrKyKWVxkMFC4CgA5564rlfi14NtbK3n1DSIZEmg+e48yYsJFJ/hBHYn1odCD319W3+bC7PM7ewm12OTS7pV3Fg1pcltwgYk5DHtG2efQgH1zwtzBLa3EsFxG0c0bFHRhgqR1FdXpOotFcSQXSu0Tg7Y0O059z9a1Nd0M6tY2iq0Z1yOLG1Wz50SqflOON6gDAHVfcct+479A3POqKUggkHgikqxHpXwLkEXiO+dlRgLU8P0+8K9W1O98xWSU2Sr2EYOTXk/wAD0MniC/VVLN9lOAP94V6Brl7exyFGtOPU0IDKvreyCs5hO73UgfzrkNTlQSkRoqj0D10s41O4jJigKj64rkdTW8jkYTA575UGmBRlieZjlFIPuDVZoJI2+VcD2xT5ojKvyuwb0C4pkVtcDhnJHuKAHgMeCOfcCnLGQejfkKUqqffcD8KYApbKkMPfNAEx+U9D+Yre0CLznGV/NuKy7eITDBwB7LWpYrb2rDa3zf7XAoA6qR/Kg8v7NC6+vI/rWbJYzTZMYVF9smrNvezSoIo5LZffqf5VoQ6TdTLua9iA9gRQByF7pk0Z3dcfhVVDKxCkbsdgc11moaNLHy8yyj0FR21raxA7vLjb1xQBm2WrXtoAttbbT/eEddJo/idoHX+1JZPL7jHNRaY9jFcfvgjp9T/QVtahpGkarADZmMS44ARj/OgDpNN8UeDpipnaT3MiityT4l/D3R4MCyjuHHcgfyFfO/iPQLzT5TuVQnbCmsHEoGG2/gtAHv8ArHx70xiY9F8OIV7NjbXFaz8X9Zugwis4bYH0ySPzNeXTzTouI931BxVBi8h/eM2fY0AdLqvivUb9ibm4cA9RvzWIb6FcsUZ29SaqeQvqQfc1G6hOAM/UUAWP7YkQ5iTHuTS/27eE8E/nxWc+CewpEiJ6AmkBffUrqbiW4bB7LTUIb/lk0h/vSEmoocJ94qKnacEYAJH1xTAChA+7GD7LUbBsfOwA9M0x3Y9Bge1Rg4PJz9KAHlwOFxSBS3P8hSB8c/Iv6mmh5JDhckfpQBOkmw8Hn608h5hjn8BRbQMzAYyfQV0+l6BPcKrTzRwQnr3JoAydI0g3VwiKC7k4xXvXgrQovDumi5u9kchGdv8A9YVj+FtP0vSIRJbxefcY4YIXOfYdKn1hNUvm8ycSRxdhI2B+QoAZ4i1KS9nY2iP1+9sAP4Csq3u5reREuQVZu78sasr50Q2Qyu7d2xtUVZtltkcM/mTSjklE4H40AdFZaclzZmTbgYzvYf1NcV4mkSykYW/7xv7x5FdVFq0twRb2doVPTfKd7fgvQVy/jS3eyiZ7lwJG/vHmgDzzU7iWaU+cSx7L0FQJA2zc4Cr6HgVNHFNcylo88nritFrBoYgZ2Ck9N3JP4UAYrElsDkfkKdCEMi/NuOegqS4SMtySx9OtPt4HWRW2bRnuKAOZ1r/kJz/UfyFUava1/wAhOf6j+QqmKQEsJEZOeD6+lWfOVoEQ7gQc59apqctgnArsfBPh+PX78W8zhE9fbuT6ADJ/ChtJXYGfdsNO8LRxrnz9WcTtnqsEbMqj/gThjj/pmpr0TT9We80xNZt0a1ikKxtGpGEdI1UHA7NtOPfNebeM723vtcuJbFdlkmIbdP7sSDao/IZ+pNV9B1N7OQwtO8cEn3sHj8R3qaa0u92Nne+H/Em3xpbPfMiGS5gPmIMbAGxmvcPGnlx6Hd3EjqyLE6neRhsjgYPc18x3f2E6sjgTSW525dchsd8DFd/461BtW0W2ttL+2pp9rFmIT/NIQerM2B71Yjh7LNzezSzFJHdi/wApwo57ewrVutU8+KKG0KQ3EDbonjONjD+LPXtUHh20QaVc3LSAxQDACjJOffpWK0zTX6pYxsZJGCpHGC7E+gA6mh7agbHjTR477Tk1/TrbyG3CK9tlHCPgYkX/AGW5Pscj0rg69esraLw5Y3beI5hPqEkTQDR4Jgcbgcm5YZC4O07Ad2R/DivLdQgEcpKD5e9YUZqSfLquj/rf1G1Y9A+A6h/E14pkaP8A0U/MpwR8wr1LXYJSjgkzr6jg/wA68p+Bq7vEN8OObU9RkfeHpXrUiSrIVLbU+mB+tbIRxdzFEAwxMjj+8CR+lcfqb7J2y24fQiu98TXFtFGdrHzP9kCvOL6eSSQ/ISPUNTAheCZhvRZGX0U1XxcK3EM/40jGZTmN3HsAKmtru5VvnkH/AAJaAGBpR95CP95aVdwOcIPoK0FuGYfP5Z+maQxCTkMB9FNAEcF4u4K2M+61v6fC8rA7IpE7/LXOGELINxyPeug0WRVkVdpI7nB/pQB1dnLbWqgrbKkn+7mtuKe9vYALeVFz0XywKwvJVsOk0KDuDurW05oFXLXUBYdljbNAFG60u8WTddoWHU7WAotLSzuJRE22I+rSA1pahK8sZWJIyP70iED9awJLfBy9xZk/3RQBsaloGmQW/mS6rj/Zjcc/lUGh6ja2kxjtI55P9sr1/Gsr7PFkea9sg9d1X0JigH2OMSnH3hxQAni4m4jDyCPOP4n/APr1wEqqrEfu/wAK6HV1upcl0wfccVyd7HLvPmPgegFADbiAHnzEA+tZ8sKEkKxY+varSw99jt9eKJS0Y+aIKKAM2XzEXAbH+6KoSbgSW3H8a2ZJLeb5cnNZ1zGin93gn6ZoApbhnjIp4k9cn8aa0ZH3uPrUfSkBPuU98U9ZAB/hVdfpmpERWPOfoKAFkcseMfnmmhc9atpGAPlRV9yaBGh9T9eBTArrGCf73sBV63tbibCxRhB6mpLWJCwG/cfRVrS2eWo42j/a5P5UAXtG8PxEq13epFnrg5NdlYJ4esCpLzXko6bug/CuJtUkmcBN5Hvxmur06yjijUzGCEdyTljQB2mleIFLbbW2jhjHfqf8K0L26EsZkMJkbHWR8KPwFcXnAH2RXx/fKYqXzLmUYlknlPZFOB+VAF43txNIRDHEMdWZeB+FQyPe3cvkW7S3LfxLHhVH5VALKVz/AKRJHCn90vuP5Cp5NSt9Pg8q2bzJewJAH5CgBmoanq2i2phsza2bEc+QvmSfixrh52nv7oyXczzzMeS53mtu/juL4mS9uT5fXYvyoKpw3EFsdlrh29VGB+dAD4ree2i+RfLY9yMt+Xas57Vnn/fyOWbtnLGtcGa4/wBZJsX+6nX8TTUkit8iDAfv5Y3N+fagCB4I7OHKQqjnueTWfF5klwv3SxP8XOK27fSL/UWBWP7PEesknLGuhsNA0vTwv2mQyy5+6hy7f4UAeGa1/wAhSf6j+QqnVzWv+QpP9R/IVSzSAcvWuo8G3tzZagy29pLdLcwvbyQxSGNmVlwSGAOCOucVzlqu6VRjJJwK+hvBXh+HRdNttRhkXzDHiUbfmB7gnrik4qSswPP7/wACaJMizW+uTaYzOE+zanCW25J6Sxg5HTkqO9SaL4GgaGWdJNNvDEAA8d8mzPvuYc/hiuh+Jt3bmOCOAKpwZWA5JOMc46VwlvLHHppJJ3Oc846Vmqc4/DL79f8AJjuuxev/AA9fLqmYhpyjAAH2+AAf+P16DoPh7VtYtRpwexE8rKo33qPvXuQATwPw6145Bate6juDwxqBwXr3rwzPZeH9BjV/EMGnzzxf66yt/NuCuOVz/DT5aj+0vu/4IaHG+MbDw54ahGj3N1Nf3Nu7eZFp4EKlueGlfJ9OAvfrXA3XjG7t1lt9BtrbQ7eRQjGzGZ3X0ac5c57gED2rpfFaeHX1EzWV1eyeYMtJdEF2bucYwK4DWYoYpQYpVfd6HkfWl7CL+N83r/lt+Ac3YhgvZEwAxCnrz1qK5kLtnnafU1BSl/lxgfWtRHpPwIjWXxPeo3Q2p7Z/iFeieJ3iiDI/lDHTJcf1rz/4AZPiy729fsp/9CFem+MXaWJlkaJcdCetCA8y1G43EqEiK+q5P865+dkLEkR/98kVt3yvCz7bmNl9BWFLKhc5JJ+tMCF3j74FIGUjiYn2p0nlkcxk+4NQqEH3QR+GaAH/ADj7soqaJZT1kDD8RUALA8Mv4ripftFyq4WTH0oAuWygONw7+ua6nTEURgoHz/v4rh4rydX+dpCK6DTb2CQgPNsP+0uaAOs23ki4jEzH/YbNLanUbeQNP9tWPPOWxVa0TcoaPUkT2WFs1LL5gU+bNJMPXkUAbzajbyQYdEJ7mVsmsC5jkmlJtSo5/gTiqZMTNgRXTH0GQKtwWvmY3/uV95KAApdRLie4hHs7AGqstx84UXasf7sZqxeWVpEN0e2ZvYZ/U1DaTLG3/IPLH1LY/lQBdt47q5j2Q24JP8cjYFVtR8KzJCbi8uYR32xhjU8lzcNzb28cJ9QcH8zWRqMl64PnyK/1lLUAYV1EI3KQKW7ZIrNu42C/PjPu2a3SCFy6j8jWXcK8smI0x74oAxxblz97j0C08xKi4LAfU/4VotYsPvAsfc8UfZWUYYAD2OKAMKURgnac/wDAartGx52tj6V0TWSOfk6+vWmNpwA+aZz7YoAwEhLH7rfjU+wpwcfRa0mt0Q9z/vUvkBhwD+C4oAoRhT99kUe5yanRYicRwvKfXGBU8cBjbcBn3Iq1BcFXGQzD0AoAlsre7K/uLStCLRrqVwb2YW6ntjFaNpq14sASBI4Fx16saryTXG4s0pVj/FjmgDd0yw0ixUNItzdSf98itVZJpz/othb2sI/ibGfzNcZFOFfJnkkf3bNa9nfQf8tSJG/22zj8BQBuXEoUEPOrNj7sXP61nSSTEHy45PyJNXIL4qmYYlC+oGKjudTmZdiKoPu39BQBhXRuDkNvX8cU7T4hGThl3H2z+talraPdsAzZPoq5ro7K2tNPtS7229hyXlIUUAcjcWMEuHvZ5XA/5ZrkCq815YQJsghCAdu5rV1u+uLwlLaGNI+5Az+pqhpOm77lRGvn3BPARd+P6UAFpp91qCeZIot7T+/K21fy6muq0jw/N5IbTrHzuP8Aj5nXan/AR3rsPCHhCUul1qNsJJByvnHcF/DoK7O+SFU2TXMQI4CqelAHkU+g3cshN5fuxH8EQwB+PamW9hBbyiKCXDfxFOT+LV3l7Y2czMAZZx3WPhfxNZk9rbRgRiNIgTwo5Y/gOaAPlbWv+QnP9R/IVRr2OP4faRfQw3c016JZ4kkYLIoGSoPHy0v/AArPRP8Antf/APfxf/iakdjx6N2jcMhwRzXouj/FO9hhjg1aziuo0UIHiPluAAAMjof881uf8Kz0T/ntf/8Afxf/AImj/hWeif8APa//AO/i/wDxNO4WON8S+KbfWZjcBZY32hVQ87R6ZrMjl+1hIUkiDdstXov/AArPRP8Antf/APfxf/iaP+FZ6J/z2v8A/v4v/wATRcLHB22nzRuJIiZgp+ZkYEKPzpX1lknZRcyxBOOuf5Cu6/4Vpon/AD2vv+/i/wDxNH/CtNE/57X/AP38X/4mi4WPK9RvDcybvMdvc1RJr2L/AIVpon/Pa+/7+L/8TR/wrTRP+e19/wB/F/8AiaLhY8cor2P/AIVpon/Pa+/7+L/8TR/wrTRP+e19/wB/F/8AiaAsYHwW8/8Aty/+yOEm+y/KxOMfOteh61bao6E3EsUg/wB8GqXhrwpYeHbqeexkuWeSPYRK4IxkHsB6Va1iPJPzPyM/eNCEcFrERQsG2H6GuZkULJkIzV1+qgozAMSPfBrCkQFjn+QpgZ5cntimMy7hkc1ZnVQOQD9RVIork8Y+lAFhWGOG21BPNIDhHz9BTduFxuJ+tSWsSscmgBLdJHOZHP0rb063BI2sAf8AdqokS56Vs6VEpZclvzoA6bSLaXaolJ2/7IrUmkhtxtRlDf7SkVStJjDEdir09Ka8jTuPMwfwoAhuTeTE+XdWqL7YJqulndBwWkEp9NprQniRI/kVVPqFArOjQm4G6SRuehY0AaUsV0tvlrCIL/e5zXMajeTRlhHmIey16MYUGmblGG29ev8AOvPtSRpZW3yuefb/AAoAwjPcXEuGuHPPqa2rDyYADNKC3oELGmWtjEx+Zn/PFdJo+h2DyrvhLE9yxNAFTHnRkx207r7lUBqg0F4X/d2ojX2yx/OvVbbw1pZtg32fn/ern9ciWx4tR5efSgDk1sZTFlrGZj67aoTxCHPmwLH/AL0gz+VXLyaWRjvldvqazZ4VxnLZoAqO9uz/ADsw9kGajkwR+7jkx6tThnJ2sV+mKpzSSGTaZX/OgB2zacmMk0v2ry8jy1/nSR26scuzv9TUiwIc4+UD0xQBEC0hywCj6VOGjjH3CT6u2B+QqNRhtqnHuOtQyIRIfnb65oAnkujjAkK/7owKgLhzzvc+rtxTSO5JJ96u2lrHIpZ8k0AQxY6lQ/sTgVdgnAI3NtA/hiXH61KtlE0e47jjtnis9zmXYMKucYAoA2Y7zK4jXA7s7bjWzosBuZlym/nrI21fyFZen26MVDZIrrrK2WO33I7qPQHA/SgDWuZrKwt1WSZycf6uFQgrMmu2kG+KxSFe0s4Lt+GeB+VMYlTiI+Wf7ygbvzPNAsoWkjaUNK7HkyMWoAqQWFxq94I0bfk43O2QPoBXq/hnwvFo9msjqZJcegRaPB+m28EG+JSrY6jA/pXTaZpcOrXmy9knZAfuh8CgDGupLq5fyTdBI/8AnlByT+Naul+FJpUDmDyUP8cvJP4V3tjpllpo2WdtFHgdduSfxqaeVlhZupx3p2A4TU9Ajgh+ctIB1ZjtUfh3rl5ooISwtkTdn5pCQo/M8mr3jfU7pywMmB2A6CvPLeWW9eQTSuFU9FOM/WkB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On this axial view of the thorax, the cardiac silhouette is displaced to the right by the left sided chest mass. The CPAM is echobright and appears \"solid\" due to many microcysts.",
"    <div class=\"footnotes\">",
"     * CPAM was previously known as congenital cystic adenomatoid malformation (CCAM).",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Courtney Stephenson, DO, and Andrew Shuller, RDMS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_32_40451=[""].join("\n");
var outline_f39_32_40451=null;
var title_f39_32_40452="Rifabutin: Patient drug information";
var content_f39_32_40452=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rifabutin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     see \"Rifabutin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/31/12792?source=see_link\">",
"     see \"Rifabutin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mycobutin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mycobutin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691908",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat infection caused by a bacteria found in patients with a weak immune system.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702869",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rifabutin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks. Alcohol may make liver disease worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698220",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low white blood cell count or low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697942",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of body fluids to orange.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A long-lasting change in color of contact lenses. Do not wear contacts while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11421 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_32_40452=[""].join("\n");
var outline_f39_32_40452=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218030\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218031\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028266\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028268\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028267\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028272\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028273\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028275\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028270\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028271\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028276\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028277\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=related_link\">",
"      Rifabutin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/31/12792?source=related_link\">",
"      Rifabutin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_32_40453="Lung abscess";
var content_f39_32_40453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lung abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Postanterior (A) and lateral (B) chest radiographs show dense right upper airspace consolidation. Contrast-enhanced computed tomography (CT) scan (C) demonstrates large focal area of decreased attentuation with rim enhancement (arrow) characteristic of lung abscess. Postanterior (D) and lateral (E) chest radiographs three weeks later show decreased size of lung abscess and development of cavitation with fluid level (arrows). The patient was a 43-year-old woman with lung abscess secondary to Haemophilus aphrophilus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: M&uuml;ller NL, Franquet T, Lee KS, Silva CIS. Bacterial pneumonia. In: Imaging of pulmonary infections, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_32_40453=[""].join("\n");
var outline_f39_32_40453=null;
var title_f39_32_40454="Endomyocardial fibrosis";
var content_f39_32_40454=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endomyocardial fibrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/32/40454/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/32/40454/contributors\">",
"     Rebecca Cogswell, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/32/40454/contributors\">",
"     Nelson B Schiller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/32/40454/contributors\">",
"     Harry Acquatella, MD, FACC, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/32/40454/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/32/40454/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/32/40454/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/32/40454/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/32/40454/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endomyocardial fibrosis (EMF) is a disease that is characterized by fibrosis of the apical endocardium of the right ventricle (RV), left ventricle (LV), or both. The clinical manifestations are largely related to the consequences of restrictive ventricular filling, including left and right sided heart failure.",
"   </p>",
"   <p>",
"    EMF refers to a specific syndrome with characteristic epidemiologic features. The epidemiology, pathophysiology, clinical manifestations, diagnosis, and treatment of EMF are reviewed here. Other cardiomyopathy syndromes with similar pathologies, including hypereosinophilia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibrotic changes of the endocardium are addressed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12472?source=see_link\">",
"     \"Carcinoid heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30090?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\", section on 'Cardiac disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/39/10874?source=see_link&amp;anchor=H19#H19\">",
"     \"Natural history and therapy of myocarditis in adults\", section on 'Eosinophilic myocarditis'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;EMF was first recognized in Uganda during the 1940s and accounts for as much as 20 percent of cardiac cases sent for echocardiography in that country in contemporary series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although accurate epidemiologic data are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/1\">",
"     1",
"    </a>",
"    ], EMF is estimated to the most common form of restrictive cardiomyopathy worldwide.",
"   </p>",
"   <p>",
"    Most studies of EMF occur in tropical regions where there is a high prevalence of disease such as Uganda [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/3\">",
"     3",
"    </a>",
"    ], Nigeria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/4\">",
"     4",
"    </a>",
"    ], Ivory Coast, south India [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/5\">",
"     5",
"    </a>",
"    ] and Brazil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/6\">",
"     6",
"    </a>",
"    ]. EMF also occurs in subtropical regions. A recent echocardiographic screening study in Mozambique found a population prevalence of 20 percent; however, this study included patients with early, subclinical disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/7\">",
"     7",
"    </a>",
"    ]. Within endemic countries, there appears to be a regional variation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EMF is primarily a disease of the young, occurring in children, adolescents and young adults. In Uganda, a bimodal peak at ages 10 and 30 has been observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/10\">",
"     10",
"    </a>",
"    ], and a similar pattern was recently found in Mozambique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/7\">",
"     7",
"    </a>",
"    ]. The differences between genders in the frequency of disease have been variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/7,10,11\">",
"     7,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15162936\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of the underlying fibrotic process of EMF is largely unknown; however, several theories exist and are briefly reviewed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15162944\">",
"    <span class=\"h2\">",
"     Eosinophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilia is the most commonly cited etiologic link in EMF. In support of the eosinophilia theory is the observation that EMF resembles a late stage of Loeffler's endocarditis (eosinophilic myocarditis) (",
"    <a class=\"graphic graphic_picture graphicRef71891 \" href=\"mobipreview.htm?4/44/4804\">",
"     picture 1",
"    </a>",
"    ), a process known to result from sustained eosinophilia in patients with hypereosinophilic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Endomyocardial fibrosis and intraventricular thrombosis have also been observed following a variety of other eosinophilic syndromes including hypersensitivity myocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/14\">",
"     14",
"    </a>",
"    ], parasitic infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], eosinophilic leukemia, sarcoma, carcinoma, and lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/15\">",
"     15",
"    </a>",
"    ], GM-CSF administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/16\">",
"     16",
"    </a>",
"    ], and prolonged drug-induced eosinophilia.",
"   </p>",
"   <p>",
"    Despite the similarities between Loeffler&rsquo;s endocarditis and EMF, serum and myocardial eosinophilia have not been consistently demonstrated in EMF. Although one study from Uganda found that 60 percent of patients with EMF had at least mild eosinophilia at the time of diagnosis compared to 10 percent of controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/17\">",
"     17",
"    </a>",
"    ], in Kerala, India, most with EMF did not have active eosinophilia at the time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/18\">",
"     18",
"    </a>",
"    ]. Endomyocardial biopsies have not demonstrated eosinophilia in EMF, even in those suspected to have early disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/19\">",
"     19",
"    </a>",
"    ]. It is possible that many with EMF have had significant eosinophilia at one time that is not detected by the time of presentation to medical care. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15163013\">",
"    <span class=\"h2\">",
"     Infectious",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several infections have been implicated in the pathophysiology of EMF, including toxoplasmosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/20\">",
"     20",
"    </a>",
"    ], rheumatic fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/21\">",
"     21",
"    </a>",
"    ], malaria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/22\">",
"     22",
"    </a>",
"    ] and helminthic parasites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/4,23\">",
"     4,23",
"    </a>",
"    ]. A consistent association with one organism, however, has not been demonstrated. For example, mice infected with plasmodium berghei develop endomyocardial fibrotic lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/24\">",
"     24",
"    </a>",
"    ], but a study of a series of 47 African children aged 5 to 15 years old with severe and complicated plasmodium falciparum infection produced insufficient evidence to link these two diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/25\">",
"     25",
"    </a>",
"    ]. Also opposing the infectious hypothesis is the observation that there are many tropical countries with similar burdens of malaria and filariasis as Uganda and Nigeria that do not have reported cases of EMF. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15163102\">",
"    <span class=\"h2\">",
"     Environmental exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the regional difference in the frequency of EMF cases and the lack of unifying infectious etiology, the idea of a geochemical basis for EMF has gained popularity. Cerium, a rare earth element, has been postulated to play a role in the pathogenesis of EMF. Cerium is abundant in the soil in areas endemic for the disease and has been shown to induce myocardial fibrosis in rodents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/18\">",
"     18",
"    </a>",
"    ]. Serum levels of cerium are high in patients with EMF compared to controls, and it is postulated that cerium is ingested from food and contaminated soil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/26\">",
"     26",
"    </a>",
"    ]. The incidence of EMF is decreasing in India, which corresponds with a reduction in soil cerium that has occurred with modernization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, cerium levels were found to be elevated in the primary teeth of Ugandan children living in regions with a high prevalence of EMF when compared to children from the United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15163159\">",
"    <span class=\"h2\">",
"     Immunologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of anti-myosin autoantibodies has been demonstrated in EMF; however, these antibodies can be detected in other forms of heart disease such as Dresser&rsquo;s syndrome, rheumatic heart disease and in patients with post-transplant rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/29\">",
"     29",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15163186\">",
"    <span class=\"h2\">",
"     Genetic",
"    </span>",
"    &nbsp;&mdash;&nbsp;A familial link has been identified in many studies; however, it is not known whether this is due to an environmental or genetic cause or both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/7,30\">",
"     7,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15163214\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In EMF, there is fibrosis of the right",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    left apical endocardial surfaces which leads to restrictive physiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/31\">",
"     31",
"    </a>",
"    ]. Additionally, tethering of the atrioventricular (AV) valve papillary muscles",
"    <span class=\"nowrap\">",
"     and/or&nbsp;fibrosis",
"    </span>",
"    of the respective ventricular inflow tracts leads to significant AV valve regurgitation. Gross pathology reveals ventricular endocardial thickening and fibrosis often with overlying thrombus. The atrium of the affected ventricle is often dramatically enlarged (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53361 \" href=\"mobipreview.htm?0/11/180\">",
"     image 1",
"    </a>",
"    ) with reduced ventricular volumes. Histopathology demonstrates increased type I collagen deposition, subendocardial infarction, fibrosis and thrombus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/9,32\">",
"     9,32",
"    </a>",
"    ]. In many pathology studies, there is a lack of inflammation or eosinophilia, implying that at end-stage disease, the inflammatory process is inactive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15163271\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of EMF are largely related to the presence of right",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    left heart failure. Patients may report dyspnea on exertion, paroxysmal nocturnal dyspnea, orthopnea, lower extremity, and abdominal swelling. A history of a febrile illness with or without urticaria is occasionally obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Africans with EMF in particular, there is often dramatic ascites (",
"    <a class=\"graphic graphic_picture graphicRef71891 \" href=\"mobipreview.htm?4/44/4804\">",
"     picture 1",
"    </a>",
"    ). Ascites may or may not be accompanied by other signs of right-sided heart failure, such as elevated jugular venous pressure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower extremity edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. The high prevalence of malnutrition and hypoalbuminemia may explain the predilection for ascites in this population. In one series, the ascitic fluid protein content was described as exudative in 35 of 47 patients with EMF, and the authors concluded that an inflammatory process might also be contributing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/36\">",
"     36",
"    </a>",
"    ]. The serum albumin to ascites gradient (which is a more accurate indicator of portal hypertension such as my result from heart failure) was not reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/43/14010?source=see_link&amp;anchor=H56451750#H56451750\">",
"     \"Evaluation of adults with ascites\", section on 'Determining the cause of the ascites'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with EMF often also have large pleural and pericardial effusions. Severe atrial enlargement leads to the appearance of cardiomegaly on chest radiography. Atrial fibrillation is common in end-stage disease and predicts a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15163383\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15163391\">",
"    <span class=\"h2\">",
"     Echo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although clinically similar to Loffler&rsquo;s endocarditis, the diagnosis of EMF should be reserved for patients from endemic regions without a clearly identified cause for sustained eosinophilia with the classic echo features listed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Apical fibrosis of the RV, LV, or both ventricles",
"      <strong>",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60129 \" href=\"mobipreview.htm?18/29/18896\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef59830 \" href=\"mobipreview.htm?28/37/29266\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tethering the AV valve papillary muscles, leading to mitral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tricuspid regurgitation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53361 \" href=\"mobipreview.htm?0/11/180\">",
"       image 1",
"      </a>",
"      )",
"      <strong>",
"      </strong>",
"     </li>",
"     <li>",
"      Giant atrial enlargement (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53361 \" href=\"mobipreview.htm?0/11/180\">",
"       image 1",
"      </a>",
"      ) &nbsp;",
"     </li>",
"     <li>",
"      A restrictive filling pattern on Doppler recordings of mitral valve inflow (",
"      <a class=\"graphic graphic_waveform graphicRef68541 \" href=\"mobipreview.htm?8/7/8304\">",
"       waveform 1",
"      </a>",
"      )",
"      <strong>",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, apical thrombi are often present (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80830 \" href=\"mobipreview.htm?26/43/27313\">",
"     image 3",
"    </a>",
"    ). In EMF, the apex maintains inward systolic contractile motion which may help to differentiate EMF from other causes of apical thrombi associated with an akinetic or dyskinetic apex such as myocardial infarction or Chagas disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/42\">",
"     42",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef59830 \" href=\"mobipreview.htm?28/37/29266\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15163461\">",
"    <span class=\"h2\">",
"     Echo staging of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An echocardiographic screening study in Mozambique included echocardiographic criteria for the diagnosis and staging of EMF. As the natural history of EMF is not well defined, these criteria will likely aid in defining the stages of this disease and in determining the clinical significance of the early EMF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15163473\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac catheterization is not required for the diagnosis of EMF. However on hemodynamic studies a restrictive pattern is observed with diastolic dip and plateau pressure tracings. Depending on the ventricle involved, mitral and tricuspid regurgitation may be demonstrated. Ventricular angiography reveals apical obliteration of the affected ventricle (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60129 \" href=\"mobipreview.htm?18/29/18896\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15163497\">",
"    <span class=\"h2\">",
"     Cardiovascular magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular magnetic resonance (CMR) imaging with contrast demonstrates myocardial fibrosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80830 \" href=\"mobipreview.htm?26/43/27313\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. However, the utility of this information in addition to echocardiography is unclear, and this modality is generally unavailable in areas with the highest burden of disease. In early disease where there is suspicion for active inflammation, CMR may be useful in identifying patients who may benefit from steroid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of EMF is not fully defined, and there are few data available to guide therapeutic decisions. Most present to medical care with end-stage disease and suffer an annual mortality as high as 25 percent despite medical treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/39,46\">",
"     39,46",
"    </a>",
"    ]. Surgical management has led to long-term survival in some patients with EMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/6\">",
"     6",
"    </a>",
"    ]; however, this option is unavailable in regions with a high disease burden.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available literature is limited to case series that do not fully define treatment regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/39,46\">",
"     39,46",
"    </a>",
"    ]. A general approach can be extrapolated from the treatment of patients with heart failure due to restrictive diastolic dysfunction from other causes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30777?source=see_link&amp;anchor=H8#H8\">",
"     \"Definition and classification of the cardiomyopathies\", section on 'Restrictive cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diuretics and rate control for atrial fibrillation are currently the mainstays of therapy.",
"   </p>",
"   <p>",
"    Pleural, pericardial or ascitic fluid removal may alleviate symptoms, but these often reaccumulate. In patients with suspected acute carditis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may be of benefit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/39/10874?source=see_link&amp;anchor=H19#H19\">",
"     \"Natural history and therapy of myocarditis in adults\", section on 'Eosinophilic myocarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endomyocardial resection with valve replacement or repair has gained prominence at many centers, especially in subjects in advanced heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/6,47,48\">",
"     6,47,48",
"    </a>",
"    ]. Immediate postoperative mortality is high, ranging from 15 to 30 percent, but surgery offers the possibility of long-term survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/48\">",
"     48",
"    </a>",
"    ]. A surgical series of 83 patients from Brazil all in NYHA functional class grade III-IV, and with a mean follow-up of 7.6 years had a survival probability at 17 years of 55 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40454/abstract/6\">",
"     6",
"    </a>",
"    ]. Published series have been small, overall experience is limited, and questions remain about the appropriate timing, peri-operative mortality, and long-term prognosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53361 \" href=\"mobipreview.htm?0/11/180\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60677 \" href=\"mobipreview.htm?40/14/41184\">",
"     image 4",
"    </a>",
"    ). Cardiac surgery is not routinely available in areas with high EMF prevalence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29222886\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endomyocardial fibrosis (EMF) is a restrictive cardiomyopathy observed in the tropics usually at the end-stage of the disease. It may be indistinguishable from Loeffler&rsquo;s endocarditis, observed in temperate climates.",
"     </li>",
"     <li>",
"      The pathogenesis remains unknown; however, eosinophilia may play a role.",
"     </li>",
"     <li>",
"      Echocardiography may show uni- or bilateral ventricular apex obliteration with severely dilated atria and a restrictive filling pattern.",
"     </li>",
"     <li>",
"      The prognosis is poor with a mortality estimated at 25 percent per year. Surgical treatment with endomyocardial resection and valve replacement may be beneficial in patients with advanced apical obliteration and sever heart failure symptoms; however, this option is largely unavailable where the disease is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95161542\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Gene Bukhman for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/1\">",
"      Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. Circulation 2005; 112:3577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/2\">",
"      BALL JD, WILLIAMS AW, DAVIES JN. Endomyocardial fibrosis. Lancet 1954; 266:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/3\">",
"      Connor DH, Somers K, Hutt MS, et al. Endomyocardial fibrosis in Uganda (Davies' disease). 1. An epidemiologic, clinical, and pathologic study. Am Heart J 1967; 74:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/4\">",
"      Andy JJ, Ogunowo PO, Akpan NA, et al. Helminth associated hypereosinophilia and tropical endomyocardial fibrosis (EMF) in Nigeria. Acta Trop 1998; 69:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/5\">",
"      Valiathan MS, Balakrishnan KG, Sankarkumar R, Kartha CC. Surgical treatment of endomyocardial fibrosis. Ann Thorac Surg 1987; 43:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/6\">",
"      Moraes F, Lapa C, Hazin S, et al. Surgery for endomyocardial fibrosis revisited. Eur J Cardiothorac Surg 1999; 15:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/7\">",
"      Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH. A population study of endomyocardial fibrosis in a rural area of Mozambique. N Engl J Med 2008; 359:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/8\">",
"      Kutty VR, Abraham S, Kartha CC. Geographical distribution of endomyocardial fibrosis in south Kerala. Int J Epidemiol 1996; 25:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/9\">",
"      Radhakumary C, Kumari TV, Kartha CC. Endomyocardial fibrosis is associated with selective deposition of type I collagen. Indian Heart J 2001; 53:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/10\">",
"      Rutakingirwa M, Ziegler JL, Newton R, Freers J. Poverty and eosinophilia are risk factors for endomyocardial fibrosis (EMF) in Uganda. Trop Med Int Health 1999; 4:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/11\">",
"      Falase AO. Endomyocardial fibrosis in Africa. Postgrad Med J 1983; 59:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/12\">",
"      Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83:2759.",
"     </a>",
"    </li>",
"    <li>",
"     Spry CJF. A Comprehensive Review and Guide to the Scientific and Medical Literature, Oxford Medical Publications, Oxford 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/14\">",
"      Kendell KR, Day JD, Hruban RH, et al. Intimate association of eosinophils to collagen bundles in eosinophilic myocarditis and ranitidine-induced hypersensitivity myocarditis. Arch Pathol Lab Med 1995; 119:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/15\">",
"      Monsuez JJ, de Kerviler E, Barboteu M, et al. Non-Hodgkin's lymphoma related eosinophilic endomyocardial disease. Eur Heart J 1994; 15:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/16\">",
"      Donhuijsen K, Haedicke C, Hattenberger S, et al. Granulocyte-macrophage colony-stimulating factor-related eosinophilia and Loeffler's endocarditis. Blood 1992; 79:2798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/17\">",
"      Freers J, Masembe V, Schmauz R, Mayanja-Kizza H. Endomyocardial fibrosis syndrome in Uganda. Lancet 2000; 355:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/18\">",
"      Valiathan SM, Kartha CC. Endomyocardial fibrosis--the possible connexion with myocardial levels of magnesium and cerium. Int J Cardiol 1990; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/19\">",
"      Patel AK, Ziegler JL, D'Arbela PG, Somers K. Familial cases of endomyocardial fibrosis in Uganda. Br Med J 1971; 4:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/20\">",
"      Ijaola O, Falase AO. Distribution of antibodies against Coxsackie B viruses, arboviruses and Toxoplasma gondii among patients with endomyocardial fibrosis (EMF) compared with normal subjects from EMF endemic and non-endemic zones of Nigeria. Afr J Med Med Sci 1990; 19:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/21\">",
"      Shaper AG. Endomyocardial fibrosis and rheumatic heart-disease. Lancet 1966; 1:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/22\">",
"      Eling WM, Jerusalem CR, Heinen-Borries UJ, et al. Is malaria involved in the pathogenesis of tropical endomyocardial fibrosis? Acta Leiden 1988; 57:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/23\">",
"      Ive FA, Willis AJ, Ikeme AC, Brockington IF. Endomyocardial fibrosis and filariasis. Q J Med 1967; 36:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/24\">",
"      Eling WM, Jerusalem CR, Heinen-Borries U. Role of macrophages in the pathogenesis of endomyocardial fibrosis in murine malaria. Trans R Soc Trop Med Hyg 1984; 78:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/25\">",
"      Mocumbi AO, Songane M, Salom&atilde;o C, et al. Lack of evidence of myocardial damage in children with Plasmodium falciparum severe and complicated malaria from an endemic area for endomyocardial fibrosis. J Trop Pediatr 2011; 57:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/26\">",
"      Eapen JT, Kartha CC, Rathinam K, Valiathan MS. Levels of cerium in the tissues of rats fed a magnesium-restricted and cerium-adulterated diet. Bull Environ Contam Toxicol 1996; 56:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/27\">",
"      Sivasankaran S. Restrictive cardiomyopathy in India: the story of a vanishing mystery. Heart 2009; 95:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/28\">",
"      Brown CJ, Chenery SR, Smith B, et al. Environmental influences on the trace element content of teeth--implications for disease and nutritional status. Arch Oral Biol 2004; 49:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/29\">",
"      Mocumbi AO, Latif N, Yacoub MH. Presence of circulating anti-myosin antibodies in endomyocardial fibrosis. PLoS Negl Trop Dis 2010; 4:e661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/30\">",
"      Lowenthal MN. Endomyocardial fibrosis: familial and other cases from northern Zambia. Med J Zambia 1978; 12:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/31\">",
"      Connor DH, Somers K, Hutt MS, et al. Endomyocardial fibrosis in Uganda (Davies' disease). II. An epidemiologic, clinical, and pathologic study. Am Heart J 1968; 75:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/32\">",
"      Mocumbi AO, Yacoub MH, Yokohama H, Ferreira MB. Right ventricular endomyocardial fibrosis. Cardiovasc Pathol 2009; 18:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/33\">",
"      Chopra P, Narula J, Talwar KK, et al. Histomorphologic characteristics of endomyocardial fibrosis: an endomyocardial biopsy study. Hum Pathol 1990; 21:613.",
"     </a>",
"    </li>",
"    <li>",
"     Freers J, Hakim J, Myanja-Kizza H, Parry E. The Heart. In: Principles of Medicine in Africa, Parry E, Godfrey R, Mabey D, Gill G (Eds), Cambridge University Press, Cambridge 2004. p.837.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/35\">",
"      Freers J, Mayanja-Kizza H, Rutakingirwa M, Gerwing E. Endomyocardial fibrosis: why is there striking ascites with little or no peripheral oedema? Lancet 1996; 347:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/36\">",
"      Barretto AC, Mady C, Oliveira SA, et al. Clinical meaning of ascites in patients with endomyocardial fibrosis. Arq Bras Cardiol 2002; 78:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/37\">",
"      Marijon E, Hausse AO, Ferreira B. Typical clinical aspect of endomyocardial fibrosis. Int J Cardiol 2006; 112:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/38\">",
"      Guimar&atilde;es AC, Esteves JP, Filho AS, Macedo V. Clinical aspects of endomyocardial fibrosis in Bahia, Brazil. Am Heart J 1971; 81:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/39\">",
"      Barretto AC, Mady C, Nussbacher A, et al. Atrial fibrillation in endomyocardial fibrosis is a marker of worse prognosis. Int J Cardiol 1998; 67:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/40\">",
"      Berensztein CS, Pi&ntilde;eiro D, Marcotegui M, et al. Usefulness of echocardiography and doppler echocardiography in endomyocardial fibrosis. J Am Soc Echocardiogr 2000; 13:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/41\">",
"      Hassan WM, Fawzy ME, Al Helaly S, et al. Pitfalls in diagnosis and clinical, echocardiographic, and hemodynamic findings in endomyocardial fibrosis: a 25-year experience. Chest 2005; 128:3985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/42\">",
"      Acquatella H, Schiller NB, Puigb&oacute; JJ, et al. Value of two-dimensional echocardiography in endomyocardial disease with and without eosinophilia. A clinical and pathologic study. Circulation 1983; 67:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/43\">",
"      Barretto AC, da Luz PL, de Oliveira SA, et al. Determinants of survival in endomyocardial fibrosis. Circulation 1989; 80:I177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/44\">",
"      Qureshi N, Amin F, Chatterjee D, et al. MR imaging of endomyocardial fibrosis (EMF). Int J Cardiol 2011; 149:e36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/45\">",
"      Smedema JP, Winckels SK, Snoep G, et al. Tropical endomyocardial fibrosis (Davies' disease): case report demonstrating the role of magnetic resonance imaging. Int J Cardiovasc Imaging 2004; 20:517.",
"     </a>",
"    </li>",
"    <li>",
"     Wynne J, Braunwald E.. The Cardiomyopathies. In: Braunwald's Heart Disease, Zipes DP, Libby P, Bonow RO, Braunwald E (Eds), Elsevier Saunders, Philadeplhia 2005. p.1659.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/47\">",
"      Schneider U, Jenni R, Turina J, et al. Long-term follow up of patients with endomyocardial fibrosis: effects of surgery. Heart 1998; 79:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40454/abstract/48\">",
"      Mocumbi AO, Yacoub S, Yacoub MH. Neglected tropical cardiomyopathies: II. Endomyocardial fibrosis: myocardial disease. Heart 2008; 94:384.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4927 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_32_40454=[""].join("\n");
var outline_f39_32_40454=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29222886\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15162936\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15162944\">",
"      Eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15163013\">",
"      Infectious",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15163102\">",
"      Environmental exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15163159\">",
"      Immunologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15163186\">",
"      Genetic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15163214\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15163271\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15163383\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15163391\">",
"      Echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15163461\">",
"      Echo staging of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15163473\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15163497\">",
"      Cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROGNOSIS AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29222886\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95161542\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4927\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4927|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/11/180\" title=\"diagnostic image 1\">",
"      Endomyocard fibros RA echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/29/18896\" title=\"diagnostic image 2\">",
"      Endomyocard fibrosis echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?26/43/27313\" title=\"diagnostic image 3\">",
"      CMR of eosinophilic endomyocardial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?40/14/41184\" title=\"diagnostic image 4\">",
"      Endomyocard fibrosis surg",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4927|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/37/29266\" title=\"figure 1\">",
"      Schematic of echo findings in EMF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4927|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/44/4804\" title=\"picture 1\">",
"      Acute eosinophilic myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4927|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?8/7/8304\" title=\"waveform 1\">",
"      Doppler restrictive CM I",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12472?source=related_link\">",
"      Carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/43/14010?source=related_link\">",
"      Evaluation of adults with ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/39/10874?source=related_link\">",
"      Natural history and therapy of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_32_40455="Subacute cutaneous lupus - annular plaques";
var content_f39_32_40455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55903%7EDERM%2F66580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55903%7EDERM%2F66580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subacute cutaneous lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous, annular plaques with scale are present on this patient with subacute cutaneous lupus erythematosus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission: from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subacute cutaneous lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous, scaly papules are present on the upper back.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_32_40455=[""].join("\n");
var outline_f39_32_40455=null;
var title_f39_32_40456="Sternum pericardium and related anatomy";
var content_f39_32_40456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Sternum, pericardium, and related anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This dissection exposes the pericardial sac posterior to the body of the sternum from just superior to the sternal angle to the level of the xiphisternal joint. The pericardial sac lies approximately one third to the right of the midsternal line and two thirds to the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AF. Clinically oriented anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_32_40456=[""].join("\n");
var outline_f39_32_40456=null;
var title_f39_32_40457="Traumatic causes of acute shoulder pain and injury in children and adolescents";
var content_f39_32_40457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Traumatic causes of acute shoulder pain and injury in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/32/40457/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/32/40457/contributors\">",
"     Joseph Chorley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/32/40457/contributors\">",
"     Gabriel P Brooks, PT, DPT, MSPT, MTC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/32/40457/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/32/40457/contributors\">",
"     George A Woodward, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/32/40457/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/32/40457/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/32/40457/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15374507\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis and treatment for shoulder injuries in the young athlete is different from treating adults because of the higher likelihood of fracture and anterior shoulder dislocations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. During the teenage years participation in many sports put the young athlete at risk for acute (eg, football, hockey) and repetitive overuse injuries (eg, swimming, baseball, tennis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/3\">",
"     3",
"    </a>",
"    ]. Understanding the anatomy and applicable biomechanics of the shoulder is essential to identifying these injuries.",
"   </p>",
"   <p>",
"    The causes of acute shoulder injury in the young athlete will be reviewed here. The physical examination of the shoulder is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27834?source=see_link\">",
"     \"Physical examination of the shoulder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15374514\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complex network of anatomic structures endows the human shoulder with tremendous mobility, greater than any other joint in the body. The shoulder girdle is composed of three bones (the clavicle, scapula, and proximal humerus) and four articular surfaces (sternoclavicular, acromioclavicular, glenohumeral, and scapulothoracic) (",
"    <a class=\"graphic graphic_figure graphicRef72709 graphicRef54102 graphicRef69995 \" href=\"mobipreview.htm?35/8/35978\">",
"     figure 1A-C",
"    </a>",
"    ). The glenohumeral joint, commonly referred to as the shoulder joint, is the principal articulation. The shoulder is an inherently unstable joint that relies on several delicate interactions to minimize the risk for injury. The shape and interaction of the bones and soft tissues of the shoulder girdle are essential to understanding the factors leading to shoulder stability.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Glenohumeral structures &ndash;",
"      </strong>",
"      The glenohumeral joint is loosely constrained within a thin capsule bounded by surrounding muscles and ligaments (",
"      <a class=\"graphic graphic_figure graphicRef72709 graphicRef54102 graphicRef69995 \" href=\"mobipreview.htm?35/8/35978\">",
"       figure 1A-C",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef70854 \" href=\"mobipreview.htm?27/36/28236\">",
"       table 1",
"      </a>",
"      ). The shoulder's great mobility is due in large part to the shallow depth of the glenoid and the limited contact between the glenoid and the humeral head. Only 25 percent of the humeral head surface makes contact with the glenoid. The labrum, a fibrocartilaginous ring attached to the outer rim of the glenoid, provides some additional depth and stability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/1,4\">",
"       1,4",
"      </a>",
"      ]. It also serves as a bumper to decrease the potential for humeral head subluxation. The shallowness and small surface area of the glenohumeral joint make it susceptible to instability and injury and require that stability be provided primarily by extrinsic supports.",
"      <br/>",
"      <br/>",
"      Surrounding muscles and ligaments provide these supports:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The glenohumeral ligaments are collagenous reinforcement of the capsule and quite variable in their thickness, anatomic position, and their contribution to shoulder stability (",
"      <a class=\"graphic graphic_figure graphicRef54102 \" href=\"mobipreview.htm?27/60/28613\">",
"       figure 1B",
"      </a>",
"      ). The glenohumeral ligaments serve as the primary static stabilizer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/5-7\">",
"       5-7",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The inferior glenohumeral ligament complex (IGHL) is made up of the anterior and posterior bands and the posterior axillary pouch that form a hammock like structure. In abduction and external rotation, the anterior band is the primary restraint to anterior translation of the humeral head [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In the absence of the anterior IGHL, the middle glenohumeral ligament may provide some restraint to anterior humeral translation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the flexion and internal rotation, the posterior band of the IGHL and the posterior capsule are the primary restraints for posterior movement (translation) of the humeral head relative to the glenoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The rotator cuff serves as the primary dynamic stabilizer. The rotator cuff is composed of four muscles (supraspinatus, infraspinatus, subscapularis, and teres minor) that form a cuff around the head of the humerus, to which these muscles attach (",
"      <a class=\"graphic graphic_figure graphicRef72027 \" href=\"mobipreview.htm?15/1/15378\">",
"       figure 2",
"      </a>",
"      ). The rotator cuff compresses the humoral head in the glenoid fossa, thereby stabilizing the glenohumeral joint, and serves to counterbalance the elevating forces of the deltoid, as well as the forces of other muscles acting on the humerus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35961?source=see_link&amp;anchor=H3#H3\">",
"       \"Evaluation of the patient with shoulder complaints\", section on 'Glenohumeral structures'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Other structures",
"      </strong>",
"      &ndash; The clavicle serves as a strut attaching the upper extremity to the axial skeleton through the acromioclavicular and sternoclavicular joints and the scapulothoracic articulation (",
"      <a class=\"graphic graphic_figure graphicRef72709 graphicRef54102 graphicRef69995 \" href=\"mobipreview.htm?35/8/35978\">",
"       figure 1A-C",
"      </a>",
"      ). The function of the clavicle includes supporting the weight of the arm, providing additional dynamic mobility to the arm, and transferring force from the arm to the rest of the skeleton.",
"      <br/>",
"      <br/>",
"      The sternoclavicular joint has the least amount of bony stability of the major joints of the body, but paradoxically bears the responsibility of being the only true articulation between the upper extremity and the axial skeleton. The convex articular surface of the clavicle is much larger than the curved notch of the sternum resulting in an incongruous mismatch. Despite this instability, dislocation at this joint is rare. Both bones are covered with thick fibrocartilage (not the usual hyaline cartilage) and are separated by an intervening fibrocartilage disk which provide added cushion to the joint.",
"      <br/>",
"      <br/>",
"      The muscles primarily responsible for scapular stability and motion are the trapezius, serratus anterior, rhomboids, and levator scapulae (",
"      <a class=\"graphic graphic_figure graphicRef50894 \" href=\"mobipreview.htm?33/47/34554\">",
"       figure 3",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The acromioclavicular (AC) joint is supported by ligaments that span its anterior, superior, posterior, and inferior aspects (",
"      <a class=\"graphic graphic_figure graphicRef62016 \" href=\"mobipreview.htm?23/41/24210\">",
"       figure 4",
"      </a>",
"      ). These ligaments also envelop the distal 1 to 2 cm of the clavicle. In addition to the AC ligaments, the distal clavicle is held in alignment with the acromion by the strong coracoclavicular (CC) ligaments. These ligaments consist of the conoid ligament medially and the trapezoid ligament laterally.",
"     </li>",
"     <li>",
"      <strong>",
"       Bony development",
"      </strong>",
"      &ndash; As a general rule, the bones that form the shoulder girdle (ie, scapula, humerus, and clavicle) are not fully ossified in the young athlete [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/8-15\">",
"       8-15",
"      </a>",
"      ] (",
"      <a class=\"graphic graphic_table graphicRef83709 \" href=\"mobipreview.htm?15/62/16364\">",
"       table 2",
"      </a>",
"      ). Thus, the skeletally immature athlete has open epiphyses that are two to five times weaker than the surrounding soft tissues and are prone to fracture.",
"      <br/>",
"      <br/>",
"      In some patients, skeletal immaturity or variation in ossification can lead to misdiagnosis as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A lateral epiphysis fracture of the clavicle can be confused with an acromioclavicular joint injury (eg, acromioclavicular sprain or separation)",
"     </li>",
"     <li>",
"      Bipartite coracoid may be mistaken as a coracoid fracture",
"     </li>",
"     <li>",
"      Salter I fracture of the proximal humerus may be misdiagnosed as a soft tissue injury",
"     </li>",
"     <li>",
"      Medial clavicular epiphysis fracture can be confused with a sternoclavicular dislocation",
"     </li>",
"     <li>",
"      Os acromionale can be mistaken for an acromion fracture",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H335158\">",
"    <span class=\"h1\">",
"     LIFE-THREATENING AND SERIOUS CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life-threatening causes of shoulder pain after an injury include posterior sternoclavicular dislocation and referred pain from a serious underlying injury to the neck, abdomen, or myocardium.",
"   </p>",
"   <p>",
"    Pathologic fractures and thoracic outlet syndrome represent conditions that are more serious than isolated injuries to a previously normal shoulder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H335289\">",
"    <span class=\"h2\">",
"     Sternoclavicular injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sternoclavicular (SC) injuries are rare in the young athlete. Because the physis (growth plate) of the medial clavicle does not close until 22 to 25 years of age, Salter-Harris I or II physeal fractures with displacement of the medial clavicular fragment are more common than true SC dislocation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. These injuries are typically a result of tremendous force applied to the shoulder or medial clavicle. However, patients with hypermobility syndromes, such as Ehlers-Danlos syndrome, Marfan syndrome, or other generalized ligament laxity syndrome, can have this injury following significantly less trauma.",
"   </p>",
"   <p>",
"    Medial clavicular fracture with anterior displacement or anterior SC dislocation is the most common type of SC injury accounting for up to 90 percent of SC dislocations in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/16\">",
"     16",
"    </a>",
"    ] and the majority of injuries reported in a systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/20\">",
"     20",
"    </a>",
"    ]. Medial clavicular fractures with posterior displacement or posterior SC dislocation can cause significant life-threatening internal injury including tracheal compression, laceration of the subclavian or brachiocephalic vessels, pneumothorax, or recurrent laryngeal nerve injury.",
"   </p>",
"   <p>",
"    The mechanism of injury may involve direct trauma to the medial clavicle and sternum (eg, misplaced kick during soccer or during mixed martial arts contest or a helmet blow during American football) or, more commonly, indirect trauma to the SC joint by anterolateral or posterolateral forces applied to the shoulder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/21\">",
"     21",
"    </a>",
"    ]. When a blow is applied directly to the anteromedial aspect of the clavicle, the clavicle is pushed posteriorly behind the sternum into the mediastinum. With indirect forces, if the shoulder is forced forward and medially, an ipsilateral posterior fracture with dislocation results; if the shoulder is forced backward and medially, an ipsilateral anterior fracture with dislocation occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H335813\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with sternoclavicular (SC) injury typically have anterior chest and shoulder pain that is worsened by arm movement. Patients with medial clavicular fracture with posterior displacement or posterior SC dislocation may also complain of difficulty breathing, dysphagia, or upper extremity paresthesias. If posterior displacement of the medial clavicle or clavicular fracture injures the recurrent laryngeal nerve, hoarseness may also be present. On physical examination, the medial end of the clavicle is displaced posterior, posteroinferior, or posterosuperior with respect to the sternum. However, this displacement may be difficult to appreciate. Patients with medial clavicular fracture and anterior displacement or anterior SC dislocation have a prominence at the SC joint that is displaced anteriorly or anterosuperiorly to the sternum.",
"   </p>",
"   <p>",
"    Plain radiographs are typically sufficient to identify medial clavicular fractures with anterior displacement or anterior SC dislocations. In addition to routine clavicle series, a modified AP view with a 40 degree cephalic tilt or the &ldquo;serendipitous view&rdquo; will best visualize the injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plain radiographs alone are insufficient to characterize medial clavicular fractures with posterior displacement or posterior SC dislocations. When these injuries are suspected, contrast-enhanced computed tomography (CT) of the chest is indicated to assess the full extent of bony abnormality and to identify potential vascular injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/23\">",
"     23",
"    </a>",
"    ]. Injuries are classified as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade I &ndash; Mild to moderate displacement without dislocation",
"     </li>",
"     <li>",
"      Grade II &ndash; Acute, traumatic, anterior dislocation",
"     </li>",
"     <li>",
"      Grade III &ndash; Chronic, traumatic, anterior dislocation",
"     </li>",
"     <li>",
"      Grade IV &ndash; Chronic, atraumatic, anterior dislocation",
"     </li>",
"     <li>",
"      Grade V &ndash; Posterior dislocation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H335820\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of SC fracture and displacement or dislocation is determined by the direction of displacement and the degree of deformity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posterior SC dislocation or medical clavicular fractures with posterior displacement (Grade III) warrant prompt delineation with contrast-enhanced chest CT. Patients with airway compromise should undergo immediate reduction. In patients without airway compromise, reduction should occur within 24 hours, preferably by an orthopedic surgeon. Consultation with a cardiovascular surgeon should be performed prior to reduction in these patients, especially when an underlying hematoma is present on CT. Otherwise, bleeding may occur post-reduction from an untreated vascular injury.",
"      <br/>",
"      <br/>",
"      Closed reduction will usually result in a stable reduction of a posterior SC dislocation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/20\">",
"       20",
"      </a>",
"      ]. Open reduction is reserved for irreducible posterior displacement with symptoms of compression with these injuries. However, displaced fractures of the medial clavicle frequently do not maintain reduction and open reduction with suture stabilization is the first-line treatment in many facilities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/19\">",
"       19",
"      </a>",
"      ]. Post-reduction treatment consists of a figure of eight brace for four to six weeks, resumption of overhead activities at six weeks, and restriction of contact sports or activities for six to eight weeks.",
"     </li>",
"     <li>",
"      Anterior SC fractures with dislocation (Grade III) should undergo reduction by a skilled practitioner but displacement usually recurs. Because of the potential for bone remodeling in the young athlete, proper healing is typically achieved without surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/26\">",
"       26",
"      </a>",
"      ]. Post-reduction treatment is the same as for posterior SC fractures with dislocation.",
"     </li>",
"     <li>",
"      Anterior or posterior SC injuries with pain and deformity but no dislocation (Grade I) should immobilized with the application of a figure-of-eight strap or sling and swathe for four to six weeks. Follow up with an orthopedic surgeon is necessary because patients with continued pain and mechanical sensation after six weeks of conservative management may warrant surgery.",
"     </li>",
"     <li>",
"      Pain is managed with local ice application and oral analgesics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5006658\">",
"    <span class=\"h3\">",
"     Reduction of posterior sternoclavicular dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Displaced medial clavicle fractures require reduction by an orthopedic surgeon. Closed reduction of SC dislocations is also best performed by an orthopedic surgeon. However, airway compromise in a patient with a posterior SC dislocation may mandate reduction by an emergency physician. The technique for closed reduction of a posterior SC dislocation is as follows (",
"    <a class=\"graphic graphic_figure graphicRef85909 \" href=\"mobipreview.htm?24/30/25057\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provide local anesthesia or procedural sedation for pain control. Patients receiving procedural sedation warrant close monitoring of airway and breathing.",
"     </li>",
"     <li>",
"      Place the patient supine with a 3 to 4 inch high bolster pad between the scapulae and positioned so that the shoulder on the affected side is placed at the edge of the table.",
"     </li>",
"     <li>",
"      Abduct the shoulder to 90 degrees.",
"     </li>",
"     <li>",
"      Perform gentle lateral traction on the arm and extend it towards the floor.",
"     </li>",
"     <li>",
"      Manually grasp the clavicle and pull it anteriorly.",
"     </li>",
"     <li>",
"      If this maneuver is unsuccessful, sterilely prep the area from the medial to proximal clavicle.",
"     </li>",
"     <li>",
"      While an assistant provides lateral traction as above, grasp the clavicle near the medial end by piercing the skin with a towel clip and reduce the dislocation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H683321\">",
"    <span class=\"h2\">",
"     Referred pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referred pain to the shoulder may indicate serious injury to the neck (cervical spine injury with nerve compression), abdomen (abdominal hemorrhage with diaphragmatic irritation), or, rarely, myocardium (blunt cardiac trauma with ischemia). Thus, the young athlete with shoulder pain warrants a careful assessment for these potential injuries and cervical spine immobilization should be maintained or applied to patients whose injury or clinical findings suggest cervical spine trauma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41368?source=see_link\">",
"     \"Approach to the young athlete with neck pain or injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/28/15815?source=see_link\">",
"     \"Field care and evaluation of the young athlete with acute neck injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cervical spine injury is suggested by neck pain or cervical spine tenderness, stepoff on palpation, or neurologic deficit on physical examination. Patients with significant trauma and altered mental status or distracting injury (eg, long bone fracture causing significant pain) should be assumed to have a neck injury. Additional evaluation is determined by the clinical assessment (",
"    <a class=\"graphic graphic_table graphicRef79881 \" href=\"mobipreview.htm?9/11/9405\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\", section on 'Cause of trauma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\", section on 'Mechanism of injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abdominal hemorrhage with diaphragmatic irritation may occur from a splenic or liver laceration after a direct blow to the upper abdomen. Variably present signs of abdominal injury include (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4777?source=see_link&amp;anchor=H14482553#H14482553\">",
"     \"Liver, spleen, and pancreas injury in children with blunt abdominal trauma\", section on 'Evaluation'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ecchymoses",
"     </li>",
"     <li>",
"      Abrasions",
"     </li>",
"     <li>",
"      Abdominal distension",
"     </li>",
"     <li>",
"      Tenderness",
"     </li>",
"     <li>",
"      Rigidity",
"     </li>",
"     <li>",
"      Masses",
"     </li>",
"     <li>",
"      Pain in the left shoulder induced by palpation of the left upper quadrant (Kehr sign)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abdominal tenderness is typically present and may be accompanied by hemodynamic instability. Computed tomography of the abdomen with intravenous contrast is diagnostic.",
"   </p>",
"   <p>",
"    The evaluation and management of liver or spleen injury after blunt abdominal trauma is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4777?source=see_link&amp;anchor=H14482553#H14482553\">",
"     \"Liver, spleen, and pancreas injury in children with blunt abdominal trauma\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4777?source=see_link&amp;anchor=H14482581#H14482581\">",
"     \"Liver, spleen, and pancreas injury in children with blunt abdominal trauma\", section on 'Definitive management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Myocardial infarction following blunt cardiac injury is rare and results from coronary artery dissection, laceration, or thrombosis. Chest pain referred to the left shoulder or arm, nausea, diaphoresis, or altered mental may be present. When indicated on the basis of severe mechanism of injury, hemodynamic instability, or physical findings pointing to significant thoracic trauma electrocardiogram and measurement of cardiac troponin assist in identifying this uncommon occurrence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27385?source=see_link&amp;anchor=H5#H5\">",
"     \"Cardiac injury from blunt trauma\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27385?source=see_link&amp;anchor=H2505321#H2505321\">",
"     \"Cardiac injury from blunt trauma\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H335466\">",
"    <span class=\"h2\">",
"     Pathologic fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proximal humerus is a preferential site for benign and malignant bone tumors. In patients with these lesions, minor injury may cause a fracture through the weakened bone (pathologic fracture) and lead to the diagnosis of the underlying tumor.",
"   </p>",
"   <p>",
"    Common benign tumors of the proximal humerus include unicameral bone cysts (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65224 \" href=\"mobipreview.htm?4/34/4642\">",
"     image 1",
"    </a>",
"    ), chondroblastomas (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82162 \" href=\"mobipreview.htm?35/60/36801\">",
"     image 2",
"    </a>",
"    ), osteochondromas, enchondromas, and periosteal chondromas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=see_link\">",
"     \"Overview of benign bone tumors in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Osteosarcoma and, less commonly, Ewing sarcoma, also can occur in the proximal humerus and may come to attention following a pathologic fracture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37769?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H335474\">",
"    <span class=\"h2\">",
"     Thoracic outlet syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic outlet syndrome refers to a constellation of signs and symptoms that arise from compression of the neurovascular bundle by various congenital or acquired structures (eg, cervical rib, supernumerary scalene muscles, or hypertrophied scalene or pectoralis minor muscles in weight lifters) in the area just above the first rib and behind the clavicle, within the confined space of the thoracic outlet (",
"    <a class=\"graphic graphic_figure graphicRef59433 \" href=\"mobipreview.htm?17/58/18338\">",
"     figure 6",
"    </a>",
"    ). Thoracic outlet syndrome may also be seen in athletes with repetitive overhead arm movements (eg, baseball pitchers, swimmers). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/6/3177?source=see_link&amp;anchor=H455545323#H455545323\">",
"     \"Overview of thoracic outlet syndromes\", section on 'Anatomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/6/3177?source=see_link&amp;anchor=H455545331#H455545331\">",
"     \"Overview of thoracic outlet syndromes\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27754?source=see_link&amp;anchor=H239061107#H239061107\">",
"     \"Primary (spontaneous) upper extremity deep vein thrombosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compression of the brachial plexus leads to upper extremity numbness, dysesthesia and weakness; venous compression may cause deep vein thrombosis of the axillary or subclavian veins and extremity swelling (Paget Shroetter syndrome); and arterial compression can lead to distal thromboembolism, arm pain with exertion (&lsquo;claudication&rsquo;) or acute arterial thrombosis. Patients with vascular thoracic outlet syndrome are at risk for pulmonary embolus (venous thoracic outlet syndrome) or stroke (arterial thoracic outlet syndrome). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/6/3177?source=see_link&amp;anchor=H293627701#H293627701\">",
"     \"Overview of thoracic outlet syndromes\", section on 'Clinical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis and management of thoracic outlet syndrome is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/6/3177?source=see_link&amp;anchor=H293628070#H293628070\">",
"     \"Overview of thoracic outlet syndromes\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/6/3177?source=see_link&amp;anchor=H293628520#H293628520\">",
"     \"Overview of thoracic outlet syndromes\", section on 'Approach to management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H781977\">",
"    <span class=\"h1\">",
"     COMMON CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common causes of shoulder pain in the young athlete include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superficial contusion",
"     </li>",
"     <li>",
"      Clavicle contusion, fractures, or osteolysis",
"     </li>",
"     <li>",
"      Proximal humeral fractures",
"     </li>",
"     <li>",
"      Shoulder (glenohumeral) dislocation",
"     </li>",
"     <li>",
"      Acromioclavicular joint dislocation (separated shoulder)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H683535\">",
"    <span class=\"h2\">",
"     Superficial contusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bruises in the shoulder area typically occur after a direct blow and may cause significant pain. Patients who can demonstrate a complete active range of motion without bony point tenderness may not require any further evaluation. Otherwise, normal plain radiographs and full motion after ice application and oral analgesia (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ) help to differentiate a shoulder contusion from more serious injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2619337\">",
"    <span class=\"h2\">",
"     Clavicle injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal clavicular contusions (&ldquo;shoulder pointer&rdquo;) and clavicle fractures comprise the common clavicle injuries seen in children and adolescents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H683479\">",
"    <span class=\"h3\">",
"     Distal clavicle contusion (shoulder pointer)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contusion to the distal clavicle without ligamentous involvement occurs after a fall onto the shoulder or a direct blow. Sometimes termed a &ldquo;shoulder pointer&rdquo;, findings include pain over the distal clavicle rather than the acromioclavicular ligaments and no evidence of separation on radiographs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/27\">",
"     27",
"    </a>",
"    ]. Oblique radiographic views should be performed to exclude distal clavicle fractures. Treatment consists of a rest, sling for comfort, application of ice, and oral analgesics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ). These injuries typically resolve in two to four weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H683486\">",
"    <span class=\"h3\">",
"     Clavicle fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clavicle fractures are typically caused by a fall onto the shoulder and, in the young athlete, most commonly involve the middle third of the clavicle. The presenting features of a clavicle fracture depend upon the fracture site:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Midshaft clavicle fractures",
"      </strong>",
"      &ndash; Pain in patients with fractures of the middle third of the clavicle is usually well localized and exacerbated by movement of the arm. The patient may describe a snapping or cracking sensation at the time of the injury and may notice localized swelling over the affected area. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/43/12985?source=see_link&amp;anchor=H7#H7\">",
"       \"Clavicle fractures\", section on 'Clinical presentation and examination'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Because the clavicle lies close to the skin, examination often reveals a visible bulge due to hematoma (often with associated ecchymosis), bone angulation, or displaced bone edges. Tenting of the skin, if present, suggests significant angulation or displacement. There is point tenderness over the fracture site. In addition, firm pressure on the clavicle, even if not applied directly to the fracture site, may elicit crepitus or palpable motion of the fragment.",
"      <br/>",
"      <br/>",
"      The evaluation and management of fractures of the middle third of the clavicle are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/43/12985?source=see_link&amp;anchor=H6#H6\">",
"       \"Clavicle fractures\", section on 'Fractures of the middle third (midshaft) of the clavicle'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Distal clavicle fractures",
"      </strong>",
"      &ndash; Fractures of the distal third of the clavicle are easily confused with acromioclavicular (AC) separations. Both present with pain and tenderness around the AC joint, often with swelling and ecchymosis. The cross arm test (adduction of the arm across the chest) increases pain in both conditions. Little or no deformity is seen on examination, unless a type II fracture is present (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57129 \" href=\"mobipreview.htm?0/47/767\">",
"       image 3",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The location of maximal tenderness may provide a clue to the diagnosis. With fractures, maximal tenderness is usually located medial to the AC joint, instead of directly over the joint. Radiographs (including oblique clavicle views) should be considered if there is clinical suspicion that the injury includes the bone.",
"      <br/>",
"      <br/>",
"      The evaluation and management of the distal clavicle fractures are reviewed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/43/12985?source=see_link&amp;anchor=H14#H14\">",
"       \"Clavicle fractures\", section on 'Fractures of the distal third of the clavicle'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Proximal clavicle fractures",
"      </strong>",
"      &ndash; Fractures of the proximal third of the clavicle are the least common type of clavicle fracture and are usually seen after high force vehicular trauma. Acute fractures are often complicated by serious injury to the head, neck, chest, or abdomen.",
"      <br/>",
"      <br/>",
"      Stress fractures may occur from repetitive injury in rowers and gymnasts and cause chronic pain over the sternoclavicular area. Evaluation and management of proximal clavicle fractures are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/43/12985?source=see_link&amp;anchor=H22#H22\">",
"       \"Clavicle fractures\", section on 'Fractures of the proximal third of the clavicle'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2619806\">",
"    <span class=\"h2\">",
"     Proximal humeral fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the proximal humerus commonly occur due to a fall on an outstretched hand (FOOSH) or from a direct blow to the lateral aspect of the shoulder (",
"    <a class=\"graphic graphic_figure graphicRef58495 \" href=\"mobipreview.htm?19/21/19793\">",
"     figure 7",
"    </a>",
"    ). Physeal fractures are most common in adolescents. Before adolescence, proximal humeral fractures typically occur at the metaphysis, although Salter-Harris type I injuries are seen occasionally (",
"    <a class=\"graphic graphic_figure graphicRef54582 \" href=\"mobipreview.htm?20/55/21361\">",
"     figure 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71443 \" href=\"mobipreview.htm?6/9/6289\">",
"     figure 9",
"    </a>",
"    ). Pathologic fracture through a benign or malignant bone tumor may occur after very minor trauma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/17/24855?source=see_link&amp;anchor=H5#H5\">",
"     \"Proximal humeral fractures in children\", section on 'Children and adolescents'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H335466\">",
"     'Pathologic fracture'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The child or adolescent with a proximal humeral fracture typically presents with a history of trauma, severe shoulder pain, and marked pain on arm movement. For nondisplaced proximal humeral fractures, the physical findings may be limited to tenderness and mild swelling. For displaced fractures, significant anterior swelling and altered shoulder appearance relative to the unaffected side are often present, and the arm is usually shortened and held in extension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/17/24855?source=see_link&amp;anchor=H8#H8\">",
"     \"Proximal humeral fractures in children\", section on 'Physical findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine AP and axillary lateral views of the humerus are generally sufficient to diagnose a proximal humeral fracture. If the injured child is tender at the physis, the treating physician should suspect a Salter-Harris I fracture, even in the presence of normal radiographs. If clinical concern for a shoulder injury is present, a complete three view shoulder series (ie, AP, axillary, and scapular &ldquo;Y&rdquo; views) should also be obtained. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/17/24855?source=see_link&amp;anchor=H12#H12\">",
"     \"Proximal humeral fractures in children\", section on 'Radiographic findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of proximal humeral fractures in children and adolescents is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/17/24855?source=see_link&amp;anchor=H16#H16\">",
"     \"Proximal humeral fractures in children\", section on 'Initial treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/17/24855?source=see_link&amp;anchor=H21#H21\">",
"     \"Proximal humeral fractures in children\", section on 'Definitive care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15374595\">",
"    <span class=\"h2\">",
"     Shoulder dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder dislocation refers to dissociation of the humeral head from the glenoid cavity and may occur anteriorly, posteriorly, or inferiorly. These injuries require reduction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10378?source=see_link&amp;anchor=H11#H11\">",
"     \"Shoulder dislocation and reduction\", section on 'Reduction procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Athletes with shoulder subluxation or instability and acute trauma may have similar findings to those with shoulder dislocation, but are less likely to have long term dysfunction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Anterior",
"      </strong>",
"      &ndash; An anterior shoulder dislocation is usually caused by a blow to the abducted, externally rotated, and extended arm (eg, blocking a basketball shot or arm tackling in American football as a player runs past). Less commonly, a blow to the posterior humerus or a fall on an outstretched arm, or any forceful forward swinging of the arm (missed punch), may cause an anterior dislocation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10378?source=see_link&amp;anchor=H5#H5\">",
"       \"Shoulder dislocation and reduction\", section on 'Mechanism of injury'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An anteriorly dislocated shoulder causes the arm to be slightly abducted and externally rotated. The patient resists all movement. The acromion appears prominent in thin individuals and there is loss of the normal rounded appearance of the shoulder (",
"    <a class=\"graphic graphic_picture graphicRef60699 \" href=\"mobipreview.htm?0/17/273\">",
"     picture 1",
"    </a>",
"    ). Axillary nerve dysfunction is common after this injury. Thus, careful evaluation for nerve dysfunction with sensory loss over the lateral deltoid is an essential part of the examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10378?source=see_link&amp;anchor=H6#H6\">",
"     \"Shoulder dislocation and reduction\", section on 'Examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographs are typically performed before and after reduction of an anterior shoulder dislocation. Initial radiographs confirm the diagnosis and exclude fractures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81951 \" href=\"mobipreview.htm?30/13/30943\">",
"     image 4",
"    </a>",
"    ); postreduction radiographs confirm successful reduction and exclude any fracture caused by the procedure. Routine films include an anteroposterior (AP), a scapular \"Y\" view, and an axillary view. In skeletally mature patients with a prior history of shoulder dislocation, some clinicians may proceed with reduction without obtaining radiographs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10378?source=see_link&amp;anchor=H7#H7\">",
"     \"Shoulder dislocation and reduction\", section on 'Radiographic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Injuries associated with anterior dislocations include a cortical depression of the humeral head (Hill-Sachs deformity) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57243 \" href=\"mobipreview.htm?41/9/42142\">",
"     image 5",
"    </a>",
"    ) and glenoid labrum disruption with or without an avulsion fracture (Bankart lesion) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54398 \" href=\"mobipreview.htm?8/44/8911\">",
"     image 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10378?source=see_link&amp;anchor=H8#H8\">",
"     \"Shoulder dislocation and reduction\", section on 'Associated injuries (Hill-Sachs and Bankart)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anterior shoulder dislocations typically require urgent reduction. The techniques for reduction of an anterior shoulder dislocation are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10378?source=see_link&amp;anchor=H11#H11\">",
"     \"Shoulder dislocation and reduction\", section on 'Reduction procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Posterior",
"      </strong>",
"      &ndash; Posterior shoulder dislocation is much less common than anterior dislocation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/2,28\">",
"       2,28",
"      </a>",
"      ]. Posterior shoulder dislocation typically arises from a blow to the anterior portion of the shoulder, axial loading of an adducted and internally rotated arm or violent muscle contractions following a seizure or electrocution. Examination reveals prominence of the posterior shoulder with flattening anteriorly. The coracoid process appears prominent. The patient holds the arm in adduction and internal rotation and is unable to externally rotate (",
"      <a class=\"graphic graphic_picture graphicRef73358 \" href=\"mobipreview.htm?43/9/44178\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef54900 \" href=\"mobipreview.htm?13/20/13632\">",
"       movie 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10378?source=see_link&amp;anchor=H9#H9\">",
"       \"Shoulder dislocation and reduction\", section on 'Posterior shoulder dislocation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiographic evidence of a posterior shoulder dislocation on a standard anteroposterior (AP) view is subtle and may go undetected in up to 50 percent of cases. Clues to the diagnosis include the \"light bulb\" sign, rim sign, and trough line sign (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54093 \" href=\"mobipreview.htm?16/38/16994\">",
"     image 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61746 \" href=\"mobipreview.htm?33/39/34431\">",
"     image 8",
"    </a>",
"    ). Posterior shoulder dislocations are commonly associated with tuberosity and surgical neck fractures of the humerus, reverse Hill-Sachs lesions, and injuries to the labrum and rotator cuff. Computed tomography may be necessary to characterize the full extent of injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10378?source=see_link&amp;anchor=H9#H9\">",
"     \"Shoulder dislocation and reduction\", section on 'Posterior shoulder dislocation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consultation with an orthopedic surgeon is typically warranted prior to attempting reduction of a posterior shoulder dislocation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10378?source=see_link&amp;anchor=H20#H20\">",
"     \"Shoulder dislocation and reduction\", section on 'Posterior shoulder dislocation reduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Inferior",
"      </strong>",
"      &ndash; Inferior shoulder dislocations (luxatio erecta) are the least common type of shoulder dislocation and are typically caused by axial loading of a fully abducted arm or forceful hyperabduction. Patients with this injury hold the involved arm above their head and are unable to adduct the arm. A prominence in the axilla is also present. The forearm is pronated and in most cases rests on the top of the head. Approximately 60 percent of patients will have some degree of neurologic dysfunction, with the axillary nerve most commonly involved. Radiographs reveal the humeral head beneath the coracoid or the glenoid (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70882 \" href=\"mobipreview.htm?39/17/40223\">",
"       image 9",
"      </a>",
"      ). Associated fractures include the greater tuberosity (most common), acromion, scapula, humeral head, coracoid, and glenoid. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10378?source=see_link&amp;anchor=H10#H10\">",
"       \"Shoulder dislocation and reduction\", section on 'Inferior shoulder dislocation (luxatio erecta)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The technique for reduction of an inferior shoulder dislocation is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10378?source=see_link&amp;anchor=H21#H21\">",
"     \"Shoulder dislocation and reduction\", section on 'Inferior shoulder dislocation reduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2622076\">",
"    <span class=\"h2\">",
"     Acromioclavicular injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury to the acromioclavicular (AC) joint usually occurs from direct trauma to the superior or lateral aspect of the shoulder (acromion) with the arm adducted, such as a direct blow or falling onto the shoulder (",
"    <a class=\"graphic graphic_figure graphicRef60132 \" href=\"mobipreview.htm?3/51/3890\">",
"     figure 10",
"    </a>",
"    ). Force correlates with injury. Low force typically causes an AC sprain. Progressive increases in force cause AC ligament rupture, and then sprain and rupture of the coracoclavicular (CC) ligaments (",
"    <a class=\"graphic graphic_figure graphicRef62016 \" href=\"mobipreview.htm?23/41/24210\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The patient with an AC injury generally exhibits tenderness directly over the AC joint, possibly with deformity. Initial radiographic evaluation of a suspected AC injury can be pursued using either of two approaches: a single anterior-posterior (AP) Zanca view including both AC joints (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82477 \" href=\"mobipreview.htm?29/3/29759\">",
"     image 10",
"    </a>",
"    ); or two AP radiographs, one of the involved shoulder and a comparison film of the uninvolved side. A system for classification is presented in the accompanying table (",
"    <a class=\"graphic graphic_table graphicRef69063 \" href=\"mobipreview.htm?16/52/17227\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/26/10663?source=see_link&amp;anchor=H4#H4\">",
"     \"Acromioclavicular joint injuries\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of AC injuries varies according to degree of injury and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/26/10663?source=see_link&amp;anchor=H8#H8\">",
"     \"Acromioclavicular joint injuries\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2620029\">",
"    <span class=\"h1\">",
"     OTHER CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scapula fractures typically occur after a direct forceful blow to the anterior or posterior shoulder and are rarely associated with sports injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2620553\">",
"    <span class=\"h2\">",
"     Scapula fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scapula fractures are rarely encountered after sports injuries and are more commonly associated with high force trauma such as motor vehicle collisions. These fractures are frequently associated with life-threatening injuries to the head, neck, and thorax. Specific patterns are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Scapula body and spine fractures",
"      </strong>",
"      &ndash; The most common sports mechanism is direct blows in American football [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/12\">",
"       12",
"      </a>",
"      ]. Associated injuries include rib fractures, pulmonary contusion, brachial plexus disruption, and axillary artery laceration. Most fractures heal with supportive measures but fractures with &gt;10 mm of displacement are associated with malunion and worse long-term outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Glenoid fractures",
"      </strong>",
"      &ndash; Glenoid neck fractures are relatively rare in the pediatric age group, but have been reported as a skiing injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/31\">",
"       31",
"      </a>",
"      ]. On plain radiographs, these fractures will extend from the suprascapular notch to the lateral scapular border inferior of the glenoid rim. When this fracture is associated with a midclavicular fracture, it is considered a &ldquo;floating shoulder&rdquo; injury because these structures are essential to providing a foundation to suspend the arm to the axial skeleton. Indications for surgical and nonsurgical management are debated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. Displaced fractures may be treated with open or closed reduction, but regardless of treatment, usually have good functional outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/32-34\">",
"       32-34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glenoid fossa fractures (excluding bony Bankart lesions associated with shoulder instability injuries) result from a direct blow to the lateral aspect of the shoulder, driving the humeral head into the glenoid fossa. The fracture can extend inferiorly through the lateral scapular border, medially through the body of the scapula, or produce comminution of the glenoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/35\">",
"     35",
"    </a>",
"    ]. In the pediatric population, a fall on the tip of the shoulder will drive the scapula inferiorly while the fracture fragment is held in place by the stronger coracoclavicular ligaments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The fracture will track along the epiphysis of glenoid fossa, located at the upper one-third of the glenoid and inferior to the coracoid process. It is rarely complicated by a suprascapular nerve injury. This injury can mimic an acromioclavicular separation and the Stryker Notch view may help to demonstrate the fracture on radiography. Most of these injuries are treated nonoperatively with immobilization for four to six weeks, but displacement of more than 10 mm or more than 40 degrees of angulation requires surgical management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Acromion fractures",
"      </strong>",
"      &ndash; Fractures of the acromion are rare and often misdiagnosed in the presence of an os acromiale because they both are most commonly located at the junction between the meso and meta-acromion. Fractures can occur with an inferiorly directed blow to the superior aspect of the acromion or a fall with a superiorly directed axial load that translates the humeral head superiorly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. The first mechanism will usually result in an acromioclavicular separation, but if fractured, it may be complicated by a brachial plexus root avulsion. The latter, when associated with significant superior displacement, may be complicated by injury to the rotator cuff [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/39\">",
"       39",
"      </a>",
"      ]. The os acromiale is bilateral in 60 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/40\">",
"       40",
"      </a>",
"      ]. Thus, contralateral radiographs may be helpful in distinguishing between a nondisplaced fracture and an os acromiale.",
"     </li>",
"     <li>",
"      <strong>",
"       Coracoid fractures",
"      </strong>",
"      &ndash; Coracoid fractures have been caused by both direct and indirect trauma. Direct trauma to the tip of the coracoid is associated with the rare subcoracoid glenohumeral dislocation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/41\">",
"       41",
"      </a>",
"      ]. Indirect trauma can occur from avulsion injury during strong muscular contraction of the pectoralis minor muscle and short head of the biceps when the arm is in the abducted and extended position [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/42\">",
"       42",
"      </a>",
"      ]. An avulsion injury can result from a fall on the acromion that usually results in an acromioclavicular separation, but in this case, results in tearing the coracoid attachment of the coracoclavicular ligament [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/36\">",
"       36",
"      </a>",
"      ]. Most fractures without displacement and intact coracoclavicular and acromioclavicular ligaments will heal with immobilization in a sling in internal rotation. Those with more displacement (&gt;5 mm) and disrupted ligamentous structures may benefit from surgical management. The more distal on the coracoid process the fracture is located, the more likely that healing will be delayed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40457/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H684359\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of shoulder pain and injury is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician should first exclude life-threatening conditions including sternoclavicular injury and referred pain from serious cervical spine, thoracic, or abdominal injury. (See",
"    <a class=\"local\" href=\"#H335158\">",
"     'Life-threatening and serious conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Once these important extrinsic causes of shoulder pain have been excluded, careful history, physical examination, and, in most cases, radiographs help identify the specific etiology. Unlike older patients, young athletes are more prone to fractures and thus plain radiographs are typically indicated.",
"   </p>",
"   <p>",
"    Clinical findings of specific conditions are discussed above by diagnosis and in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H684351\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diagnosis and treatment for shoulder injuries in the young athlete is different from treating adults because of the higher likelihood of fracture caused by skeletal immaturity. (See",
"      <a class=\"local\" href=\"#H15374507\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15374514\">",
"       'Relevant anatomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Life-threatening causes of shoulder pain after an injury include posterior sternoclavicular dislocation and referred pain from a serious underlying injury to the neck, abdomen, or myocardium. More serious conditions include pathologic fracture through a proximal humeral bony malignancy and thoracic outlet syndrome. (See",
"      <a class=\"local\" href=\"#H335158\">",
"       'Life-threatening and serious conditions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Common causes of shoulder pain after trauma include superficial contusions, clavicle and proximal humeral fractures, shoulder (glenohumeral) dislocation and acromioclavicular joint injuries. (See",
"      <a class=\"local\" href=\"#H781977\">",
"       'Common conditions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Scapular fractures typically occur after a direct forceful blow to the anterior or posterior shoulder and are rarely associated with sports injuries. (See",
"      <a class=\"local\" href=\"#H2620029\">",
"       'Other conditions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In children and adolescents, the clinician should first exclude life-threatening conditions including sternoclavicular injury and referred pain from serious cervical spine, thoracic, or abdominal injury. Once these important extrinsic causes of shoulder pain have been excluded, careful history, physical examination, and, in most cases, radiographs help identify the specific etiology. Unlike older patients, young athletes are more prone to fractures and thus plain radiographs are typically indicated. (See",
"      <a class=\"local\" href=\"#H684359\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/1\">",
"      Howell SM, Galinat BJ. The glenoid-labral socket. A constrained articular surface. Clin Orthop Relat Res 1989; :122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/2\">",
"      ROWE CR. Prognosis in dislocations of the shoulder. J Bone Joint Surg Am 1956; 38-A:957.",
"     </a>",
"    </li>",
"    <li>",
"     National Sporting Good Association, Mt. Prospect, Illinois, Sports Participation in (yr), Annual: Series I and II, based on the US Census Bureau Data, US Department of Commerce, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/4\">",
"      Lippitt, SB, Vanderhooft, JE, Harris, SL, et al. Glenohumeral stability from concavity compression. A quantitative analysis. J Shoulder Elbow Surg 1993; 2:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/5\">",
"      O'Brien SJ, Neves MC, Arnoczky SP, et al. The anatomy and histology of the inferior glenohumeral ligament complex of the shoulder. Am J Sports Med 1990; 18:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/6\">",
"      Urayama M, Itoi E, Hatakeyama Y, et al. Function of the 3 portions of the inferior glenohumeral ligament: a cadaveric study. J Shoulder Elbow Surg 2001; 10:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/7\">",
"      Schwartz E, Warren RF, O'Brien SJ, Fronek J. Posterior shoulder instability. Orthop Clin North Am 1987; 18:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/8\">",
"      Szilv&aacute;ssy J. [Estimation of age by the sternal articular surfaces of the clavicle]. Beitr Gerichtl Med 1977; 35:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/9\">",
"      Cmap JD, Cilley EIL. Diagrammatic chart showing time of appearnce of the various centers of ossification and period of union. Am J Roentgenol Radium Ther 1931; 26:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/10\">",
"      McClure JG, Raney RB. Anomalies of the scapula. Clin Orthop Relat Res 1975; :22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/11\">",
"      Samilson RL. Congenital and developmental anomalies of the shoulder girdle. Orthop Clin North Am 1980; 11:219.",
"     </a>",
"    </li>",
"    <li>",
"     Rockwood CA. The Shoulder, Saunders Elsevier, Philadelphia 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/13\">",
"      Mudge MK, Wood VE, Frykman GK. Rotator cuff tears associated with os acromiale. J Bone Joint Surg Am 1984; 66:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/14\">",
"      Bigliani LU, Morrison DS, April EW. The morphology of the acromion and its relationship to rotator cuff tears. Orthop Trans 1986; 10:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/15\">",
"      Boehm TD, Rolf O, Martetschlaeger F, et al. Rotator cuff tears associated with os acromiale. Acta Orthop 2005; 76:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/16\">",
"      Habernek H, Hertz H. [Origin, diagnosis and treatment of sternoclavicular joint dislocation]. Aktuelle Traumatol 1987; 17:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/17\">",
"      Nordqvist A, Redlund-Johnell I, von Scheele A, Petersson CJ. Shortening of clavicle after fracture. Incidence and clinical significance, a 5-year follow-up of 85 patients. Acta Orthop Scand 1997; 68:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/18\">",
"      Rowe CR. An atlas of anatomy and treatment of midclavicular fractures. Clin Orthop Relat Res 1968; 58:29.",
"     </a>",
"    </li>",
"    <li>",
"     Sarwark JF, King EC, Janicki JA. Proximal humerus, scapula, and clavicle. In: Rockwood and Wilkins' Fractures in Children, 7th edition, Beaty JH, Kasser JR.  (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2010. p.620.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/20\">",
"      Glass ER, Thompson JD, Cole PA, et al. Treatment of sternoclavicular joint dislocations: a systematic review of 251 dislocations in 24 case series. J Trauma 2011; 70:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/21\">",
"      Heinig CF. Retrosternal dislocation of the clavicle: Early recognition, x-ray diagnosis, and management [abstract]. J Bone Joint Surg Am 1968; 50:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/22\">",
"      Hobbs DW. Sternoclavicular joint: a new axial radiographic view. Radiology 1968; 90:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/23\">",
"      Doss A, Lang IM, Roberts I, et al. Posterior sternoclavicular joint dislocation in children-role of spiral computed tomography. Pediatr Emerg Care 2005; 21:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/24\">",
"      Jaggard MK, Gupte CM, Gulati V, Reilly P. A comprehensive review of trauma and disruption to the sternoclavicular joint with the proposal of a new classification system. J Trauma 2009; 66:576.",
"     </a>",
"    </li>",
"    <li>",
"     Wirth M, Rockwood C. DeLee &amp; Drez's Orthopaedic Sports Medicine: Principles and Practice, 2nd, DeLee J, Drez D (Eds), Saunders, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/26\">",
"      de Jong KP, Sukul DM. Anterior sternoclavicular dislocation: a long-term follow-up study. J Orthop Trauma 1990; 4:420.",
"     </a>",
"    </li>",
"    <li>",
"     Baskin MN. Injury - Shoulder. In: Textbook of Pediatric Emergency Medicine, 6th edition, Fleisher GR, Ludwig S.  (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2010. p.353.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/28\">",
"      Owens BD, Duffey ML, Nelson BJ, et al. The incidence and characteristics of shoulder instability at the United States Military Academy. Am J Sports Med 2007; 35:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/29\">",
"      Antonio GE, Griffith JF, Yu AB, et al. First-time shoulder dislocation: High prevalence of labral injury and age-related differences revealed by MR arthrography. J Magn Reson Imaging 2007; 26:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/30\">",
"      Nordqvist A, Petersson C. Fracture of the body, neck, or spine of the scapula. A long-term follow-up study. Clin Orthop Relat Res 1992; :139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/31\">",
"      Toro FG, Vaisman A, Villal&oacute;n IE, Calvo R. Fracture dislocation of the glenoid fossa with open physis: a case report. J Pediatr Orthop 2010; 30:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/32\">",
"      Cain TE, Hamilton WP. Scapular fractures in professional football players. Am J Sports Med 1992; 20:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/33\">",
"      Carro LP, Nu&ntilde;ez MP, Llata JI. Arthroscopic-assisted reduction and percutaneous external fixation of a displaced intra-articular glenoid fracture. Arthroscopy 1999; 15:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/34\">",
"      Edeland HG, Zachrisson BE. Fracture of the scapular notch associated with lesion of the suprascapular nerve. Acta Orthop Scand 1975; 46:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/35\">",
"      Goss TP. Scapular Fractures and Dislocations: Diagnosis and Treatment. J Am Acad Orthop Surg 1995; 3:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/36\">",
"      Montgomery SP, Loyd RD. Avulsion fracture of the coracoid epiphysis with acromioclavicular separation. Report of two cases in adolescents and review of the literature. J Bone Joint Surg Am 1977; 59:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/37\">",
"      Froimson AI. Fracture of the coracoid process of the scapula. J Bone Joint Surg Am 1978; 60:710.",
"     </a>",
"    </li>",
"    <li>",
"     Goss T. The scapula. In: The Shoulder, 3rd, Rockwood, C, Frederick M, Wirth M, Lippitt S (Eds), Saunders, Philadelphia 2004. Vol 1, p.413.",
"    </li>",
"    <li>",
"     Neer C. Shoulder Reconstruction, Saunders, Philadelphia 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/40\">",
"      Liberson F. OS Acromiale-A contested anomaly. J Bone Joint Surg Am 1937; 19:683.",
"     </a>",
"    </li>",
"    <li>",
"     McLaughlin HL. Trauma, WB Saunders, Philadelphia 1959. p.239.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/42\">",
"      Mariani PP. Isolated fracture of the coracoid process in an athlete. Am J Sports Med 1980; 8:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40457/abstract/43\">",
"      Garcia-Elias M, Salo JM. Non-union of a fractured coracoid process after dislocation of the shoulder. A case report. J Bone Joint Surg Br 1985; 67:722.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13885 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-FB51BAF4EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_32_40457=[""].join("\n");
var outline_f39_32_40457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H684351\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15374507\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15374514\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H335158\">",
"      LIFE-THREATENING AND SERIOUS CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H335289\">",
"      Sternoclavicular injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H335813\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H335820\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5006658\">",
"      - Reduction of posterior sternoclavicular dislocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H683321\">",
"      Referred pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H335466\">",
"      Pathologic fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H335474\">",
"      Thoracic outlet syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H781977\">",
"      COMMON CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H683535\">",
"      Superficial contusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2619337\">",
"      Clavicle injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H683479\">",
"      - Distal clavicle contusion (shoulder pointer)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H683486\">",
"      - Clavicle fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2619806\">",
"      Proximal humeral fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15374595\">",
"      Shoulder dislocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2622076\">",
"      Acromioclavicular injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2620029\">",
"      OTHER CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2620553\">",
"      Scapula fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H684359\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H684351\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13885\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13885|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?4/34/4642\" title=\"diagnostic image 1\">",
"      Fallen fragment sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/60/36801\" title=\"diagnostic image 2\">",
"      Chondroblastoma humerus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/47/767\" title=\"diagnostic image 3\">",
"      Xray of distal clavicle fracture Type II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?30/13/30943\" title=\"diagnostic image 4\">",
"      Anterior shoulder dislocation radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/9/42142\" title=\"diagnostic image 5\">",
"      Hill Sachs lesion AP radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/44/8911\" title=\"diagnostic image 6\">",
"      Bankart lesion AP radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/38/16994\" title=\"diagnostic image 7\">",
"      Posterior shoulder dislocation radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/39/34431\" title=\"diagnostic image 8\">",
"      Posterior shoulder dislocation and fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/17/40223\" title=\"diagnostic image 9\">",
"      Inferior shoulder dislocation radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/3/29759\" title=\"diagnostic image 10\">",
"      Zanca view radiograph of AC joint",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13885|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/28/15814\" title=\"figure 1A\">",
"      Basic shoulder anatomy anterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/60/28613\" title=\"figure 1B\">",
"      Basic shoulder anatomy lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/6/27748\" title=\"figure 1C\">",
"      Basic shoulder anatomy posterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/1/15378\" title=\"figure 2\">",
"      Rotator cuff muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/47/34554\" title=\"figure 3\">",
"      Scapular motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/41/24210\" title=\"figure 4\">",
"      Normal shoulder ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/30/25057\" title=\"figure 5\">",
"      Closed reduction for posterior sternoclavicular dislocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/58/18338\" title=\"figure 6\">",
"      Anatomy of the thoracic outlet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/21/19793\" title=\"figure 7\">",
"      Sports mechanism for proximal humeral fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/55/21361\" title=\"figure 8\">",
"      Salter-Harris classification system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/9/6289\" title=\"figure 9\">",
"      Physeal fractures of the proximal humerus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/51/3890\" title=\"figure 10\">",
"      Mechanism of acromioclavicular joint injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13885|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/17/273\" title=\"picture 1\">",
"      Anterior shoulder dislocation appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/9/44178\" title=\"picture 2\">",
"      Posterior shoulder dislocation appearance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13885|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?13/20/13632\" title=\"movie 1\">",
"      Posterior shoulder dislocation with blocked external rotation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13885|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/36/28236\" title=\"table 1\">",
"      Glenohumeral joint movements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/62/16364\" title=\"table 2\">",
"      Shoulder girdle ossification centers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/11/9405\" title=\"table 3\">",
"      Radiologic evaluation of the C spine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/52/17227\" title=\"table 4\">",
"      Acromioclavicular injury grading",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/26/10663?source=related_link\">",
"      Acromioclavicular joint injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41368?source=related_link\">",
"      Approach to the young athlete with neck pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27385?source=related_link\">",
"      Cardiac injury from blunt trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/43/12985?source=related_link\">",
"      Clavicle fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37769?source=related_link\">",
"      Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/28/15815?source=related_link\">",
"      Field care and evaluation of the young athlete with acute neck injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4777?source=related_link\">",
"      Liver, spleen, and pancreas injury in children with blunt abdominal trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/6/3177?source=related_link\">",
"      Overview of thoracic outlet syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27834?source=related_link\">",
"      Physical examination of the shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27754?source=related_link\">",
"      Primary (spontaneous) upper extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/17/24855?source=related_link\">",
"      Proximal humeral fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10378?source=related_link\">",
"      Shoulder dislocation and reduction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_32_40458="HIV protease inhibitors";
var content_f39_32_40458=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   HIV protease inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/32/40458/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/32/40458/contributors\">",
"     Amy L Graziani, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/32/40458/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/32/40458/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/32/40458/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/32/40458/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/32/40458/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protease inhibitors (PIs) are potent antiretroviral drugs recommended as part of the \"preferred regimen\" for patients in the guidelines of the International AIDS Society-USA (IAS-USA) and the Department of Health and Human Services (DHHS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to understand the pharmacology of the protease inhibitors since exposure to low doses of PIs for relatively short periods of time is associated with the development of HIV drug resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. As a result, underdosing, intermittent dosing, non-adherence, and drug malabsorption should be avoided during PI therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, these drugs should be taken in combination with other antiretroviral agents.",
"   </p>",
"   <p>",
"    This topic review will provide information that will highlight the relevant dosing and administration differences between these agents. Some of the information is intended for the prescriber, while patient information and the important drug interactions that can occur are presented elsewhere. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/56/2946?source=see_link\">",
"     \"Patient information: Tips for taking HIV medications (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DOSING AND ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Serum concentrations and drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is essential to dose the PIs correctly to avoid low serum drug concentrations, which can lead to the development of resistance to an individual agent or cross-resistance to other members of this class. Significant differences in absorption, serum half-lives, routes of metabolism, and dosing frequency exist among the protease inhibitors. For detailed information about PI dosing, see the DHHS Antiretroviral Guidelines for Adults and Adolescents, which can be accessed at",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf\">",
"     file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf",
"    </a>",
"    (see Appendix B, Table 3).",
"   </p>",
"   <p>",
"    The early dose-ranging studies with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    , for example, showed maximum antiretroviral effect with &ge;2.4",
"    <span class=\"nowrap\">",
"     g/day;",
"    </span>",
"    lower doses were associated with a reduced response, increased resistance, and diminished effectiveness of dose adjustment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/3\">",
"     3",
"    </a>",
"    ]. Only newly enrolled patients who started therapy at 2.4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    showed a sustained, good viral load response, while those who started at too low a dose and later increased their dose did not achieve viral suppression. Subsequent trials have shown that all patients treated with PIs should receive combination antiviral regimens, usually consisting of one to two PIs and two nucleoside reverse transcriptase inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are significant differences among the PIs with respect to absorption in the presence of food. If the drugs are not taken properly, reductions in bioavailability up to 80 percent can occur, predisposing the patient to the development of resistance. One factor that limits the absorption of most HIV PIs is that they are substrates for P-glycoprotein (the multidrug resistance transporter), which is an ATP-dependent efflux membrane transporter. Oral administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    to knockout mice lacking this transporter resulted in a two- to fivefold increase in plasma drug concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is also important to carefully check for potential drug interactions between the PI being considered and other concomitant medications the patient is already taking. Under-recognition of these interactions may result in loss of therapeutic effect or excess toxicity. Some studies have demonstrated that unsuspected drug-drug interactions were more common among HIV-infected patients taking protease inhibitors than those taking antiretroviral medications within other drug classes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/8\">",
"     8",
"    </a>",
"    ]. For detailed PI drug interaction information, see the DHHS Antiretroviral Guidelines for Adults and Adolescents at",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf\">",
"     file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf",
"    </a>",
"    (Tables 14, 15A, and 16).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SAQUINAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     Saquinavir",
"    </a>",
"    has potent anti-HIV activity in vitro and has demonstrated efficacy as a component of antiretroviral therapy (ART). It is sometimes used as an alternative to",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    in pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1\">",
"     1",
"    </a>",
"    ]. Disadvantages include its relatively high pill burden, gastrointestinal side effects, and potential for PR and QTc prolongation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1\">",
"     1",
"    </a>",
"    ]. For this reason, it is in the lowest category of acceptable regimens in the DHHS Guidelines (&ldquo;Regimens that may be acceptable but should be used with caution&rdquo;); furthermore, an electrocardiogram is now recommended both prior to and four days after taking saquinavir to evaluate for any PR or QT prolongation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral absorption of the original capsule formulation (Invirase) is poor, even in the presence of food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/3,10,11\">",
"     3,10,11",
"    </a>",
"    ]. For that reason, a more bioavailable gel cap formulation (Fortovase) was developed and became available in late 1997. Despite its improved bioavailability, dosing still required 18 capsules a day (6 x 200 mg every eight hours) in the presence of food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/11\">",
"     11",
"    </a>",
"    ]. Because adherence to this bulky regimen was understandably poor, neither of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    formulations was commonly used \"unboosted\". Rather, they were combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    , which \"boosts\" saquinavir levels dramatically and consequently decreases the pill burden [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Pharmacokinetic boosting'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A third formulation of Invirase subsequently became available in a 500 mg strength tablet. This is the most commonly used dosage form; the Fortovase gelcap was discontinued in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/12\">",
"     12",
"    </a>",
"    ]. When combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    tablets are listed in the DHHS Guidelines as an \"alternative\" but not preferred PI for na&iuml;ve patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1\">",
"     1",
"    </a>",
"    ]. Invirase (1000 mg twice daily) should always be combined with ritonavir (100 mg twice daily) within two hours of a meal. Rarely, if use of a second protease inhibitor is required, saquinavir can also be combined with",
"    <span class=\"nowrap\">",
"     ritonavir/lopinavir",
"    </span>",
"    (Kaletra).",
"   </p>",
"   <p>",
"    The original capsule formulation and new tablet formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    (Invirase&reg;) have no special storage requirements (17 to 34&ordm;C). However, as with all medications, they should not be stored in damp areas like bathrooms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Boosted regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of \"boosted\" regimens has been studied with a variety of dosing regimens, one of which has been approved by the FDA: twice-daily dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    (1000 mg) plus twice-daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    (100 mg). The drugs should be taken at the same time, within two hours of a meal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/11\">",
"     11",
"    </a>",
"    ]. A once-daily regimen of 2000 mg saquinavir hard gel capsules and 100 mg ritonavir has been studied. However, this once-daily dosing is not approved by the Federal Drug Administration (FDA). Trough levels are low, and the DHHS guidelines do not list it as a preferred regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1,13\">",
"     1,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all protease inhibitors, many clinically significant interactions are possible with this agent. Patients should be screened carefully for potential drug interactions. One study from the National Institutes of Health (NIH) in normal volunteers found that administration of garlic caplets reduced the PI",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    's area under the curve, mean maximum concentrations, and trough levels by 51, 54, and 49 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/14\">",
"     14",
"    </a>",
"    ]. Garlic caplets were administered for 20 days beginning four days after the start of saquinavir. After a 10-day period of washout of garlic supplements, saquinavir was readministered for four days and the pharmacokinetic variables only returned to 60 to 70 percent of those preceding garlic intake. This study demonstrates the potential importance of interactions with nutritional supplements; many HIV-infected patients take garlic supplements, perhaps to counteract the hypercholesterolemia induced by a number of antiretroviral regimens.",
"   </p>",
"   <p>",
"    In healthy volunteers,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    40 mg daily can increase the area under the curve concentrations (AUC) for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    (Invirase tablets) by 82 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/15\">",
"     15",
"    </a>",
"    ]. No significant adverse events occurred although the study period was short. In a pharmacokinetic drug interaction study with saquinavir and omeprazole 40 mg once daily in HIV-infected patients, the saquinavir exposure (AUC) was also elevated significantly by 54 to 67 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/11,16\">",
"     11,16",
"    </a>",
"    ]. Although not contraindicated, patients who are receiving saquinavir and omeprazole should be monitored closely for dose-related saquinavir side effects including gastrointestinal complaints, elevated triglycerides, and perhaps thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/11\">",
"     11",
"    </a>",
"    ]. The effect of combining omeprazole with saquinavir is the opposite of what is seen when omeprazole is taken with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    ; in that circumstance, atazanavir levels are remarkably reduced by over 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/15\">",
"     15",
"    </a>",
"    ] and those drugs should not be coadministered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RITONAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     Ritonavir",
"    </a>",
"    has good in vitro and in vivo activity against HIV; however, due to significant gastrointestinal side effects and large pill burden, essentially all of the current use of ritonavir is for pharmacokinetic boosting of other protease inhibitors. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Pharmacokinetic boosting'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the past, when it was used as the sole protease inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    therapy was initiated at 300 mg twice daily and increased every two to three days by 100 mg twice-daily increments up to 600 mg twice daily to decrease gastrointestinal side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/17\">",
"     17",
"    </a>",
"    ]. Meals have less of an effect on the absorption of ritonavir than on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    . Ideally, ritonavir should be administered with meals to enhance gastric absorption and minimize the gastrointestinal side effects. However, the absence of food in the stomach only reduces the absorption of the capsule formulation 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/17\">",
"     17",
"    </a>",
"    ]. The oral bioavailability is 60 to 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. If patients are also being treated with medications that should be taken on an empty stomach (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    , Videx EC capsules) pills will need to be taken separately to optimize absorption.",
"   </p>",
"   <p>",
"    The liquid formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    is available in a 600",
"    <span class=\"nowrap\">",
"     mg/7.5",
"    </span>",
"    mL castor oil-based liquid, which contains ethanol and propylene glycol. Most adult patients find it very unpalatable, despite its use by pediatric patients. It is oily and has a caramel-peppermint flavor and strong aftertaste. Fortunately, the volume of the dose is relatively small, usually 1 to 1",
"    <span class=\"nowrap\">",
"     1/2",
"    </span>",
"    teaspoons. Suggestions for improving palatability include eating peanut butter before and after to coat the tongue and mouth, swigging the dose and then chasing it with water or another beverage as one would with a shot of alcohol, using a straw, holding one's nose, and diluting with 8 ounces of chocolate milk, Ensure, or Advera and ingesting within one hour of mixing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/5,17\">",
"     5,17",
"    </a>",
"    ]. If possible, prescriptions should be written for multiples of 240 mL as this is how the drug is supplied by the manufacturer. It comes with a dose-measuring cup.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     Ritonavir",
"    </a>",
"    tablets, which do not require refrigeration, were approved by the FDA in early 2010. This is now the preferred formulation and should be specified on prescriptions to ensure patients do not get the older gelcaps inadvertently. Ritonavir gel capsules may be phased out eventually, but they are currently still available. These older gel capsules must be stored in the refrigerator (3 to 9&ordm;C) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/17\">",
"     17",
"    </a>",
"    ] by the pharmacist, and it is recommended that patients do the same. But patients may store them at room temperature if they are used within 30 days and the room temperature remains below 77&ordm;F. Ritonavir liquid can be stored at room temperature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/17\">",
"     17",
"    </a>",
"    ]. Refrigeration of the capsules may be problematic for patients who do not routinely keep their homes below 77&ordm;F and for those who do not have a refrigerator, are homeless, and those who have their electric service turned off periodically due to insufficient funds. Keeping the capsules in the refrigerator, apart from all their other medications, can make adherence difficult. Reminder \"dummy\" vials of ritonavir can be stored along with the other medications to minimize this problem. Ritonavir should be protected from light [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of the coformulated combination product",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    is described below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Lopinavir/ritonavir (Kaletra)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;While drug interactions should be examined closely whenever prescribing medications in combination with protease inhibitors, this is a particularly important consideration with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    given its powerful inhibition of CYP3A4 and CYP2D6 and its effects on several other mechanisms of drug interactions. These can lead to large increases in levels of many coadministered medications and can even result in Cushing's syndrome in patients treated with nasal or inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    as a result of 350-fold increases in levels of systemic steroids. Ritonavir can increase levels of many other concomitant medications dramatically (eg, 3000 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    , 11-fold with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ; 49-fold with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    ; fourfold with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1\">",
"     1",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    may require dose reduction from twice daily to just once a week;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    doses also require large reductions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -associated drug interactions most often result in increased levels of concomitant meds, ritonavir can also reduce the levels of some medications dramatically due to its induction of CYPs 1A2, 2C9.19, 2B6, 3A4 or glucuronosyltransferase. For example, concomitant use with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    is not recommended because voriconazole levels may be reduced by 82 percent.",
"   </p>",
"   <p>",
"    Clinicians also should be aware that patients with chronic viral hepatitis have additional impairment of CYP3A activity in the presence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    compared to patients without viral hepatitis, even at low doses of 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    typically used for pharmacokinetic boosting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INDINAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     Indinavir",
"    </a>",
"    was one of the first protease inhibitors to receive FDA approval and in 1996 was the most commonly prescribed PI. Due to concerns regarding toxicity (eg, nephrolithiasis) and need for frequent dosing, it has largely been replaced by other more potent agents.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     Indinavir",
"    </a>",
"    has good in vitro and in vivo anti-HIV activity; it has sustained antiviral activity with approximately 80 percent of patients showing no detectable virus (&lt;400",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    in naive patients who have taken indinavir in combination with nucleosides for more than 100 weeks. The usual dose of indinavir is 800 mg, two 400 mg capsules, three times daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/20\">",
"     20",
"    </a>",
"    ]. There is a 200 mg capsule that can be used in patients with mild to moderate liver disease and should take a reduced dose of indinavir (600 mg three times daily).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     Indinavir",
"    </a>",
"    must be taken on an empty stomach, one hour before or two hours after meals or with a light, low-fat snack [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/20\">",
"     20",
"    </a>",
"    ]. Administration with a full meal results in a dramatic 75 to 80 percent decrease in serum concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/20\">",
"     20",
"    </a>",
"    ]. If patients cannot take indinavir on an empty stomach due to scheduling or other concerns, it may be taken with a light, low-fat snack. Dry toast, skim milk, orange juice, or corn flakes have been studied and do not appear to have a significant adverse impact on bioavailability.",
"   </p>",
"   <p>",
"    Another unique requirement of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    is good hydration. Because the drug can cause kidney stones in 10 to 28 percent and acute renal failure (see below), patients should be instructed to drink at least 1.5 liters of liquids a day; it has been suggested that 150",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    for three hours after each dose may be particularly effective. Grapefruit juice should be avoided; eight ounces of grapefruit juice can decrease the AUC of a 400 mg indinavir dose by 26&plusmn;18 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/20\">",
"     20",
"    </a>",
"    ]. The oral bioavailability is 60 to 65 percent, similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    If possible, prescriptions should be written in multiples of 18, 90, or 180 capsules (for the 400 mg capsule) or 135 (for the 333 mg) or 270 or 360 (for the 200 mg capsule) since this is how it is supplied by the manufacturer.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     Indinavir",
"    </a>",
"    is sensitive to moisture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/20\">",
"     20",
"    </a>",
"    ]. To avoid degradation, it should not be stored in a bathroom and should be retained in the original container. The three desiccants that come with the product should also be retained in the original container.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Boosted regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;When",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    is administered with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    as part of a boosted, dual protease inhibitor regimen, it may be taken without regard to meals. Because ritonavir so effectively \"boosts\" indinavir concentrations, the clinical trials of such regimens administered indinavir without regard to meals. Boosted regimens that have been studied include indinavir 400 mg twice daily and ritonavir 400 mg twice daily, indinavir 800 mg twice daily and ritonavir 100 to 200 mg twice daily. GI side effects were more common in the 400 mg to 400 mg regimen and nephrolithiasis more common in the 800 mg to 100 mg regimen. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Pharmacokinetic boosting'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 200 mg capsule is also used in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    who require a dose reduction to 600 mg three times a day due to inhibition of the hepatic metabolism of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    . A 333 mg indinavir capsule is available for use in patients taking concomitant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    who require a dose increase to 1000 mg indinavir three times a day, due to efavirenz-related induction of hepatic metabolism. The manufacturer recommends a 50 percent rifabutin dose reduction. As with all protease inhibitors, many clinically significant interactions are possible with this agent. Patients should be screened carefully for potential drug interactions.",
"   </p>",
"   <p>",
"    The capsules are white and have a blue (200 mg) or red (333 mg) or green (400 mg) \"Crixivan\" imprint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     NELFINAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     Nelfinavir",
"    </a>",
"    (Viracept&reg;) was formerly one of the most widely prescribed and effective protease inhibitors. &nbsp;However, easier-to-administer protease inhibitors with greater potency have led to decreased utilization of nelfinavir.",
"   </p>",
"   <p>",
"    The FDA-approved adult doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    are 1250 mg twice daily (two 625 mg tablets twice a day) and the older, original dosing of 750 mg three times a day (three 250 mg tablets three times a day).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     Nelfinavir",
"    </a>",
"    should be taken with a meal. Administration on an empty stomach can result in a two- to threefold reduction in serum concentrations. Bioavailability varies between 20 and 80 percent.",
"   </p>",
"   <p>",
"    Patients who are taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    have a challenging regimen to which they must adhere. They must space the nelfinavir and didanosine doses apart because didanosine must be taken at least 60 minutes before or two hours after food. It is recommended that nelfinavir be taken with food one hour after or more than two hours before didanosine.",
"   </p>",
"   <p>",
"    A powder for pediatric patients is also available in a 144 gram bottle. One gram (one level scoop) of the powder provides 50 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    base. Due to the large volumes of powder required, this formulation is not practical for adults. The drug should be stored at room temperature. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/39/37495?source=see_link\">",
"     \"Treatment of HIV-infected adults who have trouble swallowing pills: Liquid, chewable, and crushable formulations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Drug Interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     Omeprazole",
"    </a>",
"    lowers",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    serum levels 36 to 40 percent and this could theoretically lead to treatment failure. As with all protease inhibitors, many other clinically significant interactions are possible with this agent. Patients should be screened carefully for potential drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     AMPRENAVIR (AGENERASE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amprenavir, which is no longer available in the United States, has been replaced by the prodrug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FOSAMPRENAVIR (LEXIVA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"     Fosamprenavir",
"    </a>",
"    is a prodrug of amprenavir and is a vast improvement over amprenavir in terms of pill size, burden, and gastrointestinal side effects. It can be administered with or without food. There are several once- and twice-daily FDA-approved dosing options (for treatment-naive patients). None are &ldquo;preferred&rdquo; first line agents for antiretroviral-na&iuml;ve patients, but the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted regimens are good alternative regimens. The unboosted regimens (without ritonavir) should be used with caution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dosing for PI-na&iuml;ve patients only:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"       Fosamprenavir",
"      </a>",
"      1400 mg twice daily (2 x 700 mg tablets twice daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"       Fosamprenavir",
"      </a>",
"      700 mg twice daily plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      100 mg twice daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"       Fosamprenavir",
"      </a>",
"      1400 mg once daily plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      200 mg once daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"       Fosamprenavir",
"      </a>",
"      1400 mg once daily plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      100 mg once daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the unusual circumstance that a naive patient is also taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    with a once-daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    regimen, the Department of Health and Human Services (DHHS) guidelines, and product labeling, state that an extra 100 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    should be added (ie, 1400 mg fosamprenavir plus 300 mg ritonavir once daily) to compensate for the potential efavirenz-related CYP p450 enzyme induction.",
"   </p>",
"   <p>",
"    Dosing for PI-experienced patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"       Fosamprenavir",
"      </a>",
"      700 mg BID plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      100 mg BID",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In treatment-experienced patients, only twice-daily dosing is recommended. At twice-daily dosing, the negative impact on lipids is similar to that of",
"    <span class=\"nowrap\">",
"     LPV/r.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17672?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors\", section on 'Fosamprenavir versus lopinavir (KLEAN study)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Drug Interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all protease inhibitors, many clinically significant interactions are possible with this agent. Patients should be screened carefully for potential drug interactions.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"     Fosamprenavir",
"    </a>",
"    absorption can be reduced 30 percent with concomitant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    . The product labeling states that this combination should be used with caution. A potential alternative is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    , or perhaps another proton pump inhibitor. Drug interaction studies of esomeprazole 20 mg or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    20 mg showed no significant reduction in fosamprenavir levels (although esomeprazole levels did increase 55 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     LOPINAVIR/RITONAVIR (KALETRA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    coformulated protease inhibitor became available in 2000. It is the only PI that has built-in ritonavir boosting in that ritonavir is coformulated with lopinavir in the same tablet. It is listed in the DHHS Guidelines as a \"preferred\" PI for pregnant treatment-naive patients; it is also classified as an &ldquo;alternative&rdquo; agent when used in non-pregnant patients.",
"   </p>",
"   <p>",
"    The current formulation for adults contains lopinavir 200",
"    <span class=\"nowrap\">",
"     mg/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    50 mg per tablet and can be given with or without food; the usual dose is two tablets twice a day in treatment-experienced patients, pregnant patients or treatment-naive patients. Compared to the original gelcap formulation, this formulation is associated with less pharmacokinetic variability, a diminished effect of food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/23\">",
"     23",
"    </a>",
"    ], and fewer gastrointestinal side effects. It also does not need to be refrigerated.",
"   </p>",
"   <p>",
"    In addition to twice-daily dosing, once-daily dosing of",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    (four tablets) is also another option for treatment-naive patients, although one study suggested that twice daily is still preferred in patients with high baseline HIV RNA &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]. Although one small study suggested higher rates of diarrhea with once-daily dosing, a larger trial of 664 patients demonstrated that virologic suppression rates and gastrointestinal side effects were similar in the once- and twice-daily dosing arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1\">",
"     1",
"    </a>",
"    ]. Once-daily",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    is not recommended in treatment-experienced patients and pregnant women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Lopinavir/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    is also available in a liquid solution 400 mg",
"    <span class=\"nowrap\">",
"     lopinavir/100",
"    </span>",
"    mg ritonavir per 5 mL. The usual dose is 5 mL BID with food. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Pharmacokinetic boosting'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The World Health Organization (WHO) has approved a heat-stable generic version of Kaletra manufactured by the pharmaceutical company Mylan for use in resource-limited settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19983184\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;For antiretroviral-experienced patients who are also taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    , the dose of",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    is three tablets twice a day. If taking the liquid formulation, the dose of",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    is 6.5 mL twice daily. Many other clinically significant interactions are possible with this agent. As with ritonavir and all the protease inhibitors,",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    patients should always be screened carefully for potential drug interactions when prescribing",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ATAZANAVIR (REYATAZ)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristics",
"    that differentiate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    from older protease inhibitors are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Modest effect on lipids",
"     </li>",
"     <li>",
"      Low pill burden",
"     </li>",
"     <li>",
"      Resistance mutation at 150L that is not associated with cross-resistance to other PIs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Requires acidic gastric pH for adequate absorption",
"     </li>",
"     <li>",
"      PR interval prolongation noted in the product labeling: AV block reported",
"     </li>",
"     <li>",
"      Coadministration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      has no effect on the steady state of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    has potent in vitro activity and was as effective as the comparator drug in clinical trials of PI-na&iuml;ve (atazanavir versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , both with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ) and PI-experienced patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two FDA-approved dosing regimens are a)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    400 mg (two 200 mg capsules) once a day unboosted (ie, without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    ), and b) atazanavir 300 mg (one 300 mg capsule) once a day plus ritonavir 100 mg once a day. The latter \"ritonavir&ndash;boosted\" regimen should be used in PI-experienced patients and patients taking concomitant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/29\">",
"     29",
"    </a>",
"    ]. Many clinicians prefer to prescribe ritonavir-boosted atazanavir (300 mg atazanavir and 100 mg ritonavir) for all patients, na&iuml;ve as well as experienced, due to better trough serum levels. The DHHS Guidelines recommend boosted atazanavir plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    (Truvada&trade;) as a \"preferred\" PI for na&iuml;ve patients; unboosted is listed in the third choice category of \"May be acceptable but more definitive data are needed&rdquo; category [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the unusual circumstance that an experienced patient is receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , the atazanavir dose should be 400 mg plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    100 mg, both once daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    concentrations are achieved in cerebrospinal fluid as documented in one study of 117 participants with paired plasma and CSF samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/30\">",
"     30",
"    </a>",
"    ]. Atazanavir CSF levels in these patients were variable and generally low. Median plasma atazanavir concentrations with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    were 1278 (525-2265) and 523 (283-1344)",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    The median CSF concentrations with or without ritonavir were 10.3 (&lt;5-21.1) and 7.9 (6.6-22)",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Furthermore, one-quarter of the samples had CSF concentrations of less than 5",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Because atazanavir's inhibitory concentration (IC50) for wild-type HIV is approximately 1-11",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    there is concern that ongoing HIV replication may occur in the CNS despite treatment with atazanavir; this concern is not unique to atazanavir, but generally applies to protease inhibitors as a class.",
"   </p>",
"   <p>",
"    Like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    is also associated with unconjugated hyperbilirubinemia, as a result of inhibition of the UGT1A1 enzyme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In a large registration trial, hyperbilirubinemia was common (ie, 44 percent), but led to jaundice or scleral icterus in only 5 percent of patients overall; less than 1 percent discontinued drug due to the side effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/33\">",
"     33",
"    </a>",
"    ]. Genetic factors may affect risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Several cases of cholelithiasis, with high levels of atazanavir found in the calculi, have been reported in patients who received atazanavir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    has also been associated with the development of nephrolithiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Summary of Atazanavir dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    varies depending on the treatment experience of the patient and the coadministered medications. For detailed dosing information, see the tables of the DHHS Antiretroviral Guidelines for Adults and Adolescents, which can be accessed at",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf\">",
"     file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Treatment-naive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment-naive patients should be given one of the following dosing regimens listed below as part of combination ART, which should include a minimum of three drugs. &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     Ritonavir",
"    </a>",
"    , when given for pharmacokinetic boosting, is not counted as an independent contributor to the ART regimen.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       Atazanavir",
"      </a>",
"      (300 mg; one capsule) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      (100 mg) administered once daily along with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      (Truvada&trade;) is the preferred regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1\">",
"       1",
"      </a>",
"      ]. Although ritonavir-boosted atazanavir is preferred, if it is not possible to administer ritonavir and if the patient is not on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , atazanavir can be given unboosted (without ritonavir) as a 400 mg dose (200 mg; two capsules) once daily.",
"     </li>",
"     <li>",
"      If dosed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      requires pharmacokinetic boosting with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      : Atazanavir (300 mg) once daily plus ritonavir (100 mg) once daily.",
"     </li>",
"     <li>",
"      If dosed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      , higher doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      and pharmacokinetic boosting with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      are required: Atazanavir (400 mg) once daily plus ritonavir (100 mg) once daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One randomized trial evaluated whether treatment simplification with unboosted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    was as efficacious as continuing boosted atazanavir among treatment-naive patients who were receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    as background nucleoside analogs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/40\">",
"     40",
"    </a>",
"    ]. The simplification strategy was evaluated among 419 patients who attained viral suppression on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted atazanavir during a 36-week induction period. In the unboosted arm, the ritonavir was stopped and the atazanavir dose was increased to 400 mg once daily. The",
"    <span class=\"nowrap\">",
"     abacavir/lamivudine",
"    </span>",
"    (Epzicom) nucleoside backbone was continued in both arms. The unboosted atazanavir combination therapy arm was as efficacious as the boosted atazanavir arm and associated with lower rates of hyperlipidemia and hyperbilirubinemia (4 versus 10 percent) (ARIES trial). This strategy should not be employed in patients with suboptimal adherence or among those taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    . There are several other ongoing and completed protease inhibitor simplification trials, which have shown mixed results. None have yet been endorsed or included in the DHHS Antiretroviral&nbsp;Guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Treatment-experienced patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of unboosted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    is not recommended in these patients. Furthermore, the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and atazanavir should be avoided. The following dosing regimens are preferred:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       Atazanavir",
"      </a>",
"      (300 mg) once daily plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      (100 mg) once daily",
"     </li>",
"     <li>",
"      If dosed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      requires pharmacokinetic boosting with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      : Atazanavir (300 mg) once-daily plus ritonavir (100 mg) once daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Drug Interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    is unique among the PIs in that it requires an acidic gastric pH for absorption. Concomitant proton pump inhibitors can reduce serum levels dramatically and should generally not be given to treatment-experienced patients taking atazanavir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the product labeling now states that treatment-na&iuml;ve patients may receive low doses of proton pump inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    20 mg taken 12 hours before",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    300 mg plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    100 mg), we remain reluctant to prescribe these drugs concomitantly because there may still be a dramatic reduction in atazanavir concentrations and patients must remember to stagger the dosing properly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, the pharmacokinetic study that supported the use of low-dose proton pump inhibitors with atazanavir used unboosted atazanavir (eg, without ritonavir) as the comparator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/41\">",
"     41",
"    </a>",
"    ]. It is well documented that unboosted atazanavir leads to lower serum levels than boosted atazanavir, which is the preferred agent for treatment-naive patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concomitant H-2 blockers can also reduce",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    concentrations. If H-2 blocker therapy is required,",
"    <span class=\"nowrap\">",
"     atazanavir/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    should be administered at the same time or at least 10 hours after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/45/728?source=see_link\">",
"     famotidine",
"    </a>",
"    . The famotidine (or equivalent dose of alternate H-2 blocker) dose should not exceed 40 mg BID in treatment-naive patients or 20 mg twice daily in treatment-experienced patients; atazanavir should always be boosted with ritonavir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1\">",
"     1",
"    </a>",
"    ]. If atazanavir is used with both an H2 blocker and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , the atazanavir dose should be increased from 300 mg to 400 mg daily and ritonavir 100 mg once daily must be given to ensure adequate atazanavir levels.",
"   </p>",
"   <p>",
"    As with all protease inhibitors, many clinically significant interactions are possible with this agent. For example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    should not be administered with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    . Atazanavir exposure is significantly lower when combined with these drugs, and the risk of nevirapine toxicity may increase due to increased nevirapine exposure. In addition, atazanavir in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    is not recommended in treatment-experienced patients, since efavirenz significantly lowers atazanavir exposure. Concomitant",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"      didanosine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"      lamivudine",
"     </a>",
"    </span>",
"    is not recommended in na&iuml;ve patients receiving unboosted atazanavir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1\">",
"     1",
"    </a>",
"    ]. All patients being considered for atazanavir therapy should be screened carefully for potential drug interactions. (See",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/51/9013?source=see_link\">",
"     \"Atazanavir: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a series of 15 patients with end-stage liver disease, administration of unboosted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    (400 mg daily) led to trough concentrations that were above the minimum effective concentration in 8 of 10 patients (including those on concomitant proton pump inhibitors or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ), with an acceptable side effect profile over the 24 weeks of the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/42\">",
"     42",
"    </a>",
"    ]. The DHHS guidelines state that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    boosting of atazanavir in patients with liver impairment (Child Pugh Score 7-9) is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because pharmacokinetic studies have shown low",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    levels in hemodialysis patients, the use of atazanavir in dialysis patients with antiretroviral experience is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     TIPRANAVIR (APTIVUS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     Tipranavir",
"    </a>",
"    (PNU-140690) is a PI that is active against strains of HIV that are resistant to other protease inhibitors. In one study, the mean IC(50) of tipranavir for 105 clinical isolates, which were highly cross-resistant to other PIs, was 0.23 micrometers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17672?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     Tipranavir",
"    </a>",
"    is the first nonpeptidic PI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/44\">",
"     44",
"    </a>",
"    ]. It is extensively protein-bound (99.9 percent). Clearance of tipranavir is higher after multiple doses compared to a single dose, suggesting that tipranavir may induce its own metabolism, similar to that of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Its oral bioavailability is low and therefore requires \"boosting\" with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    . The dosing regimen that has been approved for clinical use is 500 mg twice daily with a ritonavir boosting dose of 200 mg twice daily. This high ritonavir boosting dose may account for some of the common GI side effects and drug interactions, and makes this regimen costly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H55\">",
"     'Cost'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    An analysis of 24-week data from the Phase III RESIST trials, which compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    to four other protease inhibitors for the treatment of highly experienced HIV-infected patients, confirmed that 36 percent of tipranavir-treated patients had a one-log drop in HIV RNA compared to 16 percent for patients receiving other protease inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/47\">",
"     47",
"    </a>",
"    ]. A similar one-log drop in HIV RNA was demonstrated in an open label, randomized trial of tipranavir alone or tipranavir added to another protease inhibitor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    , lopinavir, or amprenavir) plus optimized background therapy; recycled protease inhibitors had limited activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In pooled safety data from the RESIST trials, 6 percent of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    patients exhibited grade 3 or 4 elevations in aminotransferases compared to 2 percent of patients in the other treatment arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. Risk was increased in patients with concomitant HCV infection and elevated baseline aminotransferases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Of note, only 5 to 15 percent of the overall population had evidence of HCV infection in the RESIST I and II trials.",
"   </p>",
"   <p>",
"    Genotypic and phenotypic testing is suggested prior to initiating treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/54\">",
"     54",
"    </a>",
"    ]. Of note, one-third of the patients who were",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    -naive achieved levels of less than 50",
"    <span class=\"nowrap\">",
"     copies/microL",
"    </span>",
"    if enfuvirtide was part of the optimized background regimens along with tipranavir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    are gastrointestinal, with approximately 20 percent of study participants developing nausea and one-third diarrhea. Tipranavir should be used with caution in patients with a known sulfonamide allergy since tipranavir contains a sulfonamide component. The potential for cross-sensitivity between drugs in the sulfonamide class and tipranavir is unknown.",
"   </p>",
"   <p>",
"    Thirteen (eight fatal) cases of intracranial hemorrhage were reported in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/55\">",
"     55",
"    </a>",
"    ], although the relationship of this adverse event to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    is unclear. The DHHS guidelines recommend avoiding tipranavir in patients with CNS lesions, recent head trauma, neurosurgery, coagulopathy, hypertension, alcohol use, and those on antiplatelet or anticoagulant medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatotoxicity, including some fatal cases, has been reported. Most patients had significant comorbidities including hepatitis B or C. Liver function tests should be assessed at baseline and during treatment. The product labeling states that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    should not be administered to patients with moderate to severe, Child-Pugh class B or C liver dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/1,55\">",
"     1,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     Tipranavir",
"    </a>",
"    is recommended for treatment-experienced patients with resistance to more than one protease inhibitor. Tipranavir is not recommended for use in treatment-naive patients; a phase IIIB study comparing",
"    <span class=\"nowrap\">",
"     tipranavir/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    was terminated at 60 weeks because the tipranavir arm did not meet the noninferiority criteria and patients assigned to that arm also had high rates of hepatotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    should",
"    <strong>",
"     NOT",
"    </strong>",
"    be dosed with other protease inhibitors since coadministration has led to significant declines in serum tipranavir levels. Other drug interactions reported to date include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (avoid),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    (avoid), antacids (reduce tipranavir levels 30 percent),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (increase tipranavir levels), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    <span class=\"nowrap\">",
"     (tipranavir/ritonavir",
"    </span>",
"    raise atorvastatin levels ninefold) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with all protease inhibitors, many clinically significant interactions are possible with this agent. Patients should be screened carefully for potential drug",
"    <span class=\"nowrap\">",
"     interactions.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     DARUNAVIR (PREZISTA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     Darunavir",
"    </a>",
"    /",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    (formerly known as TMC114) is a novel PI that, like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    , has activity against a broad range of drug-resistant clinical isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/59\">",
"     59",
"    </a>",
"    ]. In vitro, darunavir has activity against viral isolates with resistance to five other protease inhibitors and also demonstrates a high genetic barrier to the development of resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     Darunavir",
"    </a>",
"    was studied in two large randomized trials (POWER 1 and POWER 2) of highly treatment-experienced patients. The proportion of patients achieving an HIV RNA &lt;400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    was higher in the darunavir arm than the comparator PI arm in these studies. Furthermore, nearly half of the patients with up to eight mutations at baseline still attained viral suppression. A positive benefit was also noted in the subgroup of patients who had",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    added to their regimen. A detailed discussion of these trials is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17672?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"      Darunavir",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    was approved by the FDA in June 2006 for use in treatment-experienced patients; the approved dosage of darunavir for treatment-experienced patients is 600 mg twice daily (one 600 mg tablet) with 100 mg ritonavir twice daily or 800 mg once-daily with ritonavir once-daily IF the patient has genotypic analysis documenting absence of darunavir mutations. This latter once-daily regimen for experienced patients was approved in December 2010. Darunavir should be administered with food. Genotypic or phenotypic testing is recommended prior to administration.",
"   </p>",
"   <p>",
"    Based on the results of the ARTEMIS trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    received FDA approval in 2008 for use in antiretroviral-na&iuml;ve patients as well as treatment-experienced patients. However, the dose and frequency of dosing for treatment-naive patients is different than for treatment-experienced patients. Treatment-naive patients should receive darunavir (800 mg) plus ritonavir (100 mg). Both drugs are given together once daily. Further information on the ARTEMIS trial is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17672?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Darunavir dosing summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The once- versus twice-daily dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    is determined by treatment experience and presence or absence of darunavir mutations on genotypic lab analysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment-na&iuml;ve patients:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      (800 mg) once daily plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      (100 mg) once daily",
"     </li>",
"     <li>",
"      Treatment-experienced patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      -associated mutations on genotype: darunavir (600 mg; given as one tablet) twice daily plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      (100 mg) twice daily. The relevant darunavir mutations include: V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V and L89V.",
"     </li>",
"     <li>",
"      Treatment-experienced patients with recent genotypic testing demonstrating the&nbsp;absence of&nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      -associated mutations: darunavir (800 mg) once daily plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      (100 mg) once daily.&nbsp;The relevant darunavir mutations include:&nbsp;V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V and L89V.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2010 FDA approval of once-daily dosing for select antiretroviral-experienced patients was based on a safety and efficacy trial that compared once-daily and twice daily dosing, both boosted with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    . Once-daily dosing (800 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    plus 100 mg ritonavir) was similar in efficacy among patients who did not have any darunavir-associated resistance mutations at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/61\">",
"     61",
"    </a>",
"    ]. In addition, once-daily therapy was associated with a lower risk of hypertriglyceridemia compared with twice-daily dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If genotypic testing is not available in antiretroviral-experienced patients, twice-daily dosing is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     Darunavir",
"    </a>",
"    is extensively metabolized by the cytochrome p450 system, particularly CYP3a. It is also a p-glycoprotein transport inhibitor. Drug interaction references should be thoroughly consulted before prescribing darunavir.",
"   </p>",
"   <p>",
"    Coadministration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    with either lopinavir or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    is not recommended due to a decrease in darunavir exposure. In contrast, darunavir can be administered with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    , despite decreases in etravirine AUC (37 percent) and Cmin (49 percent), due to demonstrated clinical efficacy and safety in phase III clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17672?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Levels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    have been shown to increase significantly when combined with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"      darunavir",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"     .",
"    </span>",
"    Therefore, these statins should be started in the lowest possible dose with careful upward titration.",
"   </p>",
"   <p>",
"    As with all protease inhibitors, many clinically significant interactions are possible with this agent. Patients should be screened carefully for potential drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PHARMACOKINETIC BOOSTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     Ritonavir",
"    </a>",
"    is a potent inhibitor of hepatic microsomal enzyme CYP (450) 3A4. This characteristic is used beneficially when ritonavir is used to \"boost\" the serum concentration of other protease inhibitors. In fact, this is the primary use of ritonavir. It is not generally used as a sole protease inhibitor due to dose-limiting GI toxicity at high doses. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Class-related adverse effects'",
"    </a>",
"    below.) Use of pharmacokinetic boosting improves trough serum concentrations and decreases pill burden.",
"   </p>",
"   <p>",
"    However, potent inhibition of CYP 450 enzymes by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    can also result in a number of undesirable drug interactions, including potentially fatal interactions; many drugs are contraindicated for concurrent use and others require dose adjustments. Careful inspection of all of the patient's current medications is necessary before prescribing ritonavir. Chronic viral hepatitis, even in the absence of advanced fibrosis, can significantly decrease CYP3A activity in the presence of ritonavir inhibition. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Ritonavir'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Ideally,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    should be administered with meals to enhance gastric absorption and minimize the gastrointestinal side effects. In many of the dual protease inhibitor \"boosting\" studies, ritonavir was given with food at the same time as the other protease inhibitor.",
"   </p>",
"   <p>",
"    The following boosted regimens, in combination with nucleoside analogues, have received FDA approval:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    (Invirase) 1000 mg twice daily plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    100 mg twice daily;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    300 mg daily plus ritonavir 100 mg daily;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    plus ritonavir;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    500 mg twice daily with a ritonavir 200 mg twice daily; and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    600 mg twice daily with ritonavir 100 mg twice daily (in treatment-experienced patients) and 800 mg darunavir once daily with 100 mg ritonavir once daily (for treatment-naive patients and experienced patients without darunavir mutations).",
"   </p>",
"   <p>",
"    Use of two active PIs combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    as an enhancing agent has been examined in treatment-experienced patients. The pharmacologic rationale for offering double-boosted PI regimens are to provide additive or synergistic antiviral activity against HIV; to use combinations with non-overlapping resistance profiles; and to achieve high plasma drug levels in patients with limited treatment options [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/65\">",
"     65",
"    </a>",
"    ]. However, administration of two PIs can produce complex drug interactions and have not shown clinical benefit; thus they are not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ideal pharmacokinetic booster would have less toxicity than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    ; alternative pharmacoenhancers are being evaluated with protease inhibitors (ie, cobicistat; formerly GS-9350 and SPI-452) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/67\">",
"     67",
"    </a>",
"    ]. Cobicistat is now available as part of a coformulated, fixed-dose single tablet containing cobicistat, elvitegravir (an integrase inhibitor),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    (Stribild). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     CLASS-RELATED ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several side effects that appear to be PI class effects while others are agent-specific. Some of the class side effects are insulin resistance, hyperglycemia, diabetes, hyperlipidemia, lipodystrophy, hepatotoxicity, bleeding in patients with hemophilia, and side effects caused by interactions with other hepatically-metabolized drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Gastrointestinal intolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;By far, the most important side effect of this class is gastrointestinal intolerance. Nausea and vomiting can be treatment-limiting. These side effects are seen with all of the protease inhibitors, but were most significant with full dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    (600 mg twice daily), which is no longer used. The use of ritonavir for pharmacokinetic boosting at 200 mg twice daily or lower, is much better tolerated, although some patients will still have difficulty with these lower doses. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Pharmacokinetic boosting'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Lipodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipodystrophy is a long-term complication of PI therapy, which includes metabolic (hyperglycemia and hyperlipidemia) and morphologic abnormalities (fat atrophy and fat deposition).",
"   </p>",
"   <p>",
"    The following hypotheses have been proposed to explain this constellation of findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/70\">",
"     70",
"    </a>",
"    ]. The catalytic region of HIV-1 protease, to which the drugs bind, has 60 percent homology to regions of two proteins that regulate lipid metabolism: cytoplasmic retinoic acid-binding protein type I (CRAB P1) and low-density-lipoprotein receptor-related protein (LRP). PI binding to LRP impairs hepatic chylomicron uptake and triglyceride clearance by the LRP-lipoprotein lipase complex. The ensuing hypertriglyceridemia contributes to central fat deposition, insulin resistance, and, in susceptible subjects, type 2 diabetes. There also is a report that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    inhibits insulin-stimulated glucose uptake in adipocytes; in Xexnopus laevis oocytes the drug inhibited Glut4 but not Glut1-mediated glucose transport [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/71\">",
"     71",
"    </a>",
"    ]. Another study documented impaired glucose transport and phosphorylation in skeletal muscle of six HIV-infected men with lipodystrophy due to PIs, resulting in reduced insulin-mediated glucose uptake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, and treatment of HIV-associated lipodystrophy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/36/44617?source=see_link\">",
"     \"Treatment of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Lipid abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the protease inhibitors, with the exception of unboosted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , are associated with significant lipid abnormalities, such as hypertriglyceridemia and hypercholesterolemia. This is particularly true of",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26650?source=see_link&amp;anchor=H2957201#H2957201\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\", section on 'Effects of antiretroviral therapy on lipid levels'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11011898\">",
"    <span class=\"h2\">",
"     Insulin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protease inhibitor therapy is associated with insulin resistance, hyperglycemia and type 2 diabetes. These effects are part of the complicated antiretroviral-associated metabolic syndrome that also involves lipodystrophy and hyperlipidemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/36/44617?source=see_link\">",
"     \"Treatment of HIV-associated lipodystrophy\"",
"    </a>",
"    .) Insulin resistance has been documented in in vitro models, animal models, HIV-negative volunteers given protease inhibitors, and in clinical trials of protease inhibitors.",
"   </p>",
"   <p>",
"    These medications appear to interfere with insulin receptor signaling and with the GLUT 4 protein that transports glucose into cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/74\">",
"     74",
"    </a>",
"    ]. Adipokines may be involved directly or indirectly; hypoadiponectinemia was observed to correlate with insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/75\">",
"     75",
"    </a>",
"    ]. There are likely quantitative differences amongst the protease inhibitors with regard to these effects, but differences in study design make comparisons difficult.&nbsp;Research to develop protease inhibitors that do not block GLUT 4 is important and underway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Electrocardiographic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is suggestive evidence that PIs may predispose individuals to PR and QT prolongation or reduction and torsades de pointes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. These observations are consistent with animal and in vitro studies showing that PIs (specifically lopinavir,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    ) block the HERG cardiac potassium channel, which is blocked by many of the drugs that cause QT prolongation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .) In addition, protease inhibitors may inhibit the CYP p450 metabolism of drugs known to prolong the QTc interval (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ), thereby increasing the risk of QTc prolongation. Whether HIV protease inhibitors are associated with a risk of sudden death is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased bleeding also has been reported in patients with hemophilia type A and B receiving several different protease inhibitors. However, causality has not been determined. Some of the more common",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distinguishing side effects of the individual agents are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Hyperbilirubinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conjugation of bilirubin is mediated by the microsomal enzyme UDP-glucuronosyltransferase (UGT). Gilbert's syndrome is the most common inherited cause of unconjugated hyperbilirubinemia, occurring in 3 to 10 percent of the population. Two protease inhibitors are also associated with hyperbilirubinemia,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    . Whether underlying genetic risk factors contribute is unclear. In a study of 96 patients who underwent genotypic analysis for polymorphisms associated with unconjugated hyperbilirubinemia, 67 percent of patients had UGT1A1*28.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Bone effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteopenia and osteoporosis and osteonecrosis have been reported in patients receiving HAART. However, it is not clearly associated with protease inhibitors or any other specific drug class [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     MEDICATION SPECIFIC ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a short discussion of each protease inhibitor and some of their potential adverse side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Amprenavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amprenavir has been mainly replaced by the prodrug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"     Fosamprenavir",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H45\">",
"     'Fosamprenavir'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Atazanavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the PI class side effects listed above,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    inhibits UDP-glucuronosyl transferase, causing a high incidence of clinically insignificant elevations of indirect (unconjugated) bilirubin, with or without jaundice and scleral icterus. Total bilirubin &gt;2.6 x upper limit of normal developed in 35 to 47 percent of na&iuml;ve patients taking atazanavir who were enrolled in clinical trials.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     Indinavir",
"    </a>",
"    also causes this in approximately 14 percent of patients. Transaminases are usually normal. If they are abnormal, other possible etiologies should be pursued. Patients should be forewarned of this possible side effect because the jaundice and icterus may pose a cosmetic and social problem for some.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    can also cause PR interval prolongation with asymptomatic first degree AV block. Therefore, it should be used with caution in patients with conduction abnormalities and those who take other medications that can prolong the PR interval (beta blockers,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ). Particular caution should be used when combining atazanavir with drugs that both prolong PR interval and are metabolized via CYP3A4 (eg, diltiazem, many other calcium channel blockers). The serum concentrations of such drugs could be greatly increased by atazanavir. In fact, the product labeling states that a diltiazem dose reduction of 50 percent and ECG monitoring should be considered in patients starting atazanavir. This aspect of other PIs has not been well studied so it is not clear if this PR interval effect is unique to atazanavir.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    (and perhaps",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    ) has little effect on serum lipids, a unique attribute among the PIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/81\">",
"     81",
"    </a>",
"    ]. This is useful in patients with cardiovascular disease and those at high risk for CV disease. Atazanavir also appears to have little effect on glucose metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Darunavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     Darunavir",
"    </a>",
"    , amprenavir,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    are the only protease inhibitors that are sulfonamides. Patients with sulfonamide allergies were not specifically excluded from the clinical trials but nonetheless, patients with a history of clinically significant sulfonamide allergy should be \"treated with caution\".",
"   </p>",
"   <p>",
"    In addition to the general protease inhibitor class side effects, the principle adverse effects associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    include nausea, diarrhea, hepatotoxicity, and headache. Rash has occurred in approximately 2 to 7 percent of patients; rare cases of Stevens-Johnson syndrome have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Darunavir contains a sulfonamide moiety and should be used with caution in patients with a known sulfonamide allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/85\">",
"     85",
"    </a>",
"    ]. We are the most cautious with patients with a history of severe sulfonamide allergy. Adverse events are similar by the sexes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In March 2008, 24 cases of hepatotoxicity were reported in the post-marketing experience, including some fatalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/86\">",
"     86",
"    </a>",
"    ]. These cases have generally occurred in patients with advanced HIV disease who were taking multiple medications and had underlying viral hepatitis. Prior to initiation of therapy, baseline aminotransferases should be checked and ongoing monitoring is suggested during the first several months of therapy. Patients should be informed of the symptoms associated with liver dysfunction and instructed to seek medical attention immediately.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     Darunavir",
"    </a>",
"    is not recommended for patients with severe liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Fosamprenavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the PI class side effects (see above), it should be noted that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    (like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    ), is a sulfonamide and has a relatively high incidence of rash (19 percent, see discussion above). Other side effects include headache and the PI class side effects of GI intolerance, elevated transaminases, hyperglycemia, fat maldistribution and lipid abnormalities, and possible increased bleeding in hemophilia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Indinavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than the PI class side effects (see above), nephrotoxicity is the major side effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]. The most common manifestation is nephrolithiasis due to precipitation of indinavir, which has a low solubility (0.03",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    at a pH of 6.0, but is much more soluble at lower pH values (100",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    at pH 3.5). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34857?source=see_link\">",
"     \"Crystal-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other related manifestations include acute renal failure, interstitial fibrosis, and dysuria, possibly due to bladder stones. Nephrolithiasis is an increasingly recognized complication of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one cohort study, urologic symptoms (nephrolithiasis, renal colic, flank pain, hematuria, renal insufficiency, or nephropathy) occurred with a significantly higher frequency among 445 patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      compared to 774 patients receiving other protease inhibitors (8.3 versus 0.8 per 100 treatment-years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/90\">",
"       90",
"      </a>",
"      ]. A low lean body mass and receipt of indinavir at doses of 1000 mg twice daily or greater were risk factors for developing these complications.",
"     </li>",
"     <li>",
"      Another study addressed the incidence of urinary tract abnormalities in patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/89\">",
"       89",
"      </a>",
"      ]. Among 240 patients, 8 percent experienced urologic symptoms and 3 percent had nephrolithiasis due to indinavir stones. In addition, among 142 patients who provided urine samples, 20 percent had urinary crystals consisting of indinavir (",
"      <a class=\"graphic graphic_picture graphicRef70939 \" href=\"mobipreview.htm?21/23/21877\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      One report described 29 patients in whom stones either passed spontaneously or were removed by ureteroscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/88\">",
"       88",
"      </a>",
"      ]. Mass spectrometry demonstrated that the stones consisted of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      base monohydrate. It has been suggested that drinking at least 150",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      in the three hours after each oral dose of indinavir (and more than 1.5",
"      <span class=\"nowrap\">",
"       L/day)",
"      </span>",
"      should minimize the risk of crystal formation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/88,91,92\">",
"       88,91,92",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nephrotoxicity can develop even in patients who are apparently well hydrated. This adverse effect can develop late in the course of therapy. Patients should be counseled to report any suggestive symptoms, such as flank pain or hematuria, which can develop late in the course of therapy. Some clinicians recommend periodic monitoring of urinalysis and serum creatinine every three to four months.",
"   </p>",
"   <p>",
"    During clinical trials, because of concern about the development of resistance during interruptions in therapy (see below),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    was sometimes continued during acute episodes of nephrolithiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/92\">",
"     92",
"    </a>",
"    ]. Hydration and a temporary interruption in therapy of only one to three days have been encouraged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperbilirubinemia is an adverse effect unique to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    . It occurs in approximately 25 percent of indinavir-treated patients. The total bilirubin rises to the 2.5 to 5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    range; most is indirect bilirubin and is inconsequential except as a possible complication of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. In the absence of pregnancy, therapy need not be stopped for this abnormality. The drug appears to impair bilirubin UDP-glucuronosyltransferase (UGT) activity; one study found that patients taking indinavir who also had Gilbert's syndrome experienced a higher rise in serum bilirubin compared to those without Gilbert's (1.45 versus 0.34",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/93\">",
"     93",
"    </a>",
"    ]. Hepatitis with aminotransferase elevations has also been reported and should be managed appropriately.",
"   </p>",
"   <p>",
"    Other adverse reactions include abdominal pain, nausea, acid regurgitation, headache, asthenia, blurred vision, dizziness, rash, metallic taste, insomnia, alopecia, thrombocytopenia, and increased serum concentrations of ALT, AST, or amylase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/18,92\">",
"     18,92",
"    </a>",
"    ]. Many patients develop dry skin, eyes, lips, mouth (sicca syndrome), ingrown toenails, and paronychia while taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    . As with all of the protease inhibitors, increased abdominal girth (\"CrixBelly\") due to visceral fat accumulation has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Lopinavir/Ritonavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;This coformulated product shares many of the side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    . However, because the dose of ritonavir is low, the gastrointestinal tolerance of this drug is better than full-dose ritonavir. However, GI disturbances are still one of the most common adverse effects of this product, with moderate to severe complaints occurring as follows: diarrhea in 14 to 25 percent, nausea in 2.2 to 15.5 percent.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     Loperamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    can be used for diarrhea.",
"   </p>",
"   <p>",
"    The liquid formulation contains 43.4 percent",
"    <span class=\"nowrap\">",
"     w/v",
"    </span>",
"    alcohol which can be problematic in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/17/5397?source=see_link\">",
"     disulfiram",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and potentially fatal in an overdose in a child. Other side effects include moderate to severe rash in 0.6 to 3.6 percent of adults, asthenia, elevated transaminases, hepatitis, and the many potential drug interactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/95\">",
"     95",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H5\">",
"     'Drug interactions'",
"    </a>",
"    above). Even though the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    content is much lower in this coformulated product, the potential interaction with other hepatically metabolized drugs should be similar to that seen with ritonavir alone because 100 to 200 mg ritonavir inhibits p450 metabolism approximately the same as 600 mg of ritonavir twice daily.",
"   </p>",
"   <p>",
"    Because the liquid contains alcohol and propylene glycol, it should not be used along with other liquid medications that contain propylene glycol. Some examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral liquids:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      (Ziagen),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (Sporonox), cyclosporin (Neoral)",
"     </li>",
"     <li>",
"      Intravenous formulations of:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , multivitamins, digoxin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/96-98\">",
"       96-98",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Nelfinavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the class side effects (see above), the major side effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    is diarrhea with loose stools that develops in 10 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/95,99\">",
"     95,99",
"    </a>",
"    ]. More severe diarrhea occurs in 10 percent. This problem appears to be dose related, although not significantly more common with the 1250 mg BID regimen compared to the older 750 mg TID regimen. It can be very disruptive for patients with busy, ambulating schedules. However, it can often be controlled with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    2 mg after each loose stool, up to eight times a day, fiber, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    500 mg BID. Patients should be counseled about this side effect when therapy is initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Ritonavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;When",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    was first introduced, side effects occurred in as many as 85 to 100 percent of patients treated with full dosing (600 mg twice daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/18\">",
"     18",
"    </a>",
"    ]. Gastrointestinal toxicity was most common, including nausea, vomiting, diarrhea, and abnormal taste sensation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/17\">",
"     17",
"    </a>",
"    ]. Ritonavir can also be associated with hepatitis, asthenia, pancreatitis, and rarely causes unusual circumoral and peripheral paresthesias, which can be dose limiting. These effects may decrease over time.",
"   </p>",
"   <p>",
"    Full dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    is almost never used anymore. However, low-dose ritonavir use for \"pharmacokinetic boosting\" is extremely common. At low doses, ritonavir causes much less gastrointestinal and hepatic toxicity. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Pharmacokinetic boosting'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Serum cholesterol and triglyceride concentrations may increase dramatically in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    , 30 to 40 percent and 100 to 300 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Elevations can also be seen in the serum concentrations of creatine kinase, uric acid, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/17\">",
"     17",
"    </a>",
"    ]. The increase in liver enzymes usually occurs in the first few weeks of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns about hepatotoxicity have been raised in HIV-infected patients receiving protease inhibitors, especially in those coinfected with Hepatitis C or B. However, in one prospective study of 298 patients receiving protease inhibitors, only",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    was associated with an increased risk of hepatotoxicity, though this was reversible; 88 percent of patients coinfected with Hepatitis C or B virus were able to tolerate these drugs without worsening of liver function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Saquinavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     Saquinavir",
"    </a>",
"    is usually well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/11,101\">",
"     11,101",
"    </a>",
"    ]. Diarrhea, nausea, abdominal discomfort, and headache occur in 2 to 4 percent of patients receiving Invirase&reg; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/11,101\">",
"     11,101",
"    </a>",
"    ]. Serum aminotransferase concentrations may be elevated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/95\">",
"     95",
"    </a>",
"    ]. Like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , it is considered a \"lipid-friendly\" protease inhibitor and may not affect insulin sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Tipranavir (Aptivus)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary results from clinical trials indicate a relatively high rate of side effects, some of which may be related to the high dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    (200 mg twice daily) required for boosting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/102,103\">",
"     102,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects reported to date include hepatotoxicity, rash, intracranial hemorrhage, nausea, vomiting, headache, abdominal pain, dizziness, fatigue, elevated transaminases, cholesterol, and triglycerides.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Close monitoring is recommended in patients with underlying liver disease;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"       tipranavir",
"      </a>",
"      is",
"      <strong>",
"       contraindicated",
"      </strong>",
"      in patients with Child-Pugh Class B and C cirrhosis.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"       Tipranavir",
"      </a>",
"      (like",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"       fosamprenavir",
"      </a>",
"      ), has a sulfonamide moiety. Skin rash has been reported in 10 to 14 percent of patients and may be more common in women taking ethinyl estradiol. Rash with joint pain, pruritus, or throat tightness has also occurred.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This is the most expensive protease inhibitor available, mainly due to the need for 200 mg twice daily of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance issues with the PIs are quite complex. A consensus statement on drug resistance has been issued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/91\">",
"     91",
"    </a>",
"    ]; information is also available online at",
"    <a class=\"external\" href=\"file://hiv-web.lanl.gov/\">",
"     hiv-web.lanl.gov",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://hivdb.stanford.edu/\">",
"     hivdb.stanford.edu",
"    </a>",
"    . A \"mutation list analysis\" is available at",
"    <a class=\"external\" href=\"file://www.iasusa.org/resistance_mutations/index.html\">",
"     www.iasusa.org/resistance_mutations/index.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Plasma drug concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variability in the plasma concentration of protease inhibitors has been demonstrated in pharmacokinetic studies in HIV-infected patients, which can lead to drug resistance. The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    for pharmacologic boosting may reduce, but not eliminate, this variability. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Ritonavir'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of inhibitory quotients has been proposed to improve the relationship between drug concentrations and virologic response to various agents. This quotient takes into account the trough drug concentration (Cmin) and the viral isolate drug susceptibility; the inhibitory quotient is \"normalized\" using population averages.",
"   </p>",
"   <p>",
"    The additive value of using a normalized inhibitory quotient was demonstrated in a cohort of 87 highly treatment-experienced individuals treated with boosted PI regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/104\">",
"     104",
"    </a>",
"    ]. Baseline viral load and the normalized inhibitory quotient were significantly predictive of virological response over 48 weeks, whereas the Cmin was not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h1\">",
"     THERAPEUTIC DRUG MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral pharmacodynamics are affected by a myriad of factors including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/105\">",
"     105",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Individual pharmacokinetics and pharmacogenetics",
"     </li>",
"     <li>",
"      HIV resistance",
"     </li>",
"     <li>",
"      Immune function",
"     </li>",
"     <li>",
"      Medication adherence",
"     </li>",
"     <li>",
"      Drug interactions",
"     </li>",
"     <li>",
"      Plasma protein binding",
"     </li>",
"     <li>",
"      Chronic liver disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The substantial interpatient variation in protease inhibitor pharmacokinetics led to studies using therapeutic drug monitoring (TDM) to measure plasma concentrations of protease inhibitors to guide dose adjustments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/105\">",
"     105",
"    </a>",
"    ]. Conflicting results regarding benefit of TDM have been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. One study demonstrated high intraindividual variability over time that was not explained by lack of adherence, since these patients had ongoing viral suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, a controlled trial was conducted in 183 patients who were randomly assigned to either standard of care or TDM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/108\">",
"     108",
"    </a>",
"    ]. Although normalized inhibitory quotients improved in the TDM arm compared to the SOC arm, there was no difference in rates of viral suppression between the two groups. A post-hoc analysis suggested some benefit of TDM in those whose virus retained some PI susceptibility.",
"   </p>",
"   <p>",
"    A subsequent meta-analysis did not support the routine use of TDM in treatment-naive or treatment-experienced patients, although the analysis was limited by underpowered trials with small sample sizes, short duration of follow-up, and poor uptake of TDM recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/109\">",
"     109",
"    </a>",
"    ]. However, in aggregate, these data suggest that single measurements of drug concentrations may have limited utility due to marked interpatient variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h1\">",
"     COST",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the PIs are quite costly.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     Indinavir",
"    </a>",
"    is the least expensive and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    is the most expensive. While aggressive antiretroviral regimens, including PIs, have been shown to increase the pharmacy costs of caring for HIV-infected patients significantly, the overall costs of care appear to be decreasing since the number of inpatient days and incidence of opportunistic infections have declined dramatically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/32/40458/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The manufacturers have financial assistance programs for patients who do not have coverage. The contact numbers are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"       Saquinavir",
"      </a>",
"      &ndash; Roche Medical Needs Program 800-285-4484",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       Ritonavir",
"      </a>",
"      &ndash; Treatment Assistance Program 1-800-659-9050",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"       Indinavir",
"      </a>",
"      &ndash; Merck Reimbursement Support Services 800-850-3430",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"       Nelfinavir",
"      </a>",
"      &ndash; Agouron Pharmaceuticals 888-847-2237",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"       Fosamprenavir",
"      </a>",
"      &ndash; Glaxo Smith Kline 888-825-5249",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Lopinavir/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"        Ritonavir",
"       </a>",
"      </span>",
"      &ndash; Assistance Program 1-800-659-9050",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       Atazanavir",
"      </a>",
"      &ndash; Bristol-Myers Squibb 800-426-7644",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"       Tipranavir",
"      </a>",
"      &ndash; Boehringer-Ingelheim 800-243-0127",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"       Darunavir",
"      </a>",
"      &ndash; Tibotec Assistance Program 1-866-836-0114",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/44/22210?source=see_link\">",
"       \"Patient information: Starting treatment for HIV (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/31/15861?source=see_link\">",
"       \"Patient information: Initial treatment of HIV (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/56/2946?source=see_link\">",
"       \"Patient information: Tips for taking HIV medications (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44060151\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protease inhibitors (PIs) are potent antiretroviral drugs that are included in preferred antiretroviral regimens for HIV-infected treatment-na&iuml;ve and experienced patients in resource-rich settings. The most commonly used PIs are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20378?source=see_link\">",
"       lopinavir-ritonavir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      for pharmacokinetic boosting. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Atazanavir (reyataz)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'Darunavir (prezista)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Lopinavir/ritonavir (Kaletra)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Ritonavir'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low and intermittently detectable serum drug concentrations can lead to the development of resistance to an individual agent or cross-resistance to other members of this class that result in loss of clinical benefit. Thus, correct dosing and administration (eg, with respect to absorption in the presence of food or other medications) and good medication adherence is essential to avoid low serum drug concentrations. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Dosing and administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are many potential drug interactions between the PIs and other medications that should be recognized to avoid loss of therapeutic effect or excess toxicity.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       Ritonavir",
"      </a>",
"      , in particular, can be an extremely potent inhibitor or activator of drug metabolism, and major dose adjustments may be indicated with particular co-administered medications. Details on dosing, absorption, and drug interactions can be found for individual PIs in the sections dedicated to the specific agents and at",
"      <a class=\"external\" href=\"file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf\">",
"       file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Dosing and administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacokinetic boosting refers to the use of low doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      , which is a potent inhibitor of hepatic microsomal enzyme CYP (450) 3A4, in order to increase the serum concentration of other concomitantly used PIs. This is the primary use of ritonavir since gastrointestinal toxicity at higher doses limits its use as a sole PI agent. Ideally, ritonavir should be administered with meals to enhance gastric absorption and minimize the gastrointestinal side effects. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most clinically important side effects that are common to most or all PIs include gastrointestinal intolerance, hyperglycemia and insulin resistance, and hyperlipidemia. Electrocardiographic effects are possible, including PR and QTc prolongation; the clinical significance is as yet unclear. Individual agents are also associated with particular side effects, such as nephrolithiasis and benign hyperbilirubinemia that can occur with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Class-related adverse effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H41\">",
"       'Medication specific adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"       Darunavir",
"      </a>",
"      , amprenavir,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"       fosamprenavir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"       tipranavir",
"      </a>",
"      are technically sulfonamides. However, patients with sulfonamide allergies were not specifically excluded from the clinical trials and therefore a history of sulfonamide allergy is not a contraindication to their use. Nonetheless, caution should be used in prescribing these sulfonaminde PIs to patients with a history of clinically significant sulfonamide allergy, especially those with severe sulfonamide allergy. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Darunavir (prezista)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Resistance issues with the PIs are quite complex. Mutations can confer resistance to an individual agent or lead to cross resistance to other members of this class. A list of drug mutations associated with PI resistance is available at",
"      <a class=\"external\" href=\"file://www.iasusa.org/resistance_mutations/index.html\">",
"       www.iasusa.org/resistance_mutations/index.html",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H52\">",
"       'Resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite the importance of maintaining adequate serum levels of PIs and the many factors that can adversely affect these levels, there is insufficient evidence to support the use of therapeutic drug monitoring to guide dosing adjustment. (See",
"      <a class=\"local\" href=\"#H54\">",
"       'Therapeutic drug monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on April 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/2\">",
"      Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/3\">",
"      Mascolini M. The rolling uncertainties of antiprotease prescribing. J Int Assoc Physicians AIDS Care 1996; 2:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/4\">",
"      Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/5\">",
"      Mascolini M. Protease inhibitors and nucleoside combinations, or, Alice in Gaithersburg. J Int Assoc Physicians AIDS Care 1996; 2:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/6\">",
"      Drugs for HIV infection. Med Lett Drugs Ther 1997; 39:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/7\">",
"      Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/8\">",
"      Evans-Jones JG, Cottle LE, Back DJ, et al. Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2010; 50:1419.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm230096.htm (Accessed on April 04, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/10\">",
"      Pollard RB. Use of proteinase inhibitors in clinical practice. Pharmacotherapy 1994; 14:21S.",
"     </a>",
"    </li>",
"    <li>",
"     Product Information, saquinavir, Roche Laboratories, revised December, 1995.",
"    </li>",
"    <li>",
"     www.fortovase.com/pdf/FTVDearDoctorFINAL.pdf (Accessed on June 03, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/13\">",
"      Autar RS, Ananworanich J, Apateerapong W, et al. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. J Antimicrob Chemother 2004; 54:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/14\">",
"      Piscitelli SC, Burstein AH, Welden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/15\">",
"      Winston A, Back D, Fletcher C, et al. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS 2006; 20:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/16\">",
"      George SL, Swindells S, Knudson R, Stapleton JT. Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases. Am J Med 1999; 107:624.",
"     </a>",
"    </li>",
"    <li>",
"     Product information, ritonavir, Abbott Laboratories, revised February, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/18\">",
"      Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995; 333:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/19\">",
"      Knox TA, Oleson L, von Moltke LL, et al. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr 2008; 49:358.",
"     </a>",
"    </li>",
"    <li>",
"     Product information, indinavir, Merck, March, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/21\">",
"      Luber AD, Brower R, Kim D, et al. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med 2007; 8:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/22\">",
"      Shelton MJ, Ford SL, Borland J, et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr 2006; 42:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/23\">",
"      Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007; 44:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/24\">",
"      Flexner C, Tierney C, Gross R, et al. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis 2010; 50:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/25\">",
"      Colonno RJ, Thiry A, Limoli K, Parkin N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother 2003; 47:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/26\">",
"      Friedland G, Andrews L, Schreibman T, et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005; 19:1635.",
"     </a>",
"    </li>",
"    <li>",
"     Squires K, et al. 42nd ICAAC 2002, Abstract H1076.",
"    </li>",
"    <li>",
"     Nieto-Cisneros L, et al. 2nd Conference on HIV Pathogenesis and Treatment, Paris, July 2003, Abstract 117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/29\">",
"      Santoro MM, Bertoli A, Lorenzini P, et al. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study. AIDS Patient Care STDS 2008; 22:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/30\">",
"      Best BM, Letendre SL, Brigid E, et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS 2009; 23:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/31\">",
"      Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 2005; 192:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/32\">",
"      Zhang D, Chando TJ, Everett DW, et al. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/33\">",
"      McDonald C, Uy J, Hu W, et al. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDS 2012; 26:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/34\">",
"      Rodr&iacute;guez-N&oacute;voa S, Mart&iacute;n-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007; 21:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/35\">",
"      Park WB, Choe PG, Song KH, et al. Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency. Clin Infect Dis 2010; 51:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/36\">",
"      Ribaudo HJ, Daar ES, Tierney C, et al. Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis 2013; 207:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/37\">",
"      Rakotondravelo S, Poinsignon Y, Borsa-Lebas F, et al. Complicated atazanavir-associated cholelithiasis: a report of 14 cases. Clin Infect Dis 2012; 55:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/38\">",
"      Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 2007; 21:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/39\">",
"      Hamada Y, Nishijima T, Watanabe K, et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis 2012; 55:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/40\">",
"      Squires KE, Young B, Dejesus E, et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS 2010; 24:2019.",
"     </a>",
"    </li>",
"    <li>",
"     Eley T, Zhu L, et al. Effect of omeprazole 20 mg daily on the bioavailability of multidose atazanavir with ritonavir in healthy subjects. International Workshop on Clinical Pharmacology of HIV Treatment, April 16-18, 2007, Budapest, Hungary. Poster 66.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/42\">",
"      Guaraldi G, Cocchi S, Motta A, et al. A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. J Antimicrob Chemother 2008; 62:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/43\">",
"      Schake D. How flexible is tipranavir in complex with the HIV-1 protease active site? AIDS 2004; 18:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/44\">",
"      Temesgen Z, Feinberg J. Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis 2007; 45:761.",
"     </a>",
"    </li>",
"    <li>",
"     Hoffmann C, Kamps BS (Eds) www.HIVMedicine.com (Accessed on March 08, 2005).",
"    </li>",
"    <li>",
"     www.aidsmeds.com/drugs/tipranavir.htm (Accessed on March 09, 2005).",
"    </li>",
"    <li>",
"     \"The Pink Sheet\" 2005; 67:16.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/48\">",
"      Walmsley SL, Katlama C, Lazzarin A, et al. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). J Acquir Immune Defic Syndr 2008; 47:429.",
"     </a>",
"    </li>",
"    <li>",
"     Hicks C. RESIST-1: A phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir to an optimized comparator protease inhibitor/r regimen in antiretroviral therapy experienced patients: 24-week data. In: Program and abstracts of the 44th Intersceince Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Abstract H-1137a.",
"    </li>",
"    <li>",
"     Cahn P. 24-week data from RESIST 2: phase 3 study of the efficacy and safety of either tipranavir/ritonavir or an optimized ritonavir-boosted standard of care comparatory PI in a large randomized multicenter trial in treatment-experienced HIV+ patients. In: Program and abstracts of the 7th International Congress of Drug Therapy in HIV infection; November 13-18, 2004; Glasgow, Scotland; Abstract PL143.3.",
"    </li>",
"    <li>",
"     Katlama C, Walmsley S, Hicks C, et al. Tipranavir achieves twice the rate of treatment responses and prolongs durability of response versus comparator PI in antiretroviral therapy experenced patients, independent of baseline CD4+ cell count or viral load: week 48 RESIST 1 and 2 combined analyses. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic infections. February 5-8, 2006; Denver, Colo. Abstract #520.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/52\">",
"      Gathe J, Cooper DA, Farthing C, et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006; 43:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/53\">",
"      Cahn P, Villacian J, Lazzarin A, et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006; 43:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/54\">",
"      Boehringer Ingelheim Aptivus gets accelerated approval. \"The Pink Sheet\" 2005; 67:3.",
"     </a>",
"    </li>",
"    <li>",
"     Product Information, Aptivus.",
"    </li>",
"    <li>",
"     Cooper D, Zajdenverg R, Ruxrungtham K, et al. Efficacy and safety of two doses of tipranavir/ritonavir versus lopinavir/ritonavir-based therapy in antiretroviral-naive patients: results of BI 1182.33 (Abstract PL13.4]. In: Program and abstracts of the 8th International Congress on Drug Therapy in HIV infection 2006.",
"    </li>",
"    <li>",
"     www.hivmedicine.com/textbook (Accessed on March 09, 2005).",
"    </li>",
"    <li>",
"     www.aidsmeds.com (Accessed on March 09, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/59\">",
"      Arast&eacute;h K, Clumeck N, Pozniak A, et al. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. AIDS 2005; 19:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/60\">",
"      De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49:2314.",
"     </a>",
"    </li>",
"    <li>",
"     Cahn P, Fourie J, Grinsztejn B, et al. Efficacy and safety at 48 weeks of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1 patients with no darunavir resistance-associated mutations: the Odin trial. In: Program and abstracts of the 17th Conference on Retroviruses and O (Accessed on January 31, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/62\">",
"      Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS 2011; 25:929.",
"     </a>",
"    </li>",
"    <li>",
"     Product labeling, Prezista, Tibotec, Inc. December 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/64\">",
"      Boffito M, Winston A, Jackson A, et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 2007; 21:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/65\">",
"      Ribera E, Azuaje C, Lopez RM, et al. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 2006; 20:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/66\">",
"      Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/67\">",
"      Hill A, van der Lugt J, Sawyer W, Boffito M. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS 2009; 23:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/68\">",
"      Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997; 127:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/69\">",
"      Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 1997; 127:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/70\">",
"      Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/71\">",
"      Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275:20251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/72\">",
"      Behrens GM, Boerner AR, Weber K, et al. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest 2002; 110:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/73\">",
"      Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/74\">",
"      Vyas AK, Koster JC, Tzekov A, Hruz PW. Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J Biol Chem 2010; 285:36395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/75\">",
"      Tsiodras S, Perelas A, Wanke C, Mantzoros CS. The HIV-1/HAART associated metabolic syndrome - novel adipokines, molecular associations and therapeutic implications. J Infect 2010; 61:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/76\">",
"      Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005; 365:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/77\">",
"      Soliman EZ, Lundgren JD, Roediger MP, et al. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 2011; 25:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/78\">",
"      Worm SW, Kamara DA, Reiss P, et al. Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. J Infect Dis 2012; 205:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/79\">",
"      Miller KD, Masur H, Jones EC, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002; 137:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/80\">",
"      Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14:F63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/81\">",
"      Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/82\">",
"      Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/83\">",
"      Introcaso CE, Hines JM, Kovarik CL. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors. J Am Acad Dermatol 2010; 63:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/84\">",
"      Currier J, Averitt Bridge D, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med 2010; 153:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/85\">",
"      Darunavir (Prezista) for HIV infection. Med Lett Drugs Ther 2006; 48:74.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.hivandhepatitis.com/recent/2008/031208_a.html (Accessed on February 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/87\">",
"      Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy. N Engl J Med 1997; 336:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/88\">",
"      Daudon M, Est&eacute;pa L, Viard JP, et al. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 1997; 349:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/89\">",
"      Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/90\">",
"      Dieleman JP, Sturkenboom MC, Jambroes M, et al. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch Intern Med 2002; 162:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/91\">",
"      Hirsch MS, Brun-V&eacute;zinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/92\">",
"      Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/93\">",
"      Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A 2001; 98:12671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/94\">",
"      Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351:871.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV infection convened by the DHHS and the Henry J. Kaiser Family Foundation. August 13, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/96\">",
"      Hayman M, Seidl EC, Ali M, Malik K. Acute tubular necrosis associated with propylene glycol from concomitant administration of intravenous lorazepam and trimethoprim-sulfamethoxazole. Pharmacotherapy 2003; 23:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/97\">",
"      Al-Khafaji AH, Dewhirst WE, Manning HL. Propylene glycol toxicity associated with lorazepam infusion in a patient receiving continuous veno-venous hemofiltration with dialysis. Anesth Analg 2002; 94:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/98\">",
"      Wilson KC, Reardon C, Farber HW. Propylene glycol toxicity in a patient receiving intravenous diazepam. N Engl J Med 2000; 343:815.",
"     </a>",
"    </li>",
"    <li>",
"     Nelfinavir Product Information, Agouron Pharmaceuticals, 1997 (also reprinted in 1998 PDR).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/100\">",
"      Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/101\">",
"      Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995; 345:952.",
"     </a>",
"    </li>",
"    <li>",
"     Hicks C. RESIST-1: A phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 2004, Washington, D.C.",
"    </li>",
"    <li>",
"     www.hivandhepatitis.com/2004icr/7thcongress/posters/resist1.pdf (Accessed on March 09, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/104\">",
"      Winston A, Hales G, Amin J, et al. The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. AIDS 2005; 19:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/105\">",
"      Morse GD, Catanzaro LM, Acosta EP. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect Dis 2006; 6:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/106\">",
"      Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000; 14:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/107\">",
"      Haas DW. Can responses to antiretroviral therapy be improved by therapeutic drug monitoring? Clin Infect Dis 2006; 42:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/108\">",
"      Demeter LM, Jiang H, Mukherjee AL, et al. A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients. AIDS 2009; 23:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/109\">",
"      Kredo T, Van der Walt JS, Siegfried N, Cohen K. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst Rev 2009; :CD007268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/110\">",
"      Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006; 42:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/32/40458/abstract/111\">",
"      Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999; 13:963.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3761 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_32_40458=[""].join("\n");
var outline_f39_32_40458=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H44060151\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DOSING AND ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Serum concentrations and drug resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Absorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SAQUINAVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Boosted regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RITONAVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INDINAVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Boosted regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NELFINAVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      AMPRENAVIR (AGENERASE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FOSAMPRENAVIR (LEXIVA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      LOPINAVIR/RITONAVIR (KALETRA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19983184\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ATAZANAVIR (REYATAZ)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Summary of Atazanavir dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Treatment-naive patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Treatment-experienced patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TIPRANAVIR (APTIVUS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      DARUNAVIR (PREZISTA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Darunavir dosing summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PHARMACOKINETIC BOOSTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      CLASS-RELATED ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Gastrointestinal intolerance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Lipid abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11011898\">",
"      Insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Electrocardiographic changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Bone effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      MEDICATION SPECIFIC ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Amprenavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Atazanavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Darunavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Fosamprenavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Indinavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Lopinavir/Ritonavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Nelfinavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Ritonavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Saquinavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Tipranavir (Aptivus)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Plasma drug concentrations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      THERAPEUTIC DRUG MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      COST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44060151\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3761\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3761|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/23/21877\" title=\"picture 1\">",
"      Indinavir crystals",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/51/9013?source=related_link\">",
"      Atazanavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17672?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34857?source=related_link\">",
"      Crystal-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26650?source=related_link\">",
"      Epidemiology of cardiovascular disease and risk factors in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/31/15861?source=related_link\">",
"      Patient information: Initial treatment of HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/44/22210?source=related_link\">",
"      Patient information: Starting treatment for HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/56/2946?source=related_link\">",
"      Patient information: Tips for taking HIV medications (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/36/44617?source=related_link\">",
"      Treatment of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/39/37495?source=related_link\">",
"      Treatment of HIV-infected adults who have trouble swallowing pills: Liquid, chewable, and crushable formulations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_32_40459="Pathophysiology gynecomastia";
var content_f39_32_40459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathophysiologic mechanisms for gynecomastia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Absolute increase in free estrogens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Direct secretion from:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Maternal-placental-fetal unit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Testes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Adrenal glands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extraglandular aromatization of precursors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Displacement from sex hormone-binding globulin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exogenous estrogen administration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Decreased endogenous free androgens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased secretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Relative increase in free estrogen/free androgen ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Androgen insensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital defects in androgen receptor structure and function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Displacement of androgens from androgen receptor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Estrogen-like effect of drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Possible enhanced sensitivity of breast tissue",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Braunstein, GD, N Engl J Med 1993; 328:490.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_32_40459=[""].join("\n");
var outline_f39_32_40459=null;
var title_f39_32_40460="Rare vulvar lesions";
var content_f39_32_40460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rare vulvar lesions by etiology*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Inflammatory",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pyoderma gangrenosum",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amebiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Loxosceles recluse bite",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leishmaniasis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neoplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Porokeratosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Langerhans cell histocytosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Angiomyxoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myxoid leiomyosarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fibroadenoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Xanthogranuloma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Desmoid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Schwannoma",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Systemic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Granulomatosis with polyangiitis (Wegener's)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lupus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pellagra",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Reiter's",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Papular acantholytic dyskeratosis (of genitalia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Extra-abdominal colonic tissue",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Laugier-Hunziker",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dowling-Degos",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hailey-Hailey disease",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Rare in the United States, prevalence will vary in other countries.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_32_40460=[""].join("\n");
var outline_f39_32_40460=null;
var title_f39_32_40461="NSVT and LVEF after MI";
var content_f39_32_40461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    NSVT and LVEF on arrhythmic mortality after acute MI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 220px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The role of nonsustained ventricular tachycardia (NSVT) on an ambulatory monitor and the left ventricular ejection fraction (LVEF) on arrhythmic mortality in 866 patients after an acute myocardial infarction (MI). Patients with NSVT and a low LVEF had the highest mortality.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The Multicenter Postinfarction Research Group, N Engl J Med 1983; 309:331.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_32_40461=[""].join("\n");
var outline_f39_32_40461=null;
var title_f39_32_40462="Somatostatin and octreotide";
var content_f39_32_40462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Amino acid sequences of somatostatin 14 and 28 and octreotide",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 467px; background-image: url(data:image/gif;base64,R0lGODlh0QHTAdUAAP///wAAAL+/v/Dw8H9/f5CQkF9fX4+PjzAwMCAgIBAQEAAz/w8PD5+fn4CAgGBgYB8fHz8/P0BAQNDQ0N/f38DAwICZ/1BQUO/v78/Pz8DN/09PT0Bm/29vby8vL6+vr6CgoBBA/1Bz/3CN/6Cz/zBZ/+Dg4PDz/2CA/+Dm/5Cm/yBN/7CwsNDZ/7DA/3BwcAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADRAdMBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycrLzLwmIA8SAdPUARIPICZPEwUXCdXTCRcFE9vd3+Di5FDc3uAB6uXs5+/x8+7p4/LN/E4g0u8CWgOhZEABdAKrJSgwIIlBhAnDMSx4MKLCiRQhRlzY0GFFixI79htZhAXECAQ+CFi58gOBCApZHCmggBoDAwRYsiRggAE1/wUFZtacdjOnTgE8fU4DioSmTZxHkfb8GbTp0ABFoyalavWpUZ1bl1YlOXLAA2oRGjRpAHPaA5EDAAYwIICJAAPUJMCVS9cu3ml6icSl1nfJ3bwihQyeVljJYcCJF8+ta/ivtcRklQ1AMM0D5ScCPExD0HDztA0UoFDYMLo05wCoVbMOQFrx69hPVrceYhp26tyzawPojduJbtqYMxvrTaAKgdEmXh+gcgC6dOqte0+fUh358Ovcs4OX0l248mMvpqm10mCpevbg1lNpH+DB2QDyp9B/AOB+fin7+QdffecdY8I0HWTRATXNIUHBAQQckIESz03TYBIPEtAABkhUaP+hY5RlIMBvRVTowIdJrMQhBiMe4WEAFx5xFIcuTlNBgcWcBQGNSbD4GRIYQBAABEnQF4GQPxohJJFK0DdNBEkIOeQS0wAgQAAe8FiElFMqcZqVMCIhJZNJgJMkEULyh+MwNW2nxIIBfLCET24WQQFWEwLwQZ5I0KnEnQzUlUGMRXRX5xHTYMAAA3wa0V0AhxpBzUphHmEolQGwpGWhASiw5jDTnKkkY5iKCkB1CToRqhKoNnFlppjC9F8Rr8LqpQcMQPBBpUa8auoQFhJAKK1VfhrMqkrseoBPmxaBrBHPNTepl7Z2yKtjzyJRTaO9TutlWgHANKwQvmJKDbYBGHv/bLVI4EUBXrMSkS0Ru0IZGruS4ltEe1AKQWK3+joLG5bNDlHrr0KEC0Bb44IZsLzp2lWsur60qQQGTwrpgRJ+IiEaXaIh3HGU4RKwQb+WThOpwAB8nMSjK8trL4qOqoxpE9V5KsQEDkigETwSOLAPxavoWLAQ1eFEgJDcDhFkl0dgMBUDxR2x5BLHQRAzAGPeTIFP8XJNDZna9otXw11T20SaAzjws0AJOJAc0aQcGECqR4hG44J4FwHntVR42DAULw7+hIk0O1eN4U5UKMFVEBhwQFQHGMClAnLTjUp6+F1B31BhO+Hke1UESPp8bvV3un5uCVg6OAx00LQRGXSg/xQCQ2suCnOK0xadzeH5Pl4U5Q2gHXbeHR88acqTB04HRwMJpwK56w5Kb55FcW/yr0XwLxMUtFVbb96rJn5H5H+P9fm8da/+n+x/9+T7GLZFFMKO+US99aSYhVboRGALNd7CG77gz0qWCYxiDOgXxAiGgZVx4AMJc8DHXGaCjKmgZYgyuydkwCcI4F8pTFINlKhEJy6xHzxuZASnEAUqRwlLp8ZCBBdiBYZgmYpYuvLCr+xEhzNMgg2zEkMgMkUoXtGKEQGCsBkhYVcBIIgISfEPkORFikh4iBXhgZEjaNGKHMnIFsMoRjB20YsfAQlHpIEybVXjVzCRwBRN8YxoBP/kGtkwBz4Uog89/swefqxHH+/xx0E6oR2FXEfCOkctTRVpYnPU3YnA4YBQzCtfwjLcqyLJv0lWo5KguKTAzpUiSHKSaJ6kBig/sTpERWwJ9DmlJN+xSk+w8WZMiKMsNZfKadSyEyCYhpzK9MokQBGLu1RXLwPwy05whlFW+CBtkkm3ZTaTExOoSaCoIAD9VY+aOLLmKLKJoOhFbXrfBGeBxDnO18Sug0So3e3Sqc7zsHMUbYOc5FYiopVU7nKZqyfF7tk/t22xHkGjp0D5QVBT8MxnB01HQBdKkoaqIp9j2+dR/vmTiVK0GRVwgEhHykJWTMCdsmOCPEej0I+6tBD/5LybOY2AAXS+tBkDAIFIWyoKcm5zCt3sFE9v6otsKgCiJU3FM+HZBGmGkKjIkIZMAMCCoXoimA+DwjGheoyzKGAc2ljFLZMgohW1yEpJ0iVXi+G/pVi1E630W5jaswEwbSyAplwrMDpSAWlckxSiHEK9AIAXBgDgOX1zmF6JcQ0WVIAzST1FYIFlWAaIJgMwSdImFyuMArwGAVNVRVyLIKs4QconRoglZ1dbh7G+bEjp8oCQ6kpaa9zCBRawgAv2MAIOPOEEGkhBETSggROwFgxYHSYSMvClCh1qq7Q4QQkWwIHpWiALHFjAEyywAA0gQQMLuC4ASCBeJmhABOEl/wIJFtDd44JhqRyDFACYG4BGOdUW3B2BEFqw2xaggAMjMC4ALEBeDpCgBSIQgXHPywEOqAAAGlhBeL3rAhE4eAgqaPAINJBdFJBgvA0WwW5RQN3rkhfCuv3vbo3A3vQKIQUhYK93XfECCbz1Ez49IBKCur9arLfELQAAjEtggRCUQAjsLUGMVzBdFAwYBRbILglIEGMDu2ABIhjBAvRL4hFYoAQqkHAJ9JtlC0g4BdNdgW+zO+AFhCC7CxCuEbhb3gZnd8atkEZkVRFT6EGhpm7FRZFbTAIVLGC3Wg4yddvs3UWfQAUisC4A2AwA9BpXyZXGsgW8y90ZpyDKEiaui//Z3GkAaFkD3JWxEOgsBBWEIAV3foWeYXFSoqR0CSulzY1RIeAWaJkDpS71ooXtWyWrwNDXpbSytXsCFEz30KUeMglILGrxkrq9nU4BcYu76lG3WNV5DsCeV4HRaURucgLopwA4uhSP1iLKJNAAiS3QAixHOARI9i2xAbCAFWhAy8k+dAuQfWURAAAFKvj3AlRAZ1GLgMPdBa+IJ63dYLd3uCRGgXdbQNzpqkDArJi1LNr2toDEbW60gHi/xUsCMQeZ3/pu76J/nN3ruiDGDx5BjBU84BiHQL8pkLDBSWzk9mYX39fm9MWJ8G3tDiHWrhA5LR5a8rxgI6zuFYbUa1H/xS1KAJlZ78XWZUFCtKTkKCmMSdh9MfZXtDVcAByCAN2C8rXPYgIVqPtFX5M9KGzPPHYPfBl4F7jdCJ4WOd1pLDgXdybQ5wWHv7sCjvqNcaPCbomlApywHvmoB2CqVX2F0QwTorMW4Wlq6rwrvApWWFjsZlfKkrV0pvpWvL3HrZgssAKgKGjuOK+1RwVf/foK3S9SVugKfp4f4FjIFj+ru58GUzerfFV4djShbcXrqcUa2c+++uCPwujV5rKopSn86G8C5r0GtiNsPv2mCOlIRWr5zY0WCo+HvyksuvfERaFCgKd/ocB//YclOkYEf6d3ArgJBHhR9wF3a2E/BLSA/6TQgKtQdk9ydij0EgpRfxTYCRbICl1nRV/3gacQgqdAdSR4dSaICiiITwYFRu7WgvtHS7bnAPqEbjrBbp0ygzQoCi+IYyjFVEKQa7jzgzVISavQZzN1ejaFhKMQhNikTQfYK94EhUBog0qFJ9EEQlg4gFp4ClhVhcY0DWD3hZkwARcAN4Z0SPSQD4oUSHC4awCASIIUh0PgWrRzFEylVmiICV+kRmeERlWXDoNoBIFoEWRURoIoEve3MODQRqkFfH8YCUOEQz+kFEHEQzfkQyshQ0eERD2kRJoYiqLYiaTIFQAwWSKCF3QxfZRYiY0gGY2RIgmEGbSoQRJUQBTUQP+QgYgQ5Bi3aHzRIjHFJIuPQBz04yDBARe3sYxHcBzmoYyyYXi2cRrQaATS+IhCUIywFIvIiAjNQzy7MY5QUDzyI1/Lgz7Dc44ltATeqAR+GI6N4DqoQyD2yDr4yI2Olzqqw0j3KEwUAjhGAF30yAgV4H9EkCEbMpDMpJD0IizKVSMPSZBSUCEVkJAW+X82AU/xeAT3dZD1CDWTiBZLwCVkc3qiEQGiYTgoqQTqxk8kYx8kuWM6cTRc8lNSwGN0KJJ7sH12ghWCwjgwkwSIVYQTWTPAgwQqpDBIkDNA6UbeopRD4WdPAGhC5ZONEFit4gQH80glQ4RfSVaH8YqlNJX/xORIMjINtYYVtwaTtsNSWrmVD/ORhoGW0KKJADSWA8k4tQJ9i5RJZzkcOJhR6KZuPIg5CjiXghBY/DIE2ciXNFWECyKJxGJ8h7WRBvNGTAAOg6kYMahGPsiYhxCVaFIyJ7MERdkhaXEYhrOafamanWKa+cIEOWMEKpgOCUWakKAjGDIbWnOSY5MibQEBjPOS8KiZQpAmvolLSnB+vCkKGsk4TYA4ytk4vgSRRGCXJWIj0+mc1iJu0TkK+QggqVOeUbAf/9h4TeKP6Il//jieoWCOT4CO9OkE9tmO9Wl494kz1iif1+M+5mON6TOg3nGN4ZKNdhI/CFo+ucGgADqf/8Foi7u4QL0YQb+IQZPhixdUBLnIoQoUoaRwiZ4oFaVIQ0VAoqm4Q5xIRDl0okqgokUEoyJ6Com4EYfooWmkiDkqGDuKo4t5owmxiDWKCnY4h1FwpHyEh02gpNQASIR0hz1ZpFRapVZ6pViapVq6pVzapV76pWAapmI6pmRapmZ6pmiapmq6pmzapm76pnAap3I6p3Rap3Z6p3iap3q6p3zap376p4AaqII6qFvqpOHQhlhgqPCAqFSgqFCaBY7KqIRqBUIKNz3qBJVqcpfKiDy6mJwKpJN6BTL6oqooBaOaiaXqBKf6iUaEok+wqiaaqqH6BB+KoR2KqRO6Y7fYBP+1KowVygS9SqEZOqu8+ozVeKDAaqzA8Z9epKzG0YyY6qxNII2eOqv9aZvM2qxLSY7Iioj6iZ/Z6q3b6o7dSqxH8J5PoJ5LgK6iE59GwK5r4a5IAK/9SCDmigTf2SMrkZzimQT5CiT76pDj9q8yopYU6YEESysGe7D3eq41aQRwkpSjknoOm5IQK5DPaa9F0JzERA0SOwTQOa8PCzEem7EU27BCQJunOReySXtHoLIgSyqs0ikvq47EBACP+ZQ0mwQwu4rpkrM667Io67MIoyzMknxpmSynxXtIKzD4UyVJ85luhDBQy7JSO7REqwTuAi9N60oIs7UAuZbHuEhPSw3/3ie2jUQtnWFO1Ie1k4Ux4aIxXZsvvwK3R4Ilc0u2mLIgO3K1dEstfMu24DirMJs0wsI0ryW0RVC4c3G49ZW4Nbs1iwSJtJUyiksEPVslMFG5lrszb7iku1ZHclENeMR5SxCpTKoEqHtjq5ukn/ukkpoErQsLHGsEeiMEfDOTSlC7RXC7AJC7YqKxRMC7tfk1YXuaJ7uxI7t7AGC8oSMk41CIF7GYIwgSJegR0vukl5qp9bCp3GuICvi90/upQ7qppJCwU4CRSoC+F2kjR8C+HNmv+KqdhPMOLoqqLHoEGFgyJ8QSafek2TcEsAqKrgoAA9yqLYqJrEqjp3i/Cyyr/wJ8FQ4cq/lbNPz4jcIrssebnvI6vBfcnhnssBsMn9VQi7r6q2+XFhE4QHtxob46rMF6wsM6HLkqI7uqoSZswxUawzo8w5uAuo81rvtJGxXwuodaAEFss9wagILxrf6JHJFamEpMrth4rNPId2RoJaLBPVW8rFzsG1bMjl38rAQqreADrelYNWccrpQgvj9BDWq8Pm9sRVcRx/AzGkW8R7ArxXZcP+EQmlvUxw6iQpI7s19MnUZpHUIMrsKzyE/MPE6MrV9cyK+FHNcqm+VKCQesiSWsi/arwBQMDjncKxt0FQc1yrSyQdUwwTLkwsJKDewJlvzBeJ7jHiOcrvExIP80ecvtuo+8HK/1Qa8YnLyRwMOkHBCsDESdzKGrDMqt3Mwl+syjOKMCgcoIqMqoSM3goEml9z4VglWZNwV/MzgZIiEOeZ0MeTSFAyJFaHrbmZ3KqSIAwCLevDggsrDvLL+SQI1e3ClbVMcKupCz4c90vMy2elBxgw6CHI0DPUbdsLzMG3s4OTYz5SNL8DQWK3cZA31XA8JPQjIQPbkSHbzmhil1dSVoU9JqO1khW8yRjMkIkMeJlMSUrLNEbMSLisRmjDWzgTl6fMQTcMmG7NOJJA8967O9B0+wmQQROydTDJlcqCdMNTLRKJTzNTiXQi1JXclPPUqU0jBZnZbyHLT/lCDMIEzMyvvL9YrW7ePIkszEaR3LSKCunQmYT/LLkknSBlAqOhvOUzuzfn2ZZYt8Z2nXuKIrG1ku1CKYfusI8Fu/+mwEj3047psEZi3L60u/lB3Zf73SsGh8Rsu0SVsj0qJ7usedYlu20ocudg0u4vJ7dl0NeTuSGW0wLMEELf2uIT3WIkI/uU0Ej60T/Fp/xGsnwhJ3v+21Jk0whY0/YAtAgTVY90K10Ae0y6jYxNR90ZPXkgIlDAPbZesqg4sImduRM3u5Q1De03EnG3mbIlvbi8RBJsuzXa3RECAaZ1sz6L249c285Zcybj3PG31XfdLfHzPd8VXIQoISqWnT/4VcJf+tlP2dMDPT3gHus/5Je7mpELsZCKadLtXBuQCTtsREJHDSMG3L35JbtSLOKfs9WXfSt1EL201Q3BDTvO1nNRT9WkqDuOYH0VLjE1QDjR39m+a2NWlzs85L0iG9imazkUnuRmtTHyQ3RqN5Bx8OJpaJgOBo2kLyAbmS2LGY5Vey5Zs5trv3K12JMYZF40ww2dgZRQiSBL4LvBer2XF+ndVpz1dgnYjMr3i+59aQg5RjOR1VrW/w4QQgGnvZ5dAXLhuwKKitWJ3tRouO12OeVfEYiylu2R+M2bQ8IKAzILCsy5c91+f56agezKp+BKPjlkQ4X3Gpa3xQ3hGgwv/nrQSZGwG70gGT7t7KTUy3Hnednt79TVdFiLdkXawXXsnj8xp/TpEI8DsTbsjT/tLWbjzY7uyu0ew2DcneDuDUYJVOgJW4hwc2PrlTztaqA99ObiUYMOnJnbITPt5Is7MVqwQt+QGi8bHLGcIOsdN3jKzYk8UJmI4OahzsU6APyp8C2vAE//AK7/DzY6D3w01XmAePbe/q66/065SZOS4dn+83u+4er5lSQxT+npmcXRA1fMw+nMLsOXdUzosZBKItfPO2GqI07MoyfKsWqvMvDPTGnMqwE+sw6YV6cOqu3sG6rdbDnNl6zgQjL8Jxtygf8LF0DQWbDMFDsL8mhHb/HPik49b1FRzBSaTNm9hCEuzMCJzA0fz2bJ/2pLoUTHTPY12QZqgHQs3tyRruSgnXHgz1Z70El9wAPtHi6DgFbhwSTFC9FnG9WfSj5Vt3jc9Fenf5REqIDp35lG+pg2Hm0TdZ83gH/DzxmZxFAu/Hqe+h2/7tQbr6g8zGUYqkUCC6d8SCbvjTOf1Ws7v7Re26vP+oTPD7/BgqeV+SfFD01/yrhv/yRu/DAT/G0wqhLu/zPQz0siCFkmB8waJJ9h4HZr/2UTD+psir0N/80r8E5l/AscD9keD9st3YeaD55mv4n6+piJ6ibQ8EBMGQSDAwAklFAdB0PqHQQSGRtF6x/4nCINr1fsFh8ZhcNjuwAYeZ3Xa/u8lGODlu1OH5PKiatiZA9KAmCi76rhIuCiYEpw79ELcECQ3TEhcFMzU389Cw1jhDRb8kAiLoAsYiAiRGXR0hLSVdaSkfky4ZaXd5ezU9r0B9h99Akj7A8MA+kgKJ8woUrBgMhIiGjJCUmJ67vb/BaYGthMPNnxACGDLyMpAQzskGSpMMBMQEDKwkuOL9/wF+G5ekXEBvE6QxuOdGABIFugxKSRdgAwUzFDYkQdAvYkePH9kMVAOyG8IkHTCYwdBBCcSPAyYeeHNAI0eSN3F+FFkwZ62JDDqwC5OhgzYELj8+kJPnToAHPaFGjf+3UyqvAQ6kJYFg4MCQDEQOGIBgRYEDmx8rJCHwZUhKDAIsdiGQpEJVu3d5UcX7ysGtWJYkOEAKUCmEZBQBCAiw1svYp3shR+6UhqdkTRMcSPD7F5FZg9JkfrEyZPEXmgosp1YdRu/qUVezBtja9ZqAsGOVeP6XZKGXAB4YQGDGuIviVK6Ru67ggHnzusk5TfgZVAxRo4PB8U4W4c4q4lGMQxc/nnwekwFQqmQZ4KE/7aJPrSrtJXx5+1UHgGCO/T4ZkwrfaIg9/p4BbbvE1DKNvf4YxAkhBTQL4LkGy0hnnXbeiaewAwHQ5zsoHKNQxI5KYaEJFggc8QljAugNDmb/AnAmnLTmy2MuCVXM0R+lFFDEBB3DKOWUL75yC64mhoBilVbOUSqAOeBo6jEgqfRmACcHrDKOJ8Fgaa07NkDQAyiaigemJEJrg6YANtLSzWH6qaCUyqp8zwtmTtGHAQDm6gCK+s45k6K4yKBAvjbfTHQXCR5goYJ0JkzUTt/2ZMCDADJYxUUEjzOTngDswUefJPhR1FRXCpgIARNPXQqMVe5g5gAkoigToGimqaY2AbIhi5tTgQ2WFiHDoGksADwYK0wlWTEIFs5wmUXYaanNhEVkiEwizBvTbAJGGQ3i4y9Aqi3X3DwsFMoLJGTKIAl1AXCHzYiehVaLs87NF4wX/yRIscr/Ni1DwPYCwjUJaqy5ptdt9G0YjFIiPfW89MpYqaWA5rEi1DDy2QdfhxuGmFrpDqZuqKI08rcbQSu6KCM2Pwb5XJGphc2K2bwCSyyydPtH0G7NWBNRmUPGsdyrNvMjgZ4Jc/UNKYl2mOZzMYvwL0ZB+PEfGj+E4gMCCMDWixsjjrraqfMF4VNoJQA3nA29wODSCC7t+okQzZ7Z6HNZeCSCsGv7Wj5cWA3HwLHRayIDsbs4LW+9yxb2Siu4s2PwB2L2ZVIyk/gb3uKU6cUFCyxwgaQROCCjBdJJcCIFFSxofeQKMjdVUA8C5vhSmLNrEQwCtOGSrdBpOaGEBf84ON6CTDhYoAwLFtDACw0WWB4AEqwXY4HtFxgBgBZCCOH41B/XUlC7ybhx6Gc2fyKleFkakj7iXYHe++9NbwEFDkY4oYnYLcABErRABCLwnwZEwAEOqAAAGlhB9aTnggQysAkqUOAINNA8FLSOBAoUgelQgLzlYa+Bpduf6aLQuhZsDwD2AwALJacfwVTrBU57WhJe8I3DyYU7HUNfExzXCxJsjwMWaAEAUiA+C4ivCdsrQQgWsILjoaCFKAjgAkhAAigK0AULEMEIugeAEI7AAiVQwQNL4L0vWuCBKTjeClLXvBYuIATNW0AKvJCCKH4PiiLAorAeFKHIJcoEJ8n/xHq09gy4FUc+EPhhE/DWiyVyjwQqWIDpwHhE5M1Reps8gQpEoDwAyBEAfvTfE0vpRQtID3rSQ2IAH6gB6llPjq0EABg1AL3tuTKVpnPjCqBIxWCV6EQqo1Jh3seWhXyFUO6LJDG4Jgiy+cJ/3wNjEaPHyRemzpabfKIKLLk8Uo7TeSdAwfEuacskloAEIZRl9ZpQy2y2MgWy1ID/TtA82fnxnrEMFo98RK0diiYVivFAMqEwF9R4w0lQuqFThhFAEmgghEb0ogND0ERuZnOTUdQAGMV5yRaEs4siEKMKProA2EGQeiLIYPRaajp5sjKbT3CjCC2QghCiwAVQxCOw/yZ3MWG1LwpJwAADLjS/Tj3jZzOpyTBeGkXrkQCNR9ymNjc5ROTBs6cqvWUf/TfJEHgvBQ80aQjFl83mZXSm2nwC9bgXvRP4cQElQCFQmyCnkQzVd6iAFRgAtbKJRKCZYjDUU8t3tkY9am/AIioUrvC5P9GPGBmrR+7+NCpW1C6xiUqVRgoXLGk8sgna+g1CE7ogcxhMHbqqzcLY86vOzvaYskFtUVNxKQPE7ZngqBdn7kVb4VKpkIk7DAAogASHPgGRABFXLMg13GotpznMGWSiaii8KOHQH78dl7Ske6rWBOt8cFAfZ33BWoTtCrZLCC+wxkveieCODQLY3fq+Yf9ZUGH2CR0jFXrfK6L4khdLlRNDAy4H4F2wrLBhwAhiA6ylAQurb1f42wcCR4DBBSAB161sTJzKuwhXacLTUhu09uG2t9mwDVAbMZVKbKqqJQ0LWEtkPKJJHwEYqcFNmOaLdRRjNyENxRxmWtMMQ9AwKeaHvQUyhYRMJZtphSu7ug3PFEyMgeK2RUxW0EKfPKIo64hk6jAZGKyTsoA8trTAEU6NwEPZMN9nzCqa2G3BYLEs7aavvuGOKeA82aXOmUF1FhHAAuQQY2quz3GIT4KUSmgBU8ZU6cLQvPyxZciewjg/DKKkC03pRLGIv2X41o5kwyEPfcHJoB7PBC4AiVz/sMEWllDEop1Q6yzcug26RgSvoUAsL3zlGpJ9wpL8kWMb0cXV5fEudMHbhWfLOtpRmLbSqm1tKhQ5uKXVbhQ2bAow2EpDLGaDi5stHvW6VmFH8NUX1p2wIribYV6IN3vpHVsw3Pu1+XYvANj8FX3Yw9hOCKw5muoGoWU53fj51MYAq9lSPUG/EGeLxM9S8VIjCePWfvjGE4NxNvs40KAbNMIH2+MvHFbEDXcNg10GYZiX4cEtn3mhXra+m4+h5hNZrlxKXis5+/bjovKYy5GTcDU9VelsWDgAmh40xEa9DGvqXBjmQloAINsg/G538P6NdNc0lClJeArZtwtRtD/0/zFrd0NTjvG7oD/h1PTaNoq7LfbVKDsKFDgAARqAZyfcyBOP/FrY5K4GSC9bQnx/w43UUXA+zV1xGQLJc2WtYr2nZpFCp1wYcJPquM2tbmAIfZKHXRvJO6bzOiaC4EMPIIYo2iPXlgXDN58TTTeBAuq4RwZIa3WgPaFPimNcFIT/KizID/ns2T1kr4DZNWWFYmTQM8Ei4vV5g122uYfMY2niJzIYp9GcMwUBJI+k0aC5YwQf3vpR8Xqllhko6VccytiEa6YWnWMd9/73y2/wKC/ORg54rODnBC0AoyDrOCb6xEAtwOb9oA4rbqbKBIDYbGNncgP34GQiWobmco4D///PIB6rO5xA5QwO/rrgfYhC3N5PAVOLtMgPBp8ACySwCYgM744MIKiODJ5uBO3i+QBgLP5mA5ivcaxg+Aavh1ZNQdBEDBgQDE5DCJ1g6Jzg03ItM/wiAQJD/77B7VrM7IDQLlrvCWoOApTwbm6GLRqJtE4PCgdwCJ2iDHFLDFptLxzPDX5sDKEiD9uA8BbPvAgiEIHukcjGD2vw5FKrsSSDDp3gLUBODqeED3sCDM9NDC3RDKAmE8vAxTiRDNAtNahwPY4PCcGMEnOiB8fg6VRRDFgRxBRu6mBx6VouNUYON3arARURFUFCUAjrIg6FI3wRBbuA5YZmGIERwqAu5ZL/sRZtkQZlBQkELwV3kRdfgv8i7ugoDhsvThudQOOM7r88TmNAzr82KznYTB8oQB8QUNCsUSq0Dxv8rfueIB55ZR7hLTbWq9+4b9/0kd22792g4/kwoHPGYkykULXeESpsLwuyjeLuzl4e8hsjErgmkiJpzCFFMCockSaqgQDGIv3ucCFvwtf+ANjKwCRxASX9oxC2kCVbshJ2DRPKww8v5X1YQvyADkdUksNgkiSBci8+0Q6SQBEyMhI2MiiVsrtm0en8YB+/TiCXcip7AhlpLtz2KxzPkSq5kiTAsf/S4ANxThm7siy77h/lTR6D5wrS0BXJ0izh0kwq8rti7dvC/xCi4jIvAaInZw0RzWAP9TIwScIRneDwShFE8FIwFdMjhFBuTKH0vmwxJTMi2Kz44uUwqXEyNZPP+KspPEcXNzM0zaEAg6cdM1M0UbMbGvP+XNALsDA1YXMXCFPDGsCHTC8xYzM3RwERBaANE8/DdDM44WAoD0wMhfM4N6EVi+UtkbM53cAqCyUYnXM69eArs1EcqTM74cAe24setfM7y6AhkRI8yRMO+PInyzM91XM92bM93fM94TM+5XM+6bM+7fM+8TM/9XM/+bM//fM/ATRABXRACbRADfRAETRBFXRBGbRBHfRBITRCJXRCKbRCLfRCMTRDNXRDObRDPfRDQf80REV0REm0RE30ROHzPGkSRXlRPP/gIlkU6bgTH8VARb0wRs/FOrsRO7XtKF80KXH0VHbOsEIwCma0H4M0apQzIW2OG+nD/5LUYTKxNqbRxYbUwYo0SvUFEbGg1MhmSZ0Qv7SUWgjzN+TvNh9gKCmgAYTAC0JxTAUqANpSNsBG606DEM3v6nYSOOH0TdjMBnVR9Lyg9wBEAHQyCkayTyWFBlsTH5IwIQ81MhV1Wv70CAFLBQtxDA5uUk1FCBt1OUfuDnIRAKbx4GyUUxuEMNkg9ErtqBaDV5bF5HBwLqENSFE1KvyyDG6ECuNldyjPcY5UKm9VPIgzDKREVR/R/sb/4gKctDigdFiTrimlDmZyNX2wQCx5LkuhNVo7hxj7TjoBoFjHDQvaElTFdFstQ0ef1BvB1DWxwDRB0TjRFTmCtd4ojhmvEgvQh0p/c16Tw0WjJWbU1Vn3IdZQj8tGThL9VTxOVQzqVd88FXfaYjlPcWFth1aprR/+1JEiEDQtdloatgoZ9QoctRo/VlFKrFIFxgpP9k1KzFMtVVJbVlhKrExjtjFwc2bFS9SioFrHADB11lRiTFy/4E2DFmV51tqkteqY82jdRMigk+fA1Wl39hPCYGDdRwA+AONMoAJujGqfNmnzMVfS8h7TAAFeckXBVkUMDWCL7EfXVszEtkZd/9LWHgEqA9Je47Y/DG0MsDazvHFvy6Nvr9YDvRUKes5WBbcPq8u6MqFdkdAZF7daiNZN5XVyxWMAWMABaCcT/LBISPUCkSRggBZzVwMEYsNky6Aj5RQAaGJMei9mE9V0IaMKfsQEckgQns9dwkQ+MOAO7OY1aTc1qgABHCC08oDNggPgLuUDWMLYNnV4JWMCDgEeBIHNMuIO7qADgCPSpHc1uGACUJcR3YDN7uAm6QYxZPV7VaMsKqACbFd3W3dQr+5GTFN42Xcv6pLDkPcNVHUs1sJdAkDlZjd/q8IEFNcJfBYOydeAtaRyu8BoHdh8ltYHm3YxUwB7eIkWsOenmv8glzxY7CSASZITX6PzghVTq5yomqCAlNxgk26JA6zqf2pK71j2OZsVPJ51M/UoBPAIjITpozbIgVgqpyaqgUZABFQAn0BpBI5oiFbAiK0nBUYgibPpo5SYhV3tht/gYcMONS3pfk6Ajm6prkQgBLQIebCHjqqnpIAYAI5nBB6oBcCojlpAjpKojmLJjRdAmJqNi9/AbfMuNaEne1hoj5BolJxnjpY4BZqHdGIpjKiHimBYnlqnlR6ZjRb5j1XXWjIyunRziIRJj1bgqpyAlGxJkUmHdGapgTqKfNoKk6tnlRsOkJ8TY7EtgZfyBKAIpUTpgVwgBUIqBYS5pkJoifX/R4844ASgh4HqKgXyyXlEGYGi55hPQH9quZO7GC3xDUlhswXQaayaoAUeiIwtaZZraq64pwSuB4q8yH/o6qUAwHjo6Hjuia7qKptF4W/7a4dF85qjAKDHYIMbSIu9YIbfCulsWR4MN+Ykd4LxkE/NAHKb76EhGkgg2PMm8aLvQnM5N4H9UnQZWKI5+iPG1woyQVU/ldVytqShIn5xNxOocKXdtWJduieK93g1YeRoen1vOiqo1wqsVw94+mYJ8KelInzHl6QPo9R6+qiRGircF34D4GvdYKY5lgCIEX+j+iP2NwH61w1U2gFZeqO7+iYQeBMWGOuY7axFJKPNz6zd/7ojqKu6mBoMKBoKfnCuQYJw8dqEpRaF+fofCJcv18bi1pVHB1sn5lbacPkv8FYthXWxGdtqw+Bh33aQKbuygwGvcxhw9yFtb3SzwyHGrhQMEpe0IaPE8voJ9lq1q6JmzU0TLxe2o2LCPrc2iLF0bRsnJswRw80NW7q3b2LCdrdjusJbuZq4OZsctsRLabC/Fpq5p6KxCzC6T5O6QSJkAS665yISo1e7u+uxNRIAqPC7V1EhxftWuJkffUVV0dsOh3u9iY4ctTIrtG6k6fsy6nYmCeS0V+5lDrDs5nu/w5O8x/NenzAW2TLEztXAycCLZUtN2RSz4K5bm/HBIfxqP/+7n48uVy/8ZnfVvsFSsTecobXlcM0wBFWVUO/BUMtawk+8DVr7CjWCCsMvvVFDkGF0xrsArp/gwqE7vwOLu328DHL7GnYbU4VuVEt1uo9crAWVWa5AuKPbVYWAAGIVqqOcFo5bH5IbVMu1V63A09S7y0XhusFbK8YAA5S1wNH8er0bu9UPT/+wreM8zed8zQc87eQ6z2V6fhEnEk+jgtPbogFdD+CbziUxag1rahOdE9a6X/nZ4Pw50jUByJ0gFGUc01/B0N3SGXlclz3dCxzdwSB9EPr719S21Gmh0jkucF0dJDp91lMRweHW1qXCyHW9133914E92IV92Im92I0Z/diRPdmVfdmZvdmd/dmhPdqlfdqpXUeCAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_32_40462=[""].join("\n");
var outline_f39_32_40462=null;
var title_f39_32_40463="Duodenal atresia";
var content_f39_32_40463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Duodenal atresia with \"double bubble sign\"",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 276px; height: 254px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD+ARQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwi6uXjVAkgxkkgdwapLI8jhgvLY69D1/+tUmAxbICjOB8vJFJHCSpdFXK8jHp6e9ADZQ2/wCUHcOuCev1rV0u8hjs5YZGkjc42tnj9B6VmRsVZzl1AHJ6/wA6avL4c5UDJPcUAWrgmS5fL7juzuJPPvmn3CyIqvwPQjk5xRas97B5Qd3deiscccmta00m7u9L2Mu0hsoc8j29/wD69AEGnXXl/JIcBueRnv69ulbum6FJdzG7t7kSEMNyx84GD+nHpXPCNyZTOMeXwyseRU1sslsq3FvP5ZP3W3EnJ7Y/OgDTk1HUI79Im3JGrAFMn5h/n3rP1WSWC4by5nYDC43cdOat2V/dTXapLK0jbc5k5Kfh+GKqatE23Mgzjksvbn/6/wCZoAoW1/PGwUTyqS24gE/rWnpk1rqFxF59/wDZHDKvzIWVR6g9eOtYEyEEbJMEHpnn2pzKUOcqu4gA8/pQB01ze/2RdyHTtUSZASNyIRvX6H1/rUUPinUY2G2Xg8NkcMc5z/n0rmv4z8ztyNv0pwG1yByD7dKAOlh1ySZvMv76TGfmQDlsYwOvtW7aeJdFsrcCE3s8xOdrEBPfOcn9K89feoXaxJ6E5zjP1NMiA8pjnBPYc4+lAHZ3njO+mhkjgMcURbcEAxuyc8njI4rHvPEGoXjgz3TuwPc4NY0ijBJyOnXrimZKlihw/Uc8fhQBYnnZvMO7c7HOScZP+c1CJCyKQdrei/zpSfmyxJDcH2psRQDEaZAPBPbNAFd3aSQPw7HqfWkkjZFBJGG+uRV2OMNEVVC/l8kjIqEDzE5IC+np+NAGeI2kwSTjPY8kmpo7UmMYHQcHB6etX7axZgDjJH8XXn8a1YbSCNFLuOgJAJ6dqAOa1bQLyDSRrAjzYtOLdnyP9Zt3cDrjHfpnvWDXoFx5DRSRsvyMChyOSO/NcPfW5trhk52nlCTyV7ZoAr0UUUAFFFFABRRRQAUUUUAFFFFAHdxhWKhSu7G4ZIqZYSCFUjIGSP8A6w5p6QExq8RbeOdmcfzqSNFI5ckg5P8ATrQBm3kcskq7j94ksccf57VXntgkTKSSD0J6itkqcEjbsQ9cg1XuN7qyeXGeOqmgDGhd4CHjcbwd2TXQ6V4kurOMhJHLMQzKRuGP8gVUWKMxKZIyG28Nj+ZzxUKW0gUAgcnnBH4CgD0TQtS8M62U/tiOSymTnzYx94k55Pp+ZqLVfDukXFyZNH1izMZb7jEByOxwcfSuIEJUbWPQ7c4xj2zUBjZV+Zjwee35UAdFeWtrp0zN9oeSReAw5JPfBHHSsG5upZZCFZUVeVwOv0qsJJS/lmQ8Hpnp/n+lSvb4QHeTI3Rc4B9P5igCNN7ln+Q465bP+elAV5QoIBAAw2cH8alS2cB22/dPTH3cj1pFjHy4XCA5wORQBXWMGT5Gw3fBHp3/ABqaMbyFLKG6Mc0/y/MboSrcZPBqeRVRsKjBVBOBz/k0AUzESFKruVuW245/GkZNxMSsQw78/l/Or0aFhJgNkgcg5/U1astJvZJXEEDYQZO3LEelAGNGGYMEbjHIAznn1/KolCKQC2ADkEjBIH9cV0cfhrVZV2R2lzhsjJXHP+e1TDwXqhKJJbsFxknB6Zx0PpQBy/lF8FGBBPQc5+tSQ20rsBGN3XpXUQeG7yBgzwsuMBSwznimPpTQlJMFVJ5wM7evr/nmgDFFsNoXOFJHfOT/AD/Cr0VmiBCwXB+Xjqe9WRbEsFnGGX5uwzUQVfNO6QBiDyOAB2HHfigAMFuhKybsE8DOKrzzRxJgnKHog7D1OKYTlsJhAueSM1DIsqne5BTBAC9BQBXuLiSaUkoVIH3V+tQ3NtZT6Xdx3fn/ANo/u/sbJt2dfn8zv0xjHfrTnRjksepGOT/kUwRtwXbk88nAAxQByRGDg9aStnV7LdF9qiB7bl9Bjr/KsagAooooAKKKKACiiigAooooA9NHms+7gRlsEEde3X8uadLbPFLgqiRuMgoe+Ota7ae8tussceMHacKCRx0NTQ6FdSW8j28bmQnIyOMH0+lAHLzYiBCkYA9SSKrhArlTwduMs2OtdBNod1G7xzRMm77qhh16fSsySxl3hXjK7AA2eMfWgCK2umZAGYMvBACjBxVqKNXLqMBuDuYAY5/wqCK2UMh3YA6x4yQatLbiORXRcAcgYxQAsCyAPiROONjELkn+lQTQDyWcBVPRQMe1PecbjvTOTjdtwV746/55olAGPNwVc7cZBA/z/WgCn5QVeiknkgHIzVlEDoNyDjGcg5Awf61aV/J2hVzEACxJx9PT/P4VM6BURotm1iDlTwo9P8+1AFJrYRy5QtuI+YluWJGOlOgs3ZsQAvLnacevXnHsK07K3N1IgWNirkcjsfX8q9M8I+C4miS7v34ID7MZyBxjOevt70AcLo/g2+1SNFhULlv9Z90D6k+vSu20X4V2EMcT6pd79+S0agg5I4J/z6V3i3KW8K2sSIkmwAAYG0g5x169Pyq/BbztFFIZIGcjcCOnTgEdO+aAMjTNA8P6cFjt9NtGcLzJOwPHODjk9unFWZWtrSEi0jVZQ6tsWIKB3xgc9OM0tysiIq+dGqAkbIs9P4R255P+HNVmvJIosCIRIG2hnABLAngev/16AFutTEaFhC6SKSTtjGFx259cY/GohO0zxyTozNvx8gxtBB6kdex/nT1u4XlVI4kxuDKN3ODyAOmOv6VYsEs5vtMRR0wdzMkhDZ+uee2OlAEMtvbtaDdbvEGwXLDkfl/jWJL4V0244Y+VLyu1Rjj1JPXAx+ddFNNcLHsgu5SjnbscbimB/ePqR/jWLLqAjdjsTcfm3o425+nHOBQBx2veB7iwXcNjoq7w6gfN78/X1ritQ0nyX8t9w/iyy8nj9P8A69e7WOqxyvJDKE2IMOGHvnnOOenT0qrfaNZ+ILZinySLnAViM+gI6+nGaAPnu9tGSbJVjk4yFGG+lR3AdIwzxlcgc9M16Tr/AINmsVMryIFRyFGfmXoeM/04rjb6ynjHlP5Qhzy3r+OfpQBzLqMlVcMzEcAfr+lMKlY3LqPlHG0cf/rrSmVULAAK2cBtp4zzxzUMyBgS2Cg5xuPA/wAaAK+lalc6Vex3thIYLuPJB2BjyCO4x045rjdTszaTcY8p8lPX6YrswsZYA5XcPlU9T6VWm099Uni0+PBlmcRxICOGOAvJ4HX260AcTRVi/s59PvrizvIzFcwO0ciEg7WBwRkcH8Kr0AFFFFABRRRQAUUUUAfcOleGLIyA3CsZ1Jzjhsk8HsDxW1FpunKkghjik2tt3OnzAgdQOox64qEtdRyRb5Ulyf3UaMC2MD1AxU8UczhmiijdfvGOVckkDsQKAHT2drNCA1nDKygMDwwAB6+tYGr+FNL1FPKWBwzjJHAJx3z1q7dXKWLGVotsqfMwGfmH1P8A9atSNN8COkqGN2DSbiSVPt6flQB4r4h8D/2WsrQSI0Y6Bj8zcfTI/E9q4V7aeJCkK4+XHzDBB78ivpvVUE8Ri2quTnGwkr2GO3+fwrx3xtpaWlwWjMgyxfbgDYPYjr27UAecNA7ANtJmyC2eTTo498hUKWB5yCeO/wCnPSrxjaOXJxtYDdGxwRjoB2qa2t9hV/LCEY/E/wD1qAIUDGNYUZR8u3IB3D6+v/16tWlifvRu8m7/AJZxgjj1Pp2/yau2lmlxKVCx9cKSM8njqfevQfBvh+FFWS4ysWAoKg4LcjBHpQBP4I8Lta7ZruBS5ThXG4cAHOP059K6q8aFZJQXjS2QBnZSAcdTjH1qK7v4oSDA2blGAY5GQo9CMcYPvWTNOtxeGKOVJIUB3ZI/DjPufrxQBs2tzD5kTJhix+VC+0oAT83A78cc08tdXJLMd6K+0gnywvPPueKoNcCBITI4Kjn5Vzknnlux/wAKmTekrtvRY2BLlW+UH689aAHwk21wLdSxkcneF5x3B57dvwqlczRwRESOFUSAgZ5bOflA65IP/wCutGzWJJWX5HIxsU5z+fQn3pktrYwmQXV/bWhBLlOZGDdRg8YAHagDLgQPdTPysBZhtU8t8vcjgZ9P59mpcPaRAxh4ZVGScknA4yB34zWjH/ZxhV4LiOVwABIxxyOwyeKZdtK0GyO2U+UhZVIP4Fc9/bFAFOaRpIvOSVtm49VAOO565znjrXKzX7pdSxRxsFjPJZAMdOTzngev9a6TSI5LkOLrcu4ZfL7QOMfdJ7H0x0qrJYNqV5+6C795RljXJx/Pp+FAGlpusmO1dNSjBtm+YNt7e5/A0kYslkiks1JXb5ghEnzHHseRWfreni1gC27zJMIxuDdzngFh/nrVDR9Ua11UIyK0Dr8xZuCf/QePWgDs0uoL4brtow7DAHl4KH659R3ri/Enh3z/ADJYlbJHDJGSGycnHv07Vt30UlyzSRiISphoyrghB2OSRjvT7XV/NUBlRvky2SVI7A5796APHdX0K/iXd5AWCMksVyDnNYszoWaF1c7Rg7OADjPbvXs/jYRw6Ku8xgqPk2qAUPr/AJ9815LLuPy+YI5Au4kEHI9fQUAYkg3klEwVxlyOM1WMZkkKxZII5OeB/X0rRmhkf5mdWQMNg9Ppk9KoyqEZgXxj+JeQPcCgDF16x82F7hGBkj+983Vf/rVzdd7avbC7ja6837NuUSFMb9nfbnjOOnb1qh8SrDRrXXfN8MpIumOgBzuKiTuF3c4xjr33Y4xQByNFFFABRRRQAUUUUAfby6vNa3B/0d0CKMp2U+vpj9K018SzTEw7VLIRiNMZYf3v/r5riTqD2kTx30e91ynJ3E8Z9qnttWiEcbW8KN1bqCcfoR+NAHeXrwXlvllHmg5ww5Jxx1FZ1neRQssbT4Z3IcOScDqOn6VUsL+3uLeQysY5E5KOcjGOCGPSqJnihYwiVHZQN3Rge46+1AG9d3LSea5U52gDgkZyM9PT9a5HxysaWiN5R+0Akbmk3Hb33Z6Ct3UQ8lvE5ZsIuW6gMMcfTmuG8SXxnkjjuZiCo3FcleT0yfYCgDlr+0VGkY7I1U53Zbnv1IGenSqVrvnuE2q3ThiQB7HvV15VcPE0iuqEbW7Een/16veGbCO91FY3thNCMMFXIAxjJyKAOi8IaIcedeRcMRtw27d74PXtXW6vq1ppkUEMJCXCphQFHzHGcA+vBq3eT2lnYQrbAxMmEG1hkDHbJHP/ANevPL+9mmuVRGATkkRj7o9Tjk/j39aALUMv2qVFjLFgMSbBgDIyT045+tbOkWzAupRC5UPtPynqMYweeO5/rVFFSMpFCkolPTcxG5sAHPb860rSKJUL3VwC0K4OWyBnk8jH+f0AL1qXF39ngLHbgybcN26HgZ+hp08dvp6l72QiJBny2IDEj0OeB9a57UvGsNiPLsoGQMQxJIJ/KuS1rVpL52a5k+VTlGdhnOBjIoA6HxL4wlkkmgtleJCMqyne2M92/H1x6Vy51B4/MDM7zSjvkcE9R7jFY9w0nH7lSu4tgZJPvj/9dSxDfcLK5eMpgDcScDr+FAFj7bcoWI8xCCCWLnHH0GK2fD/ie/hlZGLSAdQWJ6Z6HrjmufuWY/JHIwJGSj45B68ds1Si3wmVIhGCOCN3P5/T+dAHtWjy6dqsaPM/KD5QFAKn+7nHGce+O1LcjBnWFPLlUg/KucHqQce3PauC8Ga4li7WzmRiVJAGAMk9c54/+tXWXF6lzHJOvloygLh28zcD19Oe39aAK0Jupp5WEMs0QXLjgAMMEcnHHHTNcfrULvclAwBUbtpXOD9R25NdMsmobypleKKQZEZGO3p+HrV6HSvsVvJLFulu2biFQcJnr16+uKAOX0F72UiNELAYIiUn5ueDj9Oa0dUS6sbjDJ5UjDEqbQS2RkD8u1a+nLbaZeSTzymE5+cZO5s+54HbineLYxc2kd1bhkfghAMsVweAT3756UAYUOrWNqskd00rGQEBSASfYelc9eWDzxmW3gIQfKoxkge59vWs29unjv0EkQHOAZQSR3JOcVv2mv8A2hDZ26ySFRyFGR+I6cUAcRdxmC4IkZWLHhEI6f8A16zJopWdl+XGMA/n0rV1KGVJpDIBGHOQFIyR9R/Ss9YR5WE2KiNzz1HoPagCmYpEcebtKgZO05JP4UTWv2mx+zzZAfgJ369T71PK4lfcgwepxwPYVJbkoVVdplbg/T29sUAcFqVlLYXbwTDpyrdnXsRVWvU/EmnXOvaDYWVuoaazaRrcE8Ybllz3yQOeeR2BNeWUAFFFFABRRRQB9G6jqdrdSr++laUgMWZuM+nGPpzVvRrhZYR5ckiTMCSzHAA+vQg154Llkk3u6FSf4s5we1bmg3/mTJArBU/jV87SeoOTwO1AHbaZPeG3mAheSAHIMaqQf8kVbtrlHKACRkH30U/Mp9A3fHpgU7TdNeGwVpZmeN2HyDnaex5OR/Ko9RBS4VYxAin+ABtyk8dM4oAdr2rz/wBn+VbuWiYAsWx68dq428v5GmRLlwytGVyQQRx39am1u+eJ2jgllVl++2cgkd8cfnXLSv5wCbWjAJYN/D6/pQBpK8rujQnaoIVgvy5BPXjrXq/gi2jt9Kkv5bebzHO3MYz046V5FY7PtQXzpRhQcso6+3evTtQ1iLStIt4ba6BKx7yI+CTwAOvJ560AVvFupI7yrC3lqBkEKFJPoec+tYemXMf2We4ljcY6ZUD5fQNzXL32qvLJITKd2cgEZH1PpVrQ3uZHERfcpz8qnkntj/8AVQB2uk3ZvLjfHbKWZScfe3Dd3yOP1+lbmqRyJYubmCePf8y+UoIx+X+c1gXzxaJpp8tJRcbQ/mefggHt169/euM1HU31CZcySkLkZLHAGePbt+tAE2pTspzDIXBHzblx/n8KyllLpIdmFLA7uOv09eKfJAArOZXYNyM/Nt98n+VVJAY5VLSNgjPB4+uM/wCcigDQsr54Zwm1CoB+VyBk98Ae5/WnXNyCRvBWTG5RwM8+o71RgMkIMihURyMEjDY9M5/lQkjeZJIFKl8AFTnGM/lQBL9pcowwvJySSScj/wDV/wDWpt55vChv3TdBjp+VN+0ykZCsjDk7hx9fr/hUU7knaJHbGBuZxx/n8KANHRohe3EKrMpdmBJyeMHGOO9er+G9OVD5TgORkqdm0n1x+FcZ4G037TJ580TmFEDHIJz6ZPPfHFdcfPjnExiVQjYBXggdsdOO/TrQB0J06KAbrW3i8+UhHdUOVJPUH19ahv8ATWsdPdI7sls5V3bLDHv6fj3qlbXF3euJQJ2hTKhyAQvqM9vqKz9Wu5minjZ5wgPLHlhz0HT09KAOe1u4nsmWWa7Z5Sd2xSAwzxyepqpJ4rjiwODIRtPXaCR69T+nWuf8Rai5uJd8uZRxvbBwP1qjpumz3UDT/JAuMmVyOfpmgDUuWjvUmmAkjUDLEr97/CqOi6jb2czJIpmwPlUk7Dx1IHX8aytRvJYh9mQlo1bJAycnk5yen4VkTFo8NlzuGcgn+tAHSa9ftqd4ZbhlKKOFjwAB26VlqN6klECAD7px/wDXNUYLpPK2Fcyd2Zs4/oPwq7GSkbfu1VepPOMe9AFOWZXYKEXjkor9Rn2+nerdlCC4d43fcc/3fpUcilrlJF2bSAoGelbml2aTMyyvtJ6kHO1fqaAOn0G2SK3e4GxGVD5ZY5LHGMEentXnXxR8L/ZZJdctpE2SzBLiA/fVyM+ZgfwnuT/Ee+a9S05QLcx2Ebsq4UvIcYx1xkj86dLYLfxT2cjIqyq0c55JKnggY9QfagD5morf8b+HZ/DHiCewnB8s/vYGZgWaIk7S2OjcYI45Hpg1gUAFFFFAHp97hZC0jYkwMgdK1tAty6iW3QBV6sOijrn1zXMS3DMh4+buN2SB7VoaLqEtqJVgyu/gjbwRQB6xda9BZ6ZGrxxzHbkSQtjn37eneuYk1IHLptjVjk7e55/I/hXMT38kkSh5F4PQYJx6H0qJLz93siO853NwCRjpz+tAGlLfxO+EVc44A6n8cjmqizSNvWJH3kcKhA+p5/zzTRIGjjYJiQDGcZz9KYnnGfIkYbTuJAPH19aANvRWWLVo3AbH91OBjvSeKL6GaaRI4jEjH5Vxjp6EH2plrcNDvuI3jZEXJXpz78cVzt1cRn5mCeWOw6CgCzYzLHLujiDjb1LZz9SR0rs9K1S2t5vOa18rYnyksRz+HJ6VwmmtG1wrOQQeAnp75rpRKViMK58gjIwPu/jQAahqJv7kzJIJFb5sKckexx0+tdZ8OSkW1ngDESfMrrk7T078/rXM6Pot1qWY7eREjBxgNgj3rvNC8NraREx3k26PGQiqAR3GSefrQBv6/DHJp00D2tsgRjIhC9j15ry3UYHkVkMaebwu1e47H1BxXr1kmXhtZyXgZCY5nGAp9B0BqVdD0ne7zWttMUGTJ5mQOc0AeN2HhHU9Sl8uBYgTyS4JCn1H5V00Pw0vlVHS8spJWGNuSuMD39a9GCKkLLaosasQdo6MPr1Gfanm4nR0ldTzw6jG3J/HgDrQB5LP8OdUDnzmBOR8ytuAb3/+txT9P8Bag0ubqKTK8E7OBn+f/wBevVrq/Ee0vJ5iYDAduv1rQt7mR0MjpsDfe3DAx+NAGBotlFo9kB9mjRtu12kcv24rI1K4t7S7YNAAQAGGSFIx2Gfw5rsRDEu7yxunPCjGBjr3ODXH63ayrdAyNHGOf9XyT6dOPyoAl0rWLWW2eN0+z2y5UY+UkZ6gjmuQ8cXkMksf2FmTOWJ5Yn39enrWrHY2ULoZluDcPgFWlABPXJ9KzddvdJiuGWH5scsQRgY7AHr+lAHEXWnXF9P/AKBAWboWH3S3v6VAljPpk2y/uAsgHOMHA9h2q/cazLcSvHF5nlAgrh8E++R0rE1JooJQsu9c88jJxQBFq1zHBMTbv52SCQcHP+frWRP5lwweRyBt5A/xp05QqCrEsOuR/wDqqONimApB79OlAEcbsG4PzHqRWh5ksqIkjAx9BkEH8BUESO7BskseCFGGrQ+yusyJI3I/hTHA+lAEC4yoRA0q/dYdM+ue9dF4Z8qR40lj3SDHI3DJ/CufWNFkKqGznBx/9euv8JRyLLHHEpDnHGdxUewoA6SechfKCq8m7BBHyge3H8/etfPkwxNZgSSlsszDgEDoB1J5/wA9aktNOABkmyZEBxGcZJ7d6sQGa71CeGJBLJEq/KvAU4PU9ABQBxPjXw2PE+mSxTP5msEhrVtuEhOQW3EdiOPTPrivnuaKSCaSGeN45Y2KOjjDKw4IIPQ19d6XbxefJLGWlbaQZOgz1J56D3ryT4zeDg6Pr+mwyeaCBcopLBowMCUZ54wAccYweMEkA8booooA7JcsuVClh1IOQanhZjLuwMqOOSMVUBKgGPBVeMdv/rUpwfnA2HrjcSP1oAsmcl+PutznBzU0YLy4HJIyDnAP0qsZQUzjBX+IHpT7EoCqkFvdjg/lQBp2zum5ArYQdEf+vH5VJmUBWX76j5XJ5/8A10yAp5mMqgwCu7HBq1AF8siZRlWyTt6dxj/GgBLmW4iiCSEyAHIbZghvc9KyJSjyf6sjHXDfyrUu5FRlWSfKvyCBkD8QaybkASY8wMOnBwRQBf0kjzlVXMbg9SeevHT6V2tnKhSQySFk8s4fcEx6kcHNc14a06CeRAbx4pWbGCnygfX1rW1+1XTkENvdJchurbSpAoAlsPEMNkZY3hO3byF6t75P9KvxeObuOErZlURjtVii7gMfTivPp5S8j7i2xRwpNEdyrSrwFKj73TFAHov9u3lxdQN9tV1xkAnPP4V6D4bZppZJVu1c7cGIMNpHrgflmvCLfUPJcMXEmRgDd2/Mf59a2F8QXdpDH5MjQ7PmBRhwPc9aAPe557OxWV9Rd9rKDvyMH6Ht+FZDeJdPkj8uOfdIjbQCM9vXOK8bk8S6rfsxvLlpYhyRu7VStdQcM7rlBnc2SAoA6cdzQB71Bdx3spbakTHA+ZRkntgk/wBaumSSznx5QbjnKfLjHXPrXj2iavJHKC7xsh5JcE/l6fWvQrLVDPpcKKUIXncemB9T2oA376S4kg/eXARiNxCHAGRxyB/hXMaxdy21gY5gxx0kRz1/D/GrF1qoH7wiPzG4TeQWPvzjB/CuE8Q6hL5/70nyhwgLA4/r+lAFLV/tAm825yFcblLMST79eaq3yq0KCaYvIuBtC9ePXrVS7uZ7okAuwUAADOeO2SabJLdG3PykBsjCnAH50AVZNTWNTGzkIo4SLAP0J/8Ar1jzSxsw2/ID2zk9KkvbZiULOm7HOO3/ANeqcsDvGJCcR/w89aAKhK7gAzdeBnn8alVGZQWJ+U4we30z/hVZ4csmCVA5y55x+daNpGSyFsEdiRwBQBr6Rp0kqqwXO0ZBxnP0xzW5FYtbZEyKM8bFwWP196i0hDGUYOy46YwK6mHyIyrySxRkfdON0jD2H9TQBy02niLaJCEbcPlUHd9cn8a6vwfbWtresVbzJG++pOAo/XNUL1I5Ufa0hxz836An1+lamiWhtPKaONTE7BWZzgn2oA6ua5RGlmEi7nGF2DO0AcZPbP8AWm2QMVnIHZ4z1KRNjefVyRz16c1JcxRsqWuAHUCRkQgbMcgMfX6Uxnt3hkRmEZwPmfkY9FXv+Q96AKlm7PGMxr5YOViZ+Hb1bPXpxn8qdcpJctPLqkcQtXjaIofm8yPHzKAeMHgHI/LNFvD5c0YDq6E7kkI3DI7Z6E8duBWXrl3JtaJJYyy4yzt0HbAB9vpmgDxrxB8L9cGqzvollFNp0rGSHFyimNSThDvYE46Z5zwc0V7NapcpAoiuZI0x0RQQffJooA+e1Kj5RnkZyW71IZTu2E4fGQR/+uq/mE/LlcfTBFGXTDAcHv1xQBaikYPggHPJz0rTtlRIWdwrcDB67fesi3GeQPl656VrW8hi+VZDg8DA5x9fSgC3IxYiLfKeN2Dzk+xFWoFhdRGx5xnAIH881WtpnUuiDk9G65/wqzavGEd3QM6n5lU4/SgDLvJlaTLPwB/Evzew4rNZtrHLZCnIyMkVo6i0Mzkr8pz/ABDBrLJG8g7gB2HQCgC3bXkiD5Xbjn5SMj+tWn1WZ+DJ0XaOf6VnwYdQu7C8YwOcVqRaO0kX2hJVMY64PIHvk0AVDMpYllITHIB6023kCucIScnn04p1xaS20gUFsHkcVFbxkSZO7noxGNtAFkyMcHfxjOF/i/GrCndHuyHXA+VVOV/HpVeGZlcGTDIPXJq0s5NuFAIHJwMbQPz5oAdBIx6P8vcZGacqmMgM7hcgjPOB645qhufDZUluu7PIH41OiRsMtL/tbef8aAL6Xk0aMYnXYhG7IwfrWzpniCe3YohDh8KS3f8ASubWVHwYSoPQ4OR+tOQrA4InOe+Acc0Adc2sFplKSSSSpyQXyD2rJvbtshsFR6LhQfXjqayYLoK2RgE8cZxj1IyKkecGQGJ1VVON7Dk/T1oAcL2YyN+8/dqT8gIx/T8qsy6nM8axRB4yD8uB26kiq7KJISH8uSQAfxcA1CzQtGGfkg4wrEqP1oAj1F5Jgcv5hPJwwyaoSpjCNvyoyAzZwPrV25fajGHCRsNuR0xiq5BIEfmDgfNlc4H9aAKgBEZ+bg9eOtW7ErF8+4qF7lc5/CozAuMxy7ZD+OPemKWEuMllHPegDTj1CZV3RsqqDzknnP41s6Nqy+cS8ZcDoT69yPYe9c0k22QbycH6mrEdxErjdJuC8qpHT/61AHp1nLbzxo4zIepZl3f56fSt+wmJWKaQcjkKcbs9iPT8q4HQdSu50it0mZlyB5ajBrs4LaaJVeOZYkBy/GQT/X9BQBpzTssqKFjjWQ/Mi/KWz+p/Hk1Yt9Pn1aaWXbGqhfLDhztwOw/vGq9sjCAGEFZ2OGkkTJI9FHb8PetOHzobJ2CvEFGGPcjsoP8AhQBXK3UFm0BWJI0bYJOpI9v/AK1YOpW9sZolUhsvkAHsO5rYuNl1EsUheacDLJv2qg9D/j/+qsMWslvMIkR3iJz5p5C/QH+dAE8D26RKJroI/ccH+dFS2VkfKYmWBdzE4KM5H1IHWigD5yXEjcpx1JFK/IAVdvY57U1CeHwBzgD0/GnnAQcnB7egoAu6cgZdyE8AdDkj3q9GGa4UqAYj0OMc/h3+tZ0EbBd4JQKMgnv+daUDK0GYWjDdSFJ5oAn2naMho2HLdj9ferMiMkLOrAo3Rgc9uv1qG3n2M25FLYB2nvxSXkqogWORYwpyU3HKn86AMe5yFOTkHJ5PP5iqscnRhyB2PenXcspmZQxIHPJ/xqufMK9RgDPBxigDoLJLSaMPvyw6JnH45FdVodnGyn93tPB2k549sVxencugZN65AwOoFepeELRTB56S7ZFXoHUMv4ntQByfiTRJIZmaC0lIblX25H865vZJE6qUkVxxudf84r2+802cxtIt3K9s65ZuRsPqOlcH4o0wxxjZOkjcFZCBkj+VAHESMWdnwd4P3eeaNofLvhehIZsZ+lSSoZJR8vKnh1OP50qr+6CqVBUcc0ARRElyu3cevztx+dSRyBCdrKPwxn8aHHlkEfeHvzTg7hSQFG/2yaAGmTaeEYK/BIPWnwnLL85MY564NJI0RiDkKrpxnd+lRqCFJKqnoo9KALDneuSjYPQn9OamVsbQ6qzj+71xiqUVyyugk2tz0cZq9BbNOdwmRFYYAX5cewFABJKEZQgWM9snJ/lRDGrHdMxBPPABz+VWpLT7BF86OUyBvI/ln+maGnhMbxwYTceMLyPxoAjkhJw6ROR1LYxmq9yqpGq4IfjvjH41chd7iMRmPa68Iw4/H1qvKuwFmaR2UYwnQf4UAV1cGM7dxkH3mIAX86rIHVyWb5gQABxmpT8zbmzt6qOuKZKc7cbSg5HOaAGHcZW8wjv69PwqSHZlQkYyMYJGB9aAAVDrg8DAParCjGPNbtkgYFAGtpcjK6vGzEjPK8BvrXZeFtQl3bHdXUH5XkbCr+A5z9a4K1kYMFSVl7Lxk10+n6klr5RUFpFGC8nIX6UAem2czq5lllAXH32H3/TAz0q1NfIGAYyFwBhV52j19uK4zTdTNw5dCxmPCEKN3/ATyc1sGCSArLLO8cbghYwdzt/XPPYUAW/tgkjfyYhFDG25s8bvdsf1rO1O5edlkiLMx+YgHA6dSM9PrV3Tra3jgl+1LIIC4xGWxk+5zx/OsnXIVjnSWGIRp/eMnyrQBXlv75SFMUhwOCBjP5UU0tOTxdSEjqQxwf5e1FAHg+75fmbODzz196ljOWX7wboNozxSxRhQOQp9TUkKBWQh+QcnJGP6UAXraF1XcdpfGRlsGrcbLG2/YSMY3EYxVTfkFfNYrnHJ6frVtnnEZVCrqR/F6fSgCRX8pkkTPB4KDNR3cwkl3yxqQTy6A5P4Y/pTklbytzrgD7p6Y+hqteyE4LMMdeOTQBm3DI87NuJQ9BTYMEYCnIOfrTXIVRhcYbnnOKQYIBDFWH+eKAOk0p4/OjeR2QDsMdf/AK9ehaPfxQzJ5WxQy5z97ePz4Pv1ryaCVlcKpZvfNblprdxGqZeMKvBIUZ/xoA9vhC3NkrI+3acBdwIX3IJyapXunWtzDLBKHYEZBMRGM9wRniuC0HxXLF5cTlHj5wXUMf16V6Fazw3+nN9lkWNVwzKiDdu9c0AeYeINBk0yYtGRIS2BgN/hxXMsrLK2R83QjuK9d1Sxe8SVpNm8f7Iyfr71xE+ltFcyLIr8HLKGHA7UAcdNBKDvZByPwapdo2oqoQ2ORn+QFdFdW+xmh3AqPmAxgj8v8KxLjcszsq7Rj+E8frQBU8pi3mSAHB9elXIbWa7l554yN3HH+NT2Fg93IoKMc+o6V2+geHxCSZFLLkEARk8+mfSgDm9P0mBQWuUZWXBVj0P171tRWHnwHDbkXlSy7R+FdM1om0qDGC52+Wi5YH6mryWC+UBIDEI0zl8cflnNAHD6hbqYj9olm+XnIf734HmsUxoqFUkcMRwvT/69ej/8I2JmMlzKqDZuUjk+xyeAazL/AEe2QCOIszKQXLsp4x0HGKAOK0+VrebeYhLKV+Vc5wfUipLmxubmHM6hYznDKwUVsyGK0PlxQjzScAlvu+wOao3EcyczGOPA7MG2/h2FAHOSK0biNHV88dc5/HgVCY0SQbcggYJyat3ju5wmwIx4JAyfxqqxCOodiVUZIz+VAB/rCWGSfc1ErjzBg4Yd/f2NNnuI9q7cADsOSarvKHwcYUenB/I0Aa0VyyjKOHbuc8/mK0LO8iXKiIjIGQTgk+2K5tZArg42IvY8ZrRtr9EYNtBPbGP5UAd9o96bZN0QSHvuIyzH0BrZ0+Wa7Zp5G8vHytLJ8xx7f/XrhLHV2BXYN0gHG7oo/wA+lbMDF7RGuXyw+6vb8F/z70AdfNq0XFtbRmWQcGU4JHvnov0/SqtzLA+6F1812+8XJwPoPT0rB+1QwDa1zISeoUg8+ntU1rdMsu6K3RNwOIwPmUepPWgDo4fJjiVIRduq8ZiRdv60VFZ3skdtGr3Dq2ORyP0zxRQB4IGDDIbLIc+lWIkATJ5/2s559qpcLIW2lcD8qtW5UgcgZ/vZyKALKI8hTapyDyeOauBGwiRnaUGcdDn9abHENm6NsMPYH8e2KVjI7MWbLLwdn+cUAWndJV2y7lOMqDk4Psax7pV3ny2OR90dTV6SRpYUDSJ5Y6knms66Ma7ghO4DuelAEDoCGwOTgnHJqNFbYQpYgepp0jMVU5OVH0P605X2hSvI69SaAFBcKVzlhzx2/GrMa79oJwo5xx+dVwzSKDuGc9zU6GNPmOMqcHbxxQBqabtikU4+Udfmzk/0rv8AwvrYt5xGIhwNo+ZsgHqcY5+tee20yljkERgcHcc1sWM9tDKjqfLfAHmdePb/ABoA9phFrckPEWLleW83jPvgZ/OoLmxjYvJeJHIoAVSit859/UfWua0XxI8RM0M1xIigZyAR9OcY/KuzTxDHcxp5kjpkZzlePzx/KgDkr7wyrrLINkhfBAR+APx61BF4JlumGIokCjvxx7HFdjHK1zdl1m3L97DMDxj64/Or6O2nSq8TmPdz5TOu3HqMgGgDmdN8Lrp4zOsSuBxGWBA/Mj+taNjBG0DrDcRZQ7XGTlx7f/rrRLQzq8s0Ls6ttzICQD64wf0NNk01hCZWgIbqrquNo98n+lAGfGllbCVUEUmcHaRkj6BQSSatSyOqw+Xa4QDKu0ZDD8v8KWFHgkjS3MFzuxgBeIx6kniq99qdlaTSGe4iDggMsUpKqPYAUAV71ZGi3sJHJO7Yje/XB/nXL39tGtwJbi4ZI1BLOxOPzAxn8at3/iNYEkkgZAjE8DkH3PTmuH1rV2uJMefLtHI/iXH480AWtbvxK+Ld2KpyH3d+3p/KubmlGQpIJ7k9R+NVribfOW29CM5/zxUku1IPMym4H7ufu/40AVri5bkuBweBwOKzzI8r7gSE7bj1q1NKCu5ASSMcAZxWbMxyQW2jqABmgC0ZsLhRnHPJqsZcOT8pA6AdqG3CPMSkH/a7VCqEsd4xjkEcYoAsLNks5+bHqc0LNI7AKdue1QOPnQMRt7AfT1pwcMVVdoJHPPSgDTiZwUAkORzkVrWd443gLvkP8WTk/rnArn43lBCRyBc8ZrbtLaSParSBuMsVPAFAG9ZESGIRqC45LKeK6jSradGMkm2KIDOFXbx9Tz+JrmrGeS1hMkTJCAAFJAOM96beag7xKzTmSJSCzElQfoO/9aAOzk1CxVyIopJF9VGRn2Iorj4Lm4MKEOY1x8qu5Bx9B0ooA87hXcCR97scDrWktrKkCHy9px15weKgit5JGPlqGwQMgcj866GwsPNtikocqOfm4x+dAGVDBcHnaz+nPH51LDYzzlf3LZXklBXULpMAtsoo80dsByf1rY0XSAEjKyySMedqcbfQc80Aee3Wi3IcOltNgnJ46VTuLC4T5ZIZAVHAxjivab3TJngDbWWIcEAKce5BrE1GxWSFo1kimRBw2AMfhQB5G4K8bW45K4pElKtw2FxgetdBqsDW7ssi7h1HOcfnWH5eMrs2jPYcj9aAI16ZGdxOcetWYOSMgkr260kUSuTuDEZ+6Sc1rwaZFPCrISOOjHgfiaAMp5WDEDOCeQBV21u3yqrHt29ckgf40t1YuhZQEUdPlGfyNUvLKqVdTlRkADtQBv22oyXEjLJctGo7LyDW5Y6gscqRtMZCvQsOPrXA+ciMpJ2ceua07S8WND5Mpj3D73OaAPQ49YZZARJvxzuSViP8+1Whr0sKKylnm6ruzke4rzlL25fG6cmPuV5/nSTXXm5aSQHaeMMeB+dAHon/AAlN1C67r1mz8xQttxVe48XybnCSliecKSQv49zXDLeRgBshABg4BNMkvlCM3Kle+Mj+dAHWS+LbswzETSpuIGB/jWZLq8rSH945THJMh5H5/wBKwbWWa5mC264Y4OQMn9a27TQLyWX/AEgttYcqqkn8QTQBTWeWZsWyOA7dVIwfc4FE1jdeXndvi6nn9egNdhYaXBbXSRGPfhQeWxg+vXipbxMTmC0EESfeYqpLfXJNAHnMkSElfMJzzgDkn8KQQSTOcwSysvOFzxXZnSZZZA6xuyDgnHT6ZwKVLWZJPJgR1Q5B9B/Md6AOQFnIyEsVhwckN1/PrWZeoEYBtpHt0+tdff2VpCXWSRpJB2Q5A/H1/CsO8igV/wByu4Y6gUAYaSZ7E9+KaFORwScZ21PMpDDYnTqM5/WoGKsSzFV47HOKAEkG1PmABA7D+tOjJUADk+me1RtJtQb24GAPUUwuSC3egC/HMoZclQ+PTpVhb5lTbkNjkYHP1rG8wnaTuFSecpIAGBjnnpQBujUpPLUHceOQTT4LmWVQHIVFOV9h7Vg+d8wxkgYGB6f41ZFwflWMnjk47f4UAbkmoDdzI/8A311orIDKR8xXPuM0UAb+jRL5nmMEJ+8cN/hXXaXFbySHcCUb05BHryf6Vy+lZRlwhdOD9PxNddZyQ26RloXkycHOAqj6dzQBrWelIVLIhx0Dbw2R25x/Wr9pbxqqRxKisBhwrEP9cYrPhuIpYyYY2Cn+91H6H9K0ILqOyKJLL/rR8rbSQPzxQAt9OkGTASWHXcF+YfUfyzXJXjgtNumXe/VRuU4/CtzUL2bypY1yZFHG5VKP3Bxn9a5CW8eSWQXabpAMnc2B+eMUAYmrSSshXfGwzjH8X51hvwhXgDpnHWtTUnh3/LEyZ9G61jsiKQCWPftx9aAJIXVAgOCB3C811Wl3NssGJlxjkErgn9a44OA4IPHYnt+tXLS5aM7QxKnnIHSgDoJIbN3MolYAtkY5/wA/nWTfxRLkA/MTx6/zpyTTeWyxtGpH8RXnH1JqldPIdwcbuOwxigCi0kiyFJPnbt35+tMkk2soI2ydcCkCEn5S4A9OacY8yAD5vqM4oAkMrleW+XuM5oikKkEH6bv6UscLnOUIUdMDgVZS1LKpw3HYkUAQxysGJdg+Tng1q6fYzXbq24bRyQDuP5U3T7AvOFeMKM88A12mnaSiW6hVaQE5fIHA980AQ6TbRWDDy5T5vU5H9P8A69bMQNxtS5YnLfKobax9884q1YaXZI/nTygIDyPLGD7cn+VdHDd6YgjS0XLAdCFUKPp/9egCC206FQrGGT5cDcu7d+Z/+tVx7OOOJnijieQAkiSTp7nrmmm4EtvIBcW+wHAVPmK+/tVYCNtmyY7E+80vJb2wMUAULmdIT5TNiJzliozz7E9KyrySOF3EbsWPPzOQCPftWtqjJCAEtWMXVS8ZyT6+tcrqE0r72nFtEGGFIBOPTjFAGffXaiQeWysCc/KvFYesCdpSXYFQPUA/gO1at1MYkXmNEA5fksfwP/1qwdVuoGBwHyP42/lQBk3MgT0DHrVGQYwCxz2wKnuWbBIjCgdMnke9UZAT8wI4GSD2oAQ5DD7zEn8Pzpjv8xBKn25FODtgFsgdBzn/APVTWYx4xyB1YnNAEilsZy3HXkc04sXkVSp2gZqI7sDJ/DPWnNKVwu3BPqeFFAEqyHBYrknv2+tOSUowwdxHQgYqBgUbJdc+p5x/hQC/HJC9uaALf2txnYCw7nPeiqxbONr8YooA9E027V3R1lMeOo+9+vaumikJgQwzCdQc/f8A/r/zFeYWE7pjJ2qpyBtya37O/dCMThVf0zg/gePyoA7e0lTeHmCNGBkkjofXpRdalBPuQK0ijgP0P0x6e5rmEvXHKzIuONpH+NH2wSFmuDH8v8Q4H0BoAmvbqUltruiqcIo6j6msOe5lkY4HC9T6+9TXd7BEd9uzPx3NZ73fyk4RUHOMDigCvcThc8fOOeCf51mTzRSEFgzE981JdT+ZKx8ttwA55qpKwJJRAjDrzQA9MEgq34E84q7HHKseYsAdfvc1nrIyqQeTxznmpzIwwchh7np+tAFkXEjBt7fOByOv/wBao2lBwCqgEcgLj8c1WlnDqpATcO5OcVG8hKrlwW9cdKANERxgBmfI/D/61IXiZhzzjoRwfyqirsqbcnd0z2/+tTo3ZCNpDd/m7UAaHnrtRdu0e3Q/jWnbRpOAEOFx125/U1i2zebIFZVz6H/9dbFvbtvy6x7AePmGPpQBv6fBLbwiR4iV3DlG3Z/H+ldRB++t1be6IvUgHJ/A/wCFYenxSARyMrBMgBU5JPrya1b21kjhEjrIjP8AxMQc/Qdf5UAQXuqrDMVha4dfug7hgn8AMfhUSaxJIGgE4hAHzAHdu/Eise7tXzIV3gdi0nWo4dOSSRF8yU/xcKfl+nrQB1unXwQyqrPyBnyyMn6nFX012a33xxQBQBwiSFvxPBrF0/To4oAZBcPCOhVM4/8Ar1YhtY1lcYMUKjOAwH4GgCC71O5mIeaf5TyqDGW+tYV9fAy5xG8mOHIyR9O9ad79nCHCKrnphjnH44rnrqEDJRwuOPlGKAMq8mdgTICSeeuKyLhpGwdu3I65rR1EsH/ePuI45GMVlSsM/OW2joetAELeZLwByBng9artDtAX7wzn61I0xRgytgj6cVGZScEkAD5s5xigBdrLyOPWmA91Pzfln6VGZyzBiSecDAzz9aMqzg5PPoOKAHN8zAA7QBk/N1qNtxYYHGM4A5pSCz4CkdskmiTcsZReR14GeKAELsPl9e//ANen7m5+Qk4/yahLNgmTOewI6ClWUghdoQZ//V1oAdJKQ33h09etFMaRSeF6cdzRQBtQPIoLCTGBnKnrWhb3LGHh2Lem41mKxiAIIwO2M478VPAQXPAUgA8LQBrRTylSzMA3fJ6/WnmWJ4uGVXzyM4/LiqFvcsUYrwBxyP8AClivfMyNvTpkUALIwDbMqBnJVRx9c1VnkYNtQIM98c/nzSzSJtEgXGfao504GDgDnFAFd5HYMM8jB471EzseJCGx/eNPeXABIHI44pFjVkDYxz2oAjjJBwV684z/AIVJmNvkyu4dsmo2QBAQTjsDSJ/rRnp2FAEjEK4+bLDnbT8fJ8uQ3p3+tNYDcAeMjjH+fpTC+2UqpPHPPNADwJQ+cb8GrlnD5mC0ZbPoKbCnHysce/51pQ+XEAH3nPYHpQBYt7ZUwXiKse/St7T7RNkZWPD9R2z9BVGzS3V1Qxkq2CeeTW7Z29uiEGMhs8bWPH60AaSwTeTH5UuV6spGT+PHNaQX7TbiKWKJ2AycHAP4CqWlTQrEwnhDRoBz1P4dMVP/AGjDaynaZioxtQIoA/nQAqaO+d++GJWHCRqTtH0zmr9tpaaeilI2fK/xZJbjr1NM+3XFxHGUjiKFc/OeR+IH6Vj6jq91p4Yl927gpklcfiaANW9kglCFYZGKe5UL9Kwb26bz2CoCB0cSYx+NY9xrEqxq0rSeU3RFwcd+p5rPn1dY48wQ7Cf4jyaALN1dsX3GTdID/e5/SsS4mlLHfhSeT70271GQcAlGxnK1lSzNKD049cn+tAElzcpg7SSQM8kHNZ0xLOOuDzzR94gKcHr06UyRvLYHLAj0oAglGWPYDtmkB3RjCru6dzii4PAkOSO3PTiowucKhIJ6knNAAzBccEsfQ8fpSgARg78cVISY0+Y/L7d6jmyo5xjsBk+tACbgDhd5z370nlSdcc+meR/WnBG3KA5yR35oYuAqggZ5447UAIowoMWdwGWOaXysfM5XHueajL/KP6/SkBBHI6c9aAF8zaSNxHNFO3swBARR6YzRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial image of the fetal abdomen of a third trimester fetus. The \"double bubble sign\" is present representing a dilated stomach and proximal duodenum. Polyhydramnios is present. The connection between the stomach and duodenum is identified in this image, confirming the diagnosis of duodenal atresia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_32_40463=[""].join("\n");
var outline_f39_32_40463=null;
             